Document:

Form of Grant Acceptance

 Exhibit 10.1 
 Form of Grant Acceptance 
  

			
	 Dear                     :
	  	                    ,
20    

 As you were previously advised, on February 18, 2009 (the “Grant Date”), the
Compensation Committee (the “Committee”) of the Board of Directors of Liberty Global, Inc. (the “Company”) approved the Award to you pursuant to the Liberty Global, Inc. 2005 Incentive Plan (As Amended and Restated Effective
October 31, 2006) (the “LGI Incentive Plan”) of the aggregate number of restricted share units (“RSUs”), each representing the right to receive one share of Series A Common Stock (the “RSU Award”), set forth on the
signature page hereto. The RSU Award represents the method of payment selected by the Committee for the                     , 2009
installment of your Earned Award under the Company’s Senior Executive Performance Incentive Plan (As Amended and Restated Effective May 2, 2007) (the “Performance Plan”) and equals
                     of the portion of your Earned Award due on such installment date. Capitalized terms used and not otherwise defined
in this Grant Acceptance have the meaning ascribed thereto in the Performance Plan, including, where applicable, the LGI Incentive Plan. The RSU Award will vest in full on
                    , 2009, subject to forfeiture or acceleration as provided in Article IV and Section 5.2 of the Performance Plan. Upon
forfeiture of any unvested RSUs, such RSUs will be immediately cancelled and you will cease to have any rights with respect thereto. You will have no rights of a stockholder with respect to any shares of Common Stock represented by any RSUs
included in the RSU Award unless and until such time as shares of Common Stock represented by vested RSUs have been delivered to you as described below. The RSU Award is subject to all of the terms and conditions of your Participation
Certificate, the Performance Plan and the LGI Incentive Plan, and administrative interpretations of the Committee under the Performance Plan and LGI Incentive Plan. 
 As soon as practicable after the vesting of the RSUs included in the RSU Award, and subject to the withholding referred to below, the Company will cause to be delivered to you a statement of holdings reflecting that
the shares of Common Stock represented by such vested RSUs are held for your benefit in uncertificated form by the third party service provider designated by the Company (currently UBS Financial Services Inc.). Delivery will be deemed effected
for all purposes when the statement of holdings reflecting such shares of Common Stock has been delivered personally to you or, if delivery is by mail, when the statement of holdings has been deposited in the United States mail, addressed to you.

 To the extent that the Company is subject to withholding tax requirements under any national, state, local or other governmental law with
respect to the vesting of all or any portion of the RSU Award, the Company shall withhold from the shares of Common Stock represented by the vested RSUs and otherwise deliverable to you a number of shares of Common Stock with an aggregate Fair
Market Value equal to the amount required to be withheld by the Company under such tax laws in connection with the vesting of such RSUs, as determined by the Company (the “Required Withholding Amount”), unless you remit the Required
Withholding Amount to the Company in cash in such form and by such time as the Company may require or other provisions for withholding such amount satisfactory to the Company have been made. Notwithstanding any other provision of this Grant
Acceptance, the delivery of any shares of Common Stock represented by vested RSUs may be postponed until any required withholding taxes have been paid to the Company. 
 Your acceptance hereof shall evidence your explicit and unambiguous consent to the collection, use and transfer, in electronic or other form, of your personal data by and among, as applicable, your employer (the
“Employer”) and the Company and its subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing your participation in the Performance Plan. You understand that the Company and the Employer may hold
certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, bonus and employee benefits, nationality, job title
and description, any shares of stock or directorships or other positions held in the Company, its subsidiaries and affiliates, details of the RSU Award, for the purpose of implementing, administering and managing the Performance Plan
(“Data”). 
  

 1 

 You understand that Data may be transferred to any third parties assisting in the implementation,
administration and management of the Performance Plan, that these recipients may be located in your home country or elsewhere, and that the recipients’ country (e.g. the United States) may have different data privacy laws and protections than
your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients to receive, possess, use, retain and
transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Performance Plan, including any requisite transfer of such Data as may be required to a broker or other third
party with whom you may elect to deposit any shares of Common Stock acquired upon settlement of the RSU Award. 
 You understand that Data
will be held only as long as is necessary to implement, administer and manage your participation in the Performance Plan. You understand that you may at any time view Data, request additional information about the storage and processing of Data,
require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. You understand, however, that refusing or withdrawing your consent may
affect your continued ability to participate in the Performance Plan. For more information on the consequences of a refusal to consent or withdrawal of consent, you may contact your local human resources representative. 
 Please signify your acceptance of the RSU Award in payment of             of the
            , 2009 installment of your Earned Award by selecting “ACCEPTED” where indicated no later than
            , 2009. The RSU Award will not be deemed granted until you accept the RSU Award. 
 Liberty Global, Inc. 
  

					
	 Grant No.
	 	                                       
               	 	

			
	 Number of RSUs (Series A Common Stock) Awarded:
	 	                                        
         

	
	
	 ACCEPTED:

					
	
	                                        
                                         
                 

					
	 Grantee Name:
	 	                                       
          	 	

					
	 Address:
	 	                                       
        	 	
		 	                                       
        	 	

					
			
	 Optionee ID:
	 	                                       
	 	

  

 2Amendment No. 1 to Restated Executive Investment Share Purchase Plan

 Exhibit 10.1 
 COTT CORPORATION 
 AMENDMENT NO. 1 TO RESTATED EXECUTIVE INVESTMENT SHARE

 PURCHASE PLAN 
 Pursuant to Section 10.1 of the Restated Executive Investment Share Purchase Plan (the “Plan”), the Plan is hereby amended as follows, effective December 28, 2008: 
  

	 	1.	Section 3.1 of the Plan is hereby amended in its entirety to read as follows: 

 “3.1 Enrollment for Fiscal Year. Eligible Employees who are designated as Active Participants for a Fiscal Year shall be automatically enrolled in the Plan for such Fiscal Year as of the date of
designation.” 
  

	 	2.	Section 3.2 of the Plan is hereby amended in its entirety to read as follows: 

 “3.2 Annual Performance Targets. No later than 90 days following the commencement of a Fiscal Year, each Eligible Employee will be informed in writing of his or her Annual Performance Targets for such
Fiscal Year.” 
  

	 	3.	Except as amended herein, all provisions of the Plan will remain in full force and effect. 

 IN WITNESS WHEREOF, a duly authorized representative of the Human Resources and Compensation
Committee has executed this Amendment No. 1 on this 25th day of February 2009. 
  

			
	By:	 	 /s/    B.J. Hess

	Name:	 	Betty Jane Hess

  

 39Asset Purchase Agreement and Amendment No.1 to Asset Purchase Agreement

 Exhibit 10.5 
 CONFIDENTIAL PROVISIONS REDACTED 
 ASSET PURCHASE AGREEMENT 
 BY AND BETWEEN 
 PDL BIOPHARMA, INC., 

 a Delaware corporation 
 and

 EKR THERAPEUTICS, INC., 
 a Delaware corporation 
 Dated as of February 4, 2008 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
		
	 ARTICLE 1 DEFINITIONS
	  	1
			
	 1.1
	  	 “Accounts Payable”
	  	1
			
	 1.2
	  	 “Accounts Receivable”
	  	1
			
	 1.3
	  	 “Affiliate”
	  	1
			
	 1.4
	  	 “Agreement”
	  	1
			
	 1.5
	  	 “Assets”
	  	1
			
	 1.6
	  	 “Assumed Contracts”
	  	1
			
	 1.7
	  	 “Assumed Liabilities”
	  	1
			
	 1.8
	  	 “Books and Records”
	  	1
			
	 1.9
	  	 “Business”
	  	2
			
	 1.10
	  	 “Business Employee”
	  	2
			
	 1.11
	  	 “Buyer”
	  	2
			
	 1.12
	  	 “Buyer Indemnitee(s)”
	  	2
			
	 1.13
	  	 “Cardene”
	  	2
			
	 1.14
	  	 “Cardene Drug Product”
	  	2
			
	 1.15
	  	 “Cardene IV”
	  	2
			
	 1.16
	  	 “Cardene Packaged Product”
	  	2
			
	 1.17
	  	 “Cardene PMB Product”
	  	2
			
	 1.18
	  	 “Cardene Product Inventory”
	  	2
			
	 1.19
	  	 “Cardene SR”
	  	2
			
	 1.20
	  	 “Claim”
	  	2
			
	 1.21
	  	 “Clinical Data”
	  	2
			
	 1.22
	  	 “Clinical Trial”
	  	2
			
	 1.23
	  	 “Clinical Trial Materials”
	  	2
			
	 1.24
	  	 “Clinical Trial Study Reports”
	  	3
			
	 1.25
	  	 “Closing”
	  	3
			
	 1.26
	  	 “Closing Date”
	  	3
			
	 1.27
	  	 “Confidential Information”
	  	3
			
	 1.28
	  	 “Confidentiality Agreement”
	  	3
			
	 1.29
	  	 “Copyrights”
	  	3

  

					
		  	-i-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 1.30
	  	 “[****]*”
	  	3
			
	 1.31
	  	 “Customer Orders”
	  	3
			
	 1.32
	  	 “CV Products”
	  	3
			
	 1.33
	  	 “Drug Products”
	  	3
			
	 1.34
	  	 “Effective Date”
	  	3
			
	 1.35
	  	 “Employee Benefit Plans”
	  	3
			
	 1.36
	  	 “Escrow Agent”
	  	4
			
	 1.37
	  	 “Escrow Agreement”
	  	4
			
	 1.38
	  	 “Escrow Amount”
	  	4
			
	 1.39
	  	 “Excluded Assets”
	  	4
			
	 1.40
	  	 “Excluded Liabilities”
	  	4
			
	 1.41
	  	 “FDA”
	  	4
			
	 1.42
	  	 “FD&C Act”
	  	4
			
	 1.43
	  	 “GAAP”
	  	4
			
	 1.44
	  	 “Governmental Entity”
	  	4
			
	 1.45
	  	 “HSR”
	  	4
			
	 1.46
	  	 “HSR Filings”
	  	4
			
	 1.47
	  	 “IND”
	  	4
			
	 1.48
	  	 “Initial FDA Approval”
	  	4
			
	 1.49
	  	 “Initial Purchase Price”
	  	4
			
	 1.50
	  	 “Intellectual Property”
	  	4
			
	 1.51
	  	 “Knowledge”
	  	5
			
	 1.52
	  	 “Liabilities”
	  	5
			
	 1.53
	  	 “Licensed IP Rights”
	  	5
			
	 1.54
	  	 “Litigation Cooperation Agreement”
	  	5
			
	 1.55
	  	 “Marketed Products”
	  	5

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	-ii-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 1.56
	  	 “Marketing and Promotional Documents”
	  	5
			
	 1.57
	  	 “Material Adverse Change” and “Material Adverse Effect”
	  	5
			
	 1.58
	  	 “Milestone and Revenue Payments”
	  	5
			
	 1.59
	  	 “Milestone Payments”
	  	5
			
	 1.60
	  	 “Net Sales”
	  	5
			
	 1.61
	  	 “Net Sales Adjustments”
	  	6
			
	 1.62
	  	 “NDA”
	  	6
			
	 1.63
	  	 “Non Product-Specific Manufacturing Information”
	  	6
			
	 1.64
	  	 “Packaging Inventory”
	  	6
			
	 1.65
	  	 “Packaged Products”
	  	6
			
	 1.66
	  	 “Patents”
	  	7
			
	 1.67
	  	 “[****]*”
	  	7
			
	 1.68
	  	 “Product Inventory”
	  	7
			
	 1.69
	  	 “Product-Specific Manufacturing Information”
	  	7
			
	 1.70
	  	 “Product Specifications”
	  	7
			
	 1.71
	  	 “Purchase Price”
	  	7
			
	 1.72
	  	 “Raw Materials and WIP”
	  	7
			
	 1.73
	  	 “Registrations”
	  	7
			
	 1.74
	  	 “Research and Development Materials”
	  	7
			
	 1.75
	  	 “Retavase”
	  	7
			
	 1.76
	  	 “Retavase Drug Product”
	  	7
			
	 1.77
	  	 “Retavase Packaged Product”
	  	7
			
	 1.78
	  	 “Retavase Product Inventory”
	  	7
			
	 1.79
	  	 “Revenue Payments”
	  	7
			
	 1.80
	  	 “SEC”
	  	7
			
	 1.81
	  	 “Seller”
	  	8

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	-iii-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 1.82
	  	 “Seller Indemnitees”
	  	8
			
	 1.83
	  	 “[****]*”
	  	8
			
	 1.84
	  	 “Sun Litigation”
	  	8
			
	 1.85
	  	 “Survival Date”
	  	8
			
	 1.86
	  	 “Tangible Assets”
	  	8
			
	 1.87
	  	 “Tax” and “Taxes”
	  	8
			
	 1.88
	  	 “Territory”
	  	8
			
	 1.89
	  	 “Third Party Consents”
	  	8
			
	 1.90
	  	 “Trade Secrets”
	  	8
			
	 1.91
	  	 “Trademarks”
	  	8
			
	 1.92
	  	 “Trademark Registrations”
	  	8
			
	 1.93
	  	 “Transition Services Agreement”
	  	9
			
	 1.94
	  	 “Ularitide”
	  	9
			
	 1.95
	  	 “Worldwide Safety Reports”
	  	9
		
	 ARTICLE 2 TRANSFER OF ASSETS; LICENSE AND SUBLICENSE
	  	9
			
	 2.1
	  	 Purchase and Sale of Assets
	  	9
			
		  	 (a)    Patents
	  	9
			
		  	 (b)    Licensed IP Rights
	  	9
			
		  	 (c)    Trademark Registrations
	  	10
			
		  	 (d)    Copyrights
	  	10
			
		  	 (e)    Registrations
	  	10
			
		  	 (f)     Product-Specific Manufacturing Information
	  	10
			
		  	 (g)    Non Product-Specific Manufacturing Information
	  	10
			
		  	 (h)    Research and Development Materials
	  	10
			
		  	 (i)     Marketing and Promotional Documents
	  	11
			
		  	 (j)     Worldwide Safety Reports
	  	11

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	-iv-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
		  	 (k)    Clinical Data
	  	11
			
		  	 (l)     Tangible Assets
	  	11
			
		  	 (m)   Domain Names
	  	11
			
		  	 (n)    Product Inventory
	  	11
			
		  	 (o)    Raw Materials and WIP
	  	11
			
		  	 (p)    Assumed Contracts
	  	12
			
		  	 (q)    Clinical Trial Materials
	  	12
			
		  	 (r)     Clinical Trial Study Reports
	  	12
			
		  	 (s)    Sun Litigation
	  	12
			
		  	 (t)     Books and Records
	  	12
			
		  	 (u)    Customer Orders
	  	12
			
		  	 (v)    Packaging Inventory
	  	12
			
		  	 (w)   Other Intellectual Property
	  	12
			
	 2.2
	  	 Excluded Assets
	  	13
			
	 2.3
	  	 Assumed Liabilities
	  	13
			
	 2.4
	  	 Excluded Liabilities
	  	14
			
	 2.5
	  	 Risk of Loss
	  	15
			
	 2.6
	  	 Taxes
	  	15
			
	 2.7
	  	 Third-Party Consents
	  	15
		
	 ARTICLE 3 CONSIDERATION
	  	16
			
	 3.1
	  	 Purchase Price
	  	16
			
	 3.2
	  	 Method of Payment
	  	17
			
	 3.3
	  	 Revenue Payments; Reports
	  	18
			
	 3.4
	  	 Accounting
	  	18
			
	 3.5
	  	 Records; Audits
	  	18
			
	 3.6
	  	 Late Payments
	  	19
			
	 3.7
	  	 Allocation of Purchase Price
	  	19
		
	 ARTICLE 4 CLOSING
	  	20
			
	 4.1
	  	 Closing
	  	20

  

					
		  	-v-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 4.2
	  	 Actions at Closing
	  	20
			
		  	 (a)    Deliveries by Seller at Closing
	  	20
			
		  	 (b)    Deliveries by Buyer at Closing
	  	21
		
	 ARTICLE 5 EMPLOYMENT MATTERS
	  	22
			
	 5.1
	  	 Employees
	  	22
		
	 ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF SELLER
	  	23
			
	 6.1
	  	 Organization and Authority
	  	23
			
	 6.2
	  	 No Violation or Conflict
	  	24
			
	 6.3
	  	 Consents and Approvals
	  	24
			
	 6.4
	  	 Assumed Contracts
	  	24
			
	 6.5
	  	 Title to Assets
	  	25
			
	 6.6
	  	 Intellectual Property
	  	25
			
	 6.7
	  	 Regulatory Status of Marketed Products
	  	28
			
	 6.8
	  	 Product Net Sales
	  	28
			
	 6.9
	  	 Violations of Law
	  	28
			
	 6.10
	  	 Litigation
	  	28
			
	 6.11
	  	 Employees
	  	28
			
	 6.12
	  	 Taxes
	  	29
			
	 6.13
	  	 Customers and Suppliers
	  	29
			
	 6.14
	  	 Inventory; Raw Materials and WIP
	  	29
			
	 6.15
	  	 Clinical Trials
	  	30
			
	 6.16
	  	 Absence of Change
	  	30
			
	 6.17
	  	 No Undisclosed Liabilities
	  	30
			
	 6.18
	  	 Sufficiency
	  	31
			
	 6.19
	  	 Brokers and Finders
	  	31
			
	 6.20
	  	 No Implied Warranty
	  	31
		
	 ARTICLE 7 REPRESENTATIONS AND WARRANTIES OF BUYER
	  	31
			
	 7.1
	  	 Organization and Authority
	  	31
			
	 7.2
	  	 No Conflict or Violation
	  	32

  

					
		  	-vi-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 7.3
	  	 Consents and Approvals
	  	32
			
	 7.4
	  	 Cash Resources
	  	32
			
	 7.5
	  	 Litigation
	  	32
			
	 7.6
	  	 Brokers and Finders
	  	32
			
	 7.7
	  	 Buyer Due Diligence
	  	32
		
	 ARTICLE 8 PRE-CLOSING COVENANTS
	  	33
			
	 8.1
	  	 Governmental Filings
	  	33
			
	 8.2
	  	 Conduct of Business
	  	33
			
	 8.3
	  	 No Solicitation
	  	34
			
	 8.4
	  	 Access
	  	35
			
	 8.5
	  	 Financing
	  	35
			
	 8.6
	  	 Payment of Certain Expenses
	  	35
			
	 8.7
	  	 Transition Services Agreement
	  	35
		
	 ARTICLE 9 CONDITIONS TO CLOSING
	  	36
			
	 9.1
	  	 Conditions to Obligations of Buyer
	  	36
			
	 9.2
	  	 Conditions to Obligations of Seller
	  	37
		
	 ARTICLE 10 POST-CLOSING COVENANTS
	  	38
			
	 10.1
	  	 Further Assurances
	  	38
			
	 10.2
	  	 Transfer of Registrations; Interim Responsibility
	  	39
			
	 10.3
	  	 Communication With Agencies
	  	40
			
	 10.4
	  	 Adverse Experience Reporting
	  	40
			
	 10.5
	  	 Medical Inquiries
	  	41
			
	 10.6
	  	 Non-Use of Trademarks
	  	41
			
	 10.7
	  	 Documents
	  	41
			
	 10.8
	  	 Governmental Inspections
	  	42
			
	 10.9
	  	 Intellectual Property Maintenance
	  	42
			
	 10.10
	  	 Insurance
	  	42
			
	 10.11
	  	 Federal Supply Schedule
	  	42
			
	 10.12
	  	 Promotion, Marketing and Labeling
	  	42

  

					
		  	-vii-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 10.13
	  	 Payments from Third Parties
	  	43
			
	 10.14
	  	 Product Returns, Chargebacks and Rebates
	  	43
			
	 10.15
	  	 Bulk Transfer Laws
	  	44
			
	 10.16
	  	 Non-Competition
	  	44
		
	 ARTICLE 11 CONFIDENTIALITY
	  	45
			
	 11.1
	  	 Confidentiality
	  	45
			
	 11.2
	  	 Publicity
	  	46
		
	 ARTICLE 12 TERM AND TERMINATION
	  	46
			
	 12.1
	  	 Termination
	  	46
			
	 12.2
	  	 Effect of Termination
	  	47
			
	 12.3
	  	 Effectiveness of Termination
	  	47
		
	 ARTICLE 13 INDEMNIFICATION
	  	47
			
	 13.1
	  	 Survivability of Representations and Warranties
	  	47
			
	 13.2
	  	 Indemnification by Buyer
	  	47
			
	 13.3
	  	 Indemnification by Seller
	  	48
			
	 13.4
	  	 Claims
	  	48
			
	 13.5
	  	 Assertion of Claims
	  	48
			
	 13.6
	  	 Payment of Claims; Limitation on Indemnification
	  	48
			
	 13.7
	  	 Limitation; Exclusivity
	  	48
		
	 ARTICLE 14 MISCELLANEOUS
	  	49
			
	 14.1
	  	 Survival of Covenants and Agreements
	  	49
			
	 14.2
	  	 No Third Party Beneficiaries
	  	49
			
	 14.3
	  	 Force Majeure
	  	49
			
	 14.4
	  	 Governing Law; Jurisdiction; Dispute Resolution and Arbitration
	  	49
			
	 14.5
	  	 Severability
	  	50
			
	 14.6
	  	 Entire Agreement
	  	51
			
	 14.7
	  	 Amendment
	  	51
			
	 14.8
	  	 Notices
	  	51

  

					
		  	-viii-	  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
			
	 14.9
	  	 Assignment
	  	52
			
	 14.10
	  	 No Agency
	  	52
			
	 14.11
	  	 Construction
	  	52
			
	 14.12
	  	 Payment of Expenses
	  	52
			
	 14.13
	  	 Counterparts
	  	53

  

					
		  	-ix-	  	CONFIDENTIAL TREATMENT REQUESTED

 LIST OF EXHIBITS, ATTACHMENT AND SCHEDULES 
 EXHIBITS 
  

			
	 Exhibit A
	  	 General Assignment and Bill of Sale

	 Exhibit B
	  	 Assignment and Assumption Agreement

	 Exhibit C
	  	 Patent Assignment Agreement

	 Exhibit D
	  	 Trademark Assignment Agreement

	 Exhibit E
	  	 Domain Name Assignment Agreement

	 Exhibit F
	  	 Transition Services Agreement

	 Exhibit G
	  	 Third Party Assignment of Assumed Contracts

	 Exhibit H
	  	 Escrow Agreement

	 Exhibit I
	  	 Litigation Cooperation Agreement

	 Exhibit J
	  	 Form of Third Party Notification Letter

		
	ATTACHMENTS	  	
		
	 Attachment 1.70(a)
	  	 Product Specifications for bulk active pharmaceutical ingredients for each CV Product

	 Attachment 1.70(b)
	  	 Product Specifications for Drug Products

	 Attachment 2.1(a)
	  	 List of Patents

	 Attachment 2.1(b)
	  	 List of Licensed IP Rights

	 Attachment 2.1(c)
	  	 List of Trademark Registrations

	 Attachment 2.1(e)
	  	 List of Registrations

	 Attachment 2.1(l)
	  	 List of Tangible Assets

	 Attachment 2.1(m)
	  	 List of Domain Names

	 Attachment 2.1(p)
	  	 List of Assumed Contracts

	 Attachment 4.2(a)
	  	 List of Third Party Consents

	 Attachment 5.1(a)
	  	 Business Employees

 DISCLOSURE SCHEDULES 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ASSET PURCHASE AGREEMENT 
 This Asset Purchase Agreement (this “Agreement”) is entered into as of February 4, 2008 (the “Effective Date”)
between PDL BioPharma, Inc., a Delaware corporation (“Seller”) and EKR Therapeutics, Inc., a Delaware corporation (“Buyer”). 
 RECITALS 
 A. Seller is engaged in the
business (the “Business”) of developing, selling, marketing and supporting its Cardene IV®, Cardene SR®,
Retavase® and Ularitide products (the “CV Products”). 
 B.
Seller desires to sell, transfer and assign to Buyer, and Buyer wishes to acquire, all right, title and interest in and to the CV Products and certain assets related to the operation of the Business, in exchange for consideration consisting of cash
and the assumption of certain Liabilities related to the Business, pursuant to the terms and conditions set forth in this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in this Agreement, and for
other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties to this Agreement agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 1.1 “Accounts Payable” shall mean all obligations of Seller or any of its Affiliates with respect to accounts payable and notes payable, including without limitation, those created or arising in respect of the Business.

 1.2 “Accounts Receivable” shall mean all of Seller’s trade accounts receivable, and all notes receivable or
evidences of indebtedness payable to Seller created or arising in respect of the sale of the Marketed Products. 
 1.3
“Affiliate” with respect to any party shall mean any entity that is directly or indirectly controlling, controlled by or under common control with such party. 
 1.4 “Agreement” shall have the meaning given in the Preamble. 
 1.5 “Assets” shall have the meaning given in Article 2. 
 1.6 “Assumed Contracts” shall have the meaning given in Section 2.1(p). 
 1.7 “Assumed Liabilities” shall have the meaning given in Section 2.3. 
 1.8 “Books and Records” shall mean all pricing lists, customer correspondence (excluding e-mail and other electronic correspondence not
readily available in hard copy) and other books and records, in any form, used solely and specifically with respect to the CV Products by Seller or any of Seller’s Affiliates. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 1 

 1.9 “Business” shall have the meaning given in the Recitals. 
 1.10 “Business Employee” shall have the meaning given in Section 5.1(a). 
 1.11 “Buyer” shall have the meaning given in the Preamble. 
 1.12 “Buyer Indemnitee(s)” shall have the meaning given in Section 13.3. 
 1.13 “Cardene” shall mean Cardene IV and Cardene SR. 
 1.14 “Cardene Drug Product” shall mean labeled or unlabelled vials containing the active pharmaceutical ingredient nicardipine hydrochloride. 
 1.15 “Cardene IV” shall mean each presentation of any pharmaceutical preparation (including formulation changes and production
intermediates) containing the pharmaceutical product known as “Cardene IV” containing the active ingredient nicardipine hydrochloride, whether registered, marketed or in development by Seller, as of the Closing Date. 
 1.16 “Cardene Packaged Product” shall mean Cardene in the Product Inventory purchased by Buyer hereunder that is packaged and labeled
for sale to the end user. 
 1.17 “Cardene PMB Product” shall mean any formulation of Cardene IV [****]*. 
 1.18 “Cardene Product Inventory” shall mean all inventory owned by Seller or its Affiliates of bulk active pharmaceutical ingredient
nicardipine hydrochloride, Cardene Packaged Product and Cardene Drug Product, in existence as of the Closing. 
 1.19 “Cardene
SR” shall mean each presentation of any pharmaceutical preparation (including formulation changes and production intermediates) containing the pharmaceutical product known as “Cardene SR” containing the active ingredient
nicardipine hydrochloride, whether registered, marketed or in development by Seller, as of the Closing Date. 
 1.20 “Claim”
shall have the meaning given in Section 13.4. 
 1.21 “Clinical Data” shall have the meaning given in
Section 2.1(k). 
 1.22 “Clinical Trial” shall mean a clinical trial conducted by or on behalf of Seller or its
Affiliates, or pursuant to any Assumed Contract, in each case in which the product Ularitide is administered to a human. 
 1.23
“Clinical Trial Materials” shall mean the product Ularitide and the placebo for this product manufactured by or on behalf of Seller or its Affiliates for use in preclinical studies or Clinical Trials, whether in bulk, formulated or
finished form and whether in existence on the Effective Date or manufactured between the Effective Date and Closing Date. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 2 

 1.24 “Clinical Trial Study Reports” shall mean all reports or summaries of all data,
records and documents resulting from the Clinical Trials for the product Ularitide. 
 1.25 “Closing” shall have the meaning
given in Section 4.1. 
 1.26 “Closing Date” shall have the meaning given in Section 4.1.

 1.27 “Confidential Information” shall have the meaning ascribed to it in the Confidentiality Agreement. 
 1.28 “Confidentiality Agreement” shall mean that certain Mutual Confidentiality Agreement between Buyer and Seller dated August 28,
2007. 
 1.29 “Copyrights” shall have the meaning set forth in Section 2.1(d). 
 1.30 “[****]*” shall mean product returns, charge-backs, rebates or Medicaid, Medicare or other reimbursements, or similar claims, with respect
to [****]*sold by Seller or its Affiliates for which [****]*. 
 1.31 “Customer Orders” shall mean orders for Packaged
Product from customers of Seller or any of Seller’s Affiliates. 
 1.32 “CV Products” shall have the meaning given in
the Recitals. 
 1.33 “Drug Products” shall mean Cardene Drug Product and Retavase Drug Product. 
 1.34 “Effective Date” shall mean the date first set forth in the opening paragraph of this Agreement. 
 1.35 “Employee Benefit Plans” shall mean any employee benefit plan, program, policy, practices, agreement or other arrangement providing
benefits to any current or former employee, officer or director of Seller or its Affiliates or any beneficiary or dependent thereof that is sponsored or maintained by Seller or its Affiliates or to which Seller or its Affiliates contributes or is
obligated to contribute, whether or not written, including without limitation any employee welfare benefit plan within the meaning of Section 3(1) of ERISA, any employee pension benefit plan within the meaning of Section 3(2) of ERISA
(whether or not such plan is subject to ERISA) and any written employment, severance, retention, termination, change in control, consulting, retirement, bonus or other incentive compensation, stock purchase, stock option, stock award or other
equity-based compensation, leave of absence, lay-off, cafeteria, health, accident, disability, workman’s compensation or other insurance, vacation or other employee benefit agreement, plan or policy (other than any governmental program), and
any related trust, as to which Seller has or may have any obligation or liability, contingent or otherwise. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 3 

 1.36 “Escrow Agent” shall have the meaning set forth in Section 3.2.

 1.37 “Escrow Agreement” shall have the meaning set forth in Section 3.2. 
 1.38 “Escrow Amount” shall have the meaning set forth in Section 3.1(c). 
 1.39 “Excluded Assets” shall have the meaning given in Section 2.2. 
 1.40 “Excluded Liabilities” shall have the meaning given in Section 2.4. 
 1.41 “FDA” shall mean the United States Food and Drug Administration, or any successor agency or entity thereto that may be established
hereafter. 
 1.42 “FD&C Act” shall mean the U.S. Federal Food, Drug and Cosmetics Act, 21 USC § 321 et
seq, as amended. 
 1.43 “GAAP” shall mean the United States generally accepted accounting principles in effect from
time to time, consistently applied. 
 1.44 “Governmental Entity” shall mean any court, tribunal, arbitrator, authority,
agency, commission, regulatory, official or other instrumentality of the government of the United States or of any foreign country, any state or any political subdivision of any such government (whether state, provincial, county, city, municipal or
otherwise). 
 1.45 “HSR” shall mean the United States Hart-Scott-Rodino Antitrust Improvements Act of l976, as amended, and
related rules. 
 1.46 “HSR Filings” shall have the meaning given in Section 8.1. 
 1.47 “IND” shall mean, with respect to each CV Product, the investigational new drug application identified on Attachment 2.1(e)
hereto. 
 1.48 “Initial FDA Approval” shall mean the first issuance by the FDA of a written approval that [****]*.

 1.49 “Initial Purchase Price” shall have the meaning given in Section 3.1(a). 
 1.50 “Intellectual Property” shall mean (i) Patents; (ii) Licensed IP Rights; (iii) Trademarks and Trademark
Registrations; (iv) Copyrights; and (v) Trade Secrets. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 4 

 1.51 “Knowledge” shall mean, whenever any representation or warranty is made by Seller
or Buyer “to the Knowledge” of the Seller or Buyer, (i) the actual knowledge of the officers of the Seller or Buyer, respectively, and (ii) the knowledge that any such person referenced in clause (i) hereof, as a prudent
business person, would have obtained in the usual course of the performance of his or her professional responsibilities to such party. 
 1.52 “Liabilities” shall mean liabilities of any kind or nature, primary or secondary, direct or indirect, absolute or contingent, known or unknown, liquidated or unliquidated, including but not limited to any liabilities
for claims of product liability, personal injury or death, liability in tort or contract (including unripened liabilities due to past actions or sales), indebtedness, and any FDA or other Governmental Entity action or notification, and all costs and
expenses (including reasonable attorneys’ fees), incurred in connection with the defense of any such claims. 
 1.53 “Licensed
IP Rights” shall have the meaning given in Section 2.1(b). 
 1.54 “Litigation Cooperation Agreement”
shall mean the agreement between Buyer and Seller, substantially in the form attached hereto as Exhibit I, pursuant to which Buyer assumes control of all aspects of the Sun Litigation, Seller agrees to assist Buyer as required, at
Buyer’s expense, in such Sun Litigation, and Buyer agrees to indemnify Seller with respect to Seller’s post-Closing assistance in such litigation. 
 1.55 “Marketed Products” shall mean Cardene IV, Cardene SR and Retavase. 
 1.56
“Marketing and Promotional Documents” shall have the meaning given in Section 2.1(i). 
 1.57 “Material
Adverse Change” and “Material Adverse Effect” shall mean any event or situation that has a material adverse change or effect, respectively, on the operations, assets, Liabilities, results of operations, cash flows or
financial condition, or relations with material customers or material suppliers, of the Business, taken as a whole, other than any such change or effect resulting from or arising in connection with (i) [****]*. 
 1.58 “Milestone and Revenue Payments” shall have the meaning given in Section 3.1(b). 
 1.59 “Milestone Payments” shall have the meaning given in Section 3.1(b). 
 1.60 “Net Sales” shall mean, the gross invoiced sales amount of the Cardene PMB Product or any Ularitide product, as applicable,
[****]*, and in each case less the following items (“Net Sales Adjustments”) as applicable to the Cardene PMB Product or the Ularitide product, as applicable, to the extent such items are reasonable and customary under industry
practices and [****]*and are consistent in application with [****]*: 
 (a) actual credits or allowances granted upon returns,
rejections or recalls (due to spoilage, damage, expiration of useful life or otherwise), retroactive price reductions, or billing corrections during the accounting period in which such sales are recorded; 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 5 

 (b) invoiced freight, postage, shipping and insurance, handling, export fees or tariffs,
customs expenses and other transportation costs actually incurred by Buyer; 
 (c) credits or allowances actually granted
including, without limitation, quantity, cash and other trade discounts (collectively, “Credits”), provided, however, Credits shall not include any credit, allowance or discount given with respect to the sale of the
[****]*; 
 (d) taxes (including, without limitation, sales, value-added or excise taxes, but excluding income taxes imposed
on the income of Buyer or its Affiliates and withholding taxes imposed on amounts payable to Buyer or its Affiliates), tariffs, customs duties, surcharges and other governmental charges incurred in connection with the production, sale,
transportation, delivery, use, exportation or importation of CV Products that are incurred at time of sale or are directly related to the sale; 
 (e) discounts, refunds, rebates, charge backs, fees, credits or allowances (including, without limitation, amounts incurred in connection with government-mandated rebate and discount programs, third party rebates and
charge backs, hospital buying group/group purchasing organization administration fees and managed care organization rebates) actually deducted from payment of invoices by customers or paid to customers during the accounting period in which such
sales are recorded, offset by any such amounts that had been deducted from invoices or paid to customers in error and have been paid back to Buyer; and 
 (f) distribution fees and sales commissions to third parties, actually paid or incurred at the time of sale and which effectively reduce the selling price, 
 all in accordance with standard allocation procedures, allowance methodologies and accounting methods consistently applied. For the avoidance of doubt, the transfer of
any Cardene PMB Product by Buyer or its Affiliates to another Affiliate of Buyer for purposes of sale to an independent third party shall not be considered a sale; in such cases, Net Sales shall be determined based on the gross invoiced sales by
such Affiliate to an independent third party, less the Net Sales Adjustments allowed under this Section. 
 1.61 “Net Sales
Adjustments” shall have the meaning given in Section 1.60. 
 1.62 “NDA” shall mean, with respect to
each CV Product, the new drug application identified on Attachment 2.1(e) hereto. 
 1.63 “Non Product-Specific Manufacturing
Information” shall have the meaning given in Section 2.1(g). 
 1.64 “Packaging Inventory” shall have
the meaning given in Section 2.1(v). 
 1.65 “Packaged Products” shall mean Cardene Packaged Product and
Retavase Packaged Product. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 6 

 1.66 “Patents” shall have the meaning given in Section 2.1(a). 

1.67 “[****]*” shall mean the [****]*. 
 1.68 “Product Inventory” shall mean Cardene Product Inventory and Retavase Product Inventory. 
 1.69 “Product-Specific Manufacturing Information” shall have the meaning given in Section 2.1(f). 
 1.70 “Product Specifications” shall mean the specifications for bulk active pharmaceutical ingredients for the respective Marketed Products, and for the respective Drug Products, as set forth in Attachments 1.70(a)
and (b), respectively. 
 1.71 “Purchase Price” shall have the meaning given in Section 3.1. 

1.72 “Raw Materials and WIP” shall mean all of the raw materials and work in progress owned by Seller or its Affiliates for use in
the manufacture of the CV Products, in existence as of the Closing. 
 1.73 “Registrations” shall have the meaning given in
Section 2.1(e). 
 1.74 “Research and Development Materials” shall have the meaning given in
Section 2.1(h). 
 1.75 “Retavase” shall mean each presentation of any pharmaceutical preparation (including
formulation changes and production intermediates) containing the active pharmaceutical ingredient reteplase, whether registered, marketed or in development by Seller or its Affiliates, as of the Closing Date. 
 1.76 “Retavase Drug Product” shall mean labeled or unlabelled vials containing the active pharmaceutical ingredient reteplase.

 1.77 “Retavase Packaged Product” shall mean Retavase in the Product Inventory purchased by Buyer hereunder that is
packaged and labeled for sale to the end user. 
 1.78 “Retavase Product Inventory” shall mean all of the inventory owned by
Seller or its Affiliates of bulk active pharmaceutical ingredient reteplase, Retavase Packaged Product and Retavase Drug Product, in existence as of the Closing. 
 1.79 “Revenue Payments” shall have the meaning given in Section 3.1(b). 
 1.80
“SEC” shall mean the United States Securities and Exchange Commission. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 7 

 1.81 “Seller” shall have the meaning given in the Preamble. 
 1.82 “Seller Indemnitees” shall have the meaning given in Section 13.2. 
 1.83 “[****]*” shall mean the [****]*. 
 1.84 “Sun Litigation” shall mean all rights relating to the patent infringement lawsuit in the United States District Court for the District of New Jersey (New Jersey Court) filed by Seller against
Sun Pharmaceutical Industries Ltd. (“Sun”) seeking, among other things, to enjoin Sun’s infringement of Seller’s United States Patent Number 5,164,405, titled “Nicardipine pharmaceutical composition for parenteral
administration” and to stay any sale of Sun’s Abbreviated New Drug Application product until at least the expiration of such patent, a related lawsuit filed by Seller in United States District Court for the Eastern District of Michigan,
and all other related litigation between Seller and Sun, and any claims and counterclaims associated therewith. 
 1.85 “Survival
Date” shall have the meaning given in Section 13.1. 
 1.86 “Tangible Assets” shall have the meaning
given in Section 2.1(l). 
 1.87 “Tax” and “Taxes” shall mean all present or future taxes,
charges, fees, levies, or other assessments including, without limitation, income, excise, property, value added, real estate, sales, use, payroll, employment, unemployment, transfer, social security, alternative, add-on minimum and franchise taxes
imposed by any federal, state, county, or local government, or a subdivision or agency thereof. Such term shall include any interest, penalties, or additions payable in connection with such taxes, charges, fees, levies, duties, or other assessments.

 1.88 “Territory” (i) for Cardene shall mean the United States of America and its possessions and territories;
(ii) for Retavase shall mean Canada and the United States of America and its possessions and territories; and (iii) for Ularitide shall mean worldwide. 
 1.89 “Third Party Consents” shall have the meaning given in Section 6.4. 
 1.90
“Trade Secrets” shall mean all technology, trade secrets and other confidential information, know-how, proprietary processes, formulae, algorithms, models, and methodologies that are related to the Business. 
 1.91 “Trademarks” shall mean all trademarks, service marks, trade names, names, slogans, taglines, logos, design marks, trade dress,
product designs, and product packaging, including all applications for and registrations of the foregoing, and including those at common law that are related to the CV Products. 
 1.92 “Trademark Registrations” shall have the meaning given in Section 2.1(c). 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 8 

 1.93 “Transition Services Agreement” shall mean the transition services agreement to be
entered into by Buyer and Seller, at the request of Buyer as contemplated in Section 8.7, whereby Seller shall, for fees specified therein, provide to Buyer certain services relating to the transition of the Business. 
 1.94 “Ularitide” shall mean each presentation of any pharmaceutical preparation (including formulation changes and production
intermediates) containing the active pharmaceutical ingredient urodilatin, whether registered, marketed or in development by Seller or its Affiliates, as of the Closing Date. 
 1.95 “Worldwide Safety Reports” shall have the meaning given in Section 2.1(j). 
 ARTICLE 2 
 TRANSFER OF ASSETS; LICENSE AND
SUBLICENSE 
 2.1 Purchase and Sale of Assets. Subject to the terms and conditions of this Agreement, Seller shall sell, transfer,
assign, convey, deliver, license or sublicense, as specified below, to Buyer, or shall cause to be sold, transferred, assigned, conveyed, delivered, licensed or sublicensed, as specified below, to Buyer, and Buyer shall acquire all of Seller’s
right, title and interest in and to the properties and assets of Seller identified in this Section 2.1 (collectively, the “Assets”). 
 (a) Patents. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred,
assigned, conveyed and delivered to Buyer, all of Seller’s rights, title and interest in and to the patent filings related to the CV Products listed in Attachment 2.1(a), and any patents of addition, re-examinations, reissues,
extensions, granted supplementary protection certifications, substitutions, confirmations, registrations, revalidations, revisions, additions and the like, of or to said patents and any and all divisionals, continuations and continuations-in-part,
and any patents issuing therefrom, as well as any patent applications related thereto (collectively, the “Patents”). Seller hereby retains a royalty-free right and license, including the right to sublicense, under the Patents,
solely to the extent necessary for, and solely for the purposes of, performing Seller’s obligations under this Agreement and the Transition Services Agreement and only until the completion of Seller’s obligations hereunder and thereunder.

 (b) Licensed IP Rights. Upon Closing, Seller shall transfer, assign, convey and deliver, or shall cause to be sold,
transferred, assigned, conveyed and delivered to Buyer, all of Seller’s rights under all patents, know-how and other intellectual property rights which Seller has a right under contract to use and which are used in the Business and those
intellectual property rights contained in the license agreements included as part of the Assumed Contracts or as otherwise set forth on Attachment 2.1(b), but subject to any restrictions and obligations in such license agreements (the
“Licensed IP Rights”). Seller hereby retains a royalty-free right and license under the Licensed IP Rights for use in the Business, solely to the extent necessary for, and solely for the purposes of, performing Seller’s
obligations under this Agreement and the Transition Services Agreement, and only until the completion of Seller’s obligations hereunder and thereunder. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 9 

 (c) Trademark Registrations. Upon Closing, Seller shall sell, transfer, assign,
convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all of Seller’s rights, title and interest in and to all Trademarks used in the Business and as set forth on Attachment 2.1(c),
together with (i) all common law rights to the Trademarks, (ii) the goodwill of the Business symbolized by the Trademarks, (iii) all causes of actions, claims and demands or other rights for, or arising from any infringement,
dilution, unfair competition, or other violation, including past infringement, dilution, unfair competition, or other violation, of the Trademarks, and (iii) all rights corresponding thereto throughout the world (the “Trademark
Registrations”). 
 (d) Copyrights. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or
shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all of Seller’s rights, title and interest in and to registered and unregistered copyrights, including all related registrations, applications and common law
rights, in any labels, product marketing materials or other copyrighted works related to the CV Products (the “Copyrights”). 
 (e) Registrations. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all of Seller’s rights, title
and interest in and to the regulatory files and approvals, registrations and governmental authorizations, each NDA, each IND, compliance notices, licenses and permits, and any applications to the FDA or the comparable foreign law or bodies in effect
or pending at the Closing Date, and all materials and information relating to the FDA and other Governmental Entity approvals for the CV Products as set forth on Attachment 2.1(e), and all information contained therein (collectively, the
“Registrations”). 
 (f) Product-Specific Manufacturing Information. Upon Closing, Seller shall sell,
transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer all of Seller’s rights, title and interest in and to all of Seller’s manufacturing information (the
“Product-Specific Manufacturing Information”) used solely and exclusively in the Business. Seller shall retain a non-exclusive license to use Product-Specific Manufacturing Information, solely for purposes of fulfilling its
obligations under this Agreement and the Transition Services Agreement, and only until completion of Seller’s obligations hereunder and thereunder. 
 (g) Non Product-Specific Manufacturing Information. Upon Closing, Seller shall grant, or shall cause to be granted to Buyer, a perpetual, paid up, irrevocable, royalty-free, non-exclusive license, with the
right to sublicense, to use, only in the Business, any manufacturing information that is used by Seller both in the Business and also in other business activities of Seller (the “Non-Product Specific Manufacturing Information”).
Seller shall retain a non-exclusive license to use Non-Product-Specific Manufacturing Information in other business activities of Seller. 
 (h) Research and Development Materials. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer,
(i) originals of all documents and electronically stored information (excluding e-mails or other electronic correspondence not readily available in hard copy) to the extent related to the research and development of the CV Products that are
owned or controlled by Seller or its Affiliates and any of their respective agents, and (ii) copies of all other documents 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 10 

 
and electronically stored information (excluding e-mails or other electronic correspondence not readily available in hard copy) to the extent related to the
research and development of the CV Products (the “Research and Development Materials”). After Closing, Seller shall retain a right to use the Research and Development Materials, solely for purposes of fulfilling its obligations
under this Agreement and the Transition Services Agreement, and only until completion of Seller’s obligations hereunder and thereunder. 
 (i) Marketing and Promotional Documents. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all marketing
and promotional documents and information (including electronic information, but excluding e-mails or other electronic correspondence not readily available in hard copy) related to the CV Products existing on the Closing Date, owned by Seller or its
Affiliates, such as customer lists, marketing and promotional plans, documents and materials, material contained on Seller’s internet sites, field force training manuals and materials, and the like, solely to the extent relating
exclusively to the Business (the “Marketing and Promotional Documents”). Buyer’s use of the Marketing and Promotional Documents shall be subject to Section 10.12. 
 (j) Worldwide Safety Reports. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold,
transferred, assigned, conveyed and delivered to Buyer, all worldwide safety reports in the possession or control of Seller or its Affiliates with respect to the CV Products in existence as of the Closing (the “Worldwide Safety
Reports”). 
 (k) Clinical Data. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or
shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all clinical data related to the CV Products and which is contained in Seller’s databases or otherwise in Seller’s possession or control (the “Clinical
Data”). 
 (l) Tangible Assets. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or
shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, certain tangible assets, as listed in Attachment 2.1(l) (the “Tangible Assets”). 
 (m) Domain Names. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred,
assigned, conveyed and delivered to Buyer, all of Seller’s rights, title and interest in and to the domain names used primarily in the Business and listed in Attachment 2.1(m) (collectively, the “Domain Names”).

 (n) Product Inventory. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be
sold, transferred, assigned, conveyed and delivered to Buyer, the Product Inventory. 
 (o) Raw Materials and WIP. Upon
Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, the Raw Materials and WIP. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 11 

 (p) Assumed Contracts. Upon Closing, Seller shall sell, transfer, assign, convey
and deliver or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all rights and benefits of Seller in existence as of the Closing Date or arising after the Closing Date under the contracts listed in Attachment
2.1(p) (the “Assumed Contracts”), including any rights to Intellectual Property. The Assumed Contracts shall be deemed to include all purchase orders and change orders related thereto. 
 (q) Clinical Trial Materials. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold,
transferred, assigned, conveyed and delivered to Buyer, all of Seller’s rights, title and interest in and to the Clinical Trial Materials. 
 (r) Clinical Trial Study Reports. Upon Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all of Seller’s
rights, title and interest in and to the Clinical Trial Study Reports. 
 (s) Sun Litigation. Upon Closing, Seller
shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all of Seller’s rights relating to the Sun Litigation, including, without limitation, all documents and
information and other things gathered or produced by any party in relation thereto. 
 (t) Books and Records. Upon
Closing, Seller shall sell, transfer, assign, convey and deliver, or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer all Books and Records. 
 (u) Customer Orders. Upon Closing, Seller shall sell, transfer, assign, convey and deliver or shall cause to be sold, transferred,
assigned, conveyed and delivered to Buyer, all of Seller’s right, title and interest in all unfilled orders for the CV Products, including without limitation, all unfilled Customer Orders as of the Closing Date (i.e. Customer Orders to the
extent that (i) the Packaged Products at issue have not been shipped to the applicable customer as of the Closing Date and (ii) Buyer (rather than Seller or any of its Affiliates) would be paid by the applicable customer after shipment by
Buyer following the Closing Date), a list of which shall be provided to Buyer within [****]* after the Closing Date. 
 (v)
Packaging Inventory. Upon Closing, Seller shall sell, transfer, assign, convey and deliver or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all packaging material for the Marketed Products, including all
package labels and product inserts used in connection with the Marketed Products owned or controlled by Seller or its Affiliates as of the Closing (the “Packaging Inventory”). 
 (w) Other Intellectual Property. Upon Closing, Seller shall sell, transfer, assign, convey and deliver or shall cause to be sold,
transferred, assigned, conveyed and delivered to Buyer all of Seller’s rights, title and interest in and to the Trade Secrets and other intellectual property not hereto forth assigned that are used solely in the Business. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 12 

 2.2 Excluded Assets. Buyer hereby acknowledges that Seller is not transferring hereunder any
assets, rights or interests of Seller or its Affiliates not specifically set forth in Section 2.1 (collectively, the “Excluded Assets”), including, without limitation: 
 (a) any contracts or agreements with any third party that are not Assumed Contracts or identified in Section 2.1(b);

 (b) any assets or rights used in the research, development, manufacture, control, packaging or release, marketing or sale
of products other than the CV Products, excluding such assets or rights of Seller or its Affiliates that were used primarily in, or were otherwise necessary for the conduct of, the Business on the Effective Date that are either (i) Assets
(transferred to Buyer pursuant to Section 2.1) or (ii) are covered in Section 10.1(a); 
 (c) any
assets or rights, including, without limitation, technical information and intellectual property, that are not used exclusively in the Business and are used in other business activities of Seller, excluding such assets or rights of Seller or its
Affiliates that were used primarily in, or were otherwise necessary for the conduct of, the Business on the Effective Date that are either (i) Assets (transferred to Buyer pursuant to Section 2.1) or (ii) are covered in
Section 10.1(a); 
 (d) equipment, computer software, and computer hardware, except as listed on Attachment
2.1(b) or Attachment 2.1(l); 
 (e) all Accounts Receivable arising on or prior to the Closing Date; and

 (f) corporate records (financial statements, formation documents, stock records, board resolutions and minutes, and the
like). 
 2.3 Assumed Liabilities. Buyer shall assume and agree to honor, pay and discharge when due only the following Liabilities of
Seller (the “Assumed Liabilities”), and no others: 
 (a) all Liabilities of Seller under the Assumed
Contracts, but only to the extent such Liabilities arise from any event, circumstance or condition occurring after the Closing Date; 
 (b) all Liabilities of Seller under the Registrations to be performed after the Closing Date, but only to the extent such Liabilities relate to any event, circumstances or conditions occurring after the Closing Date; 
 (c) all Liabilities relating to the Sun Litigation, other than (i) Liabilities that arise as a result of actions taken or omitted by
Seller and its Affiliates on or prior to the Closing Date (unless taken or omitted with the consent of Buyer), and (ii) all fees, costs and expenses incurred by or on behalf of Seller or any of its Affiliates with respect to the Sun Litigation
on or prior to the Closing Date (including attorneys’ fees); 
 (d) all other Liabilities (other than Excluded
Liabilities) arising out of the conduct of the Business or arising out of or related to the Assets, but in each case solely to the extent such Liabilities are incurred or relate to events, circumstances, conditions, actions or 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 13 

 
activities occurring after the Closing Date, including, without limitation, any product liability, product warranty, product return, charge-back, rebate or
Medicaid, Medicare or other reimbursements, or similar claim, related to the CV Products sold after the Closing Date; 
 (e)
all [****]*; 
 (f) all Liabilities relating to Taxes attributable to ownership of the Assets and operation of the Business
during periods beginning after the Closing Date, but not including, for the avoidance of doubt, Taxes that are payable after the Closing Date relating to taxable periods, or portions thereof, ending on or prior to the Closing Date, determined, in
the case of any period that includes but does not end on the Closing Date, on a pro rata per diem basis; and 
 (g) all costs
and expenses incurred after the Closing Date in connection with or related to the[****]*, including without limitation, any and all work or agreements related thereto, and the [****]*relating to the [****]*, [****]*. 
 2.4 Excluded Liabilities. Except for the Assumed Liabilities, Buyer shall not assume by virtue of this Agreement or the transactions contemplated
hereby, and shall have no liability for, any Liabilities of Seller or any of its Affiliates (including, without limitation, those related to the Business) of any kind, character or description whatsoever (the “Excluded
Liabilities”). Seller shall discharge in a timely manner or shall make adequate provision for all of the Excluded Liabilities that affect the Business, Assets or Assumed Liabilities, provided that Seller shall have the ability to contest,
in good faith, any such claim of liability asserted in respect thereof by any person or entity. Excluded Liabilities shall include, without limitation: 
 (a) all Taxes (other than Taxes that are Assumed Liabilities) including those that result from or have accrued in connection with the operation of the Business on or prior to the Closing Date; 
 (b) any Liability or obligation of Seller of any nature owed to any employees, directors, former employees, agents or independent
contractors, whether or not employed by Buyer after the Closing, that (A) arises out of or relates to the employment or service provider relationship between Seller or its Affiliates (or any predecessor in interest) and any such individual(s)
(including, but not limited to, claims for compensation, discrimination, harassment, or retaliation and any Liability under Seller’s Employee Benefit Plans); or (B) arises out of or relates to events, circumstances or conditions occurring
on or prior to the Closing Date (including the transactions contemplated by this Agreement); 
 (c) all Accounts Payable
arising on or prior to the Closing Date; 
 (d) Liabilities of Seller under the Assumed Contracts that were incurred, arose or
became payable on or prior to the Closing Date; 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 14 

 (e) all Liabilities of Seller and its Affiliates under the Registrations, to be
performed, or which relate to any event, circumstance or condition occurring, on or prior to the Closing Date; 
 (f) all
Liabilities with respect to accrued expenses incurred on or prior to the Closing in connection with the CV Products or the Business; 
 (g) all Liabilities arising out of claims of third parties for damage or injury suffered as the result of defective products sold or manufactured on or prior to the Closing Date; 
 (h) all Liabilities incurred (i) up through the Closing Date and (ii) after the Closing Date [****]*, in connection with or
related to the [****]*, including without limitation the [****]* and of any and all work and agreements relating thereto, and the [****]* relating the [****]*; and 
 (i) Liabilities of Seller and its Affiliates relating to or arising under this Agreement. 
 2.5 Risk of Loss. All risk of loss with respect to the Assets (whether or not covered by insurance) shall be on Seller or its Affiliates up to the
time of Closing, whereupon such risk of loss shall pass to Buyer. 
 2.6 Taxes. All applicable sales, transfer, documentary, use,
stamp, filing, recording, conveyance, excise, mortgage, documentary recording taxes and other similar taxes and fees that may be levied on the sale, assignment, transfer or delivery of the Assets to be sold and transferred as provided in this
Agreement shall be borne by the parties equally. The parties shall cooperate with each other and use commercially reasonable efforts to minimize such Taxes. 
 2.7 Third-Party Consents. To the extent that any Assumed Contract, Intellectual Property or Registration is not assignable without the consent of another party, this Agreement shall not constitute an assignment
or an attempted assignment thereof if such assignment or attempted assignment would constitute a breach thereof or a default thereunder. Seller and Buyer shall each use commercially reasonable efforts to obtain the consent of [****]*, to the extent
required, for the assignment of any Assumed Contracts to which it is a party. Seller shall use its commercially reasonable efforts to obtain any and all consents necessary for the effective assignment to and assumption by Buyer of the Assumed
Contracts, the Intellectual Property, the Registrations and the Assumed Liabilities, including the Third Party Consents set forth on Attachment 4.2(a) hereto and the consents set forth on Schedule 6.3 of the Disclosure Schedule. All
such consents shall be in writing and executed counterparts thereof shall be delivered promptly to Buyer. If any such consent shall not be obtained, Seller shall cooperate with Buyer in any reasonable arrangement designed to provide for Buyer the
benefits intended to be assigned to Buyer under the relevant Assumed Contract, Intellectual Property or Registration, including enforcement at the cost and for the account of Buyer of any and all rights of Seller against the other party thereto
arising out of the breach or cancellation thereof by such other party or 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 15 

 otherwise. If and to the extent that such arrangement cannot be made, Buyer shall have no obligation pursuant to
Section 2.3 or otherwise with respect to any such Assumed Contract, Intellectual Property or Registration. The provisions of this Section 2.7 shall not affect the right of Buyer not to consummate the transactions contemplated
by this Agreement if the condition to its obligations hereunder contained in Section 9.1 has not been fulfilled. 
 ARTICLE 3

 CONSIDERATION 
 3.1
Purchase Price. As full consideration of Seller’s sale, transfer, assignment, conveyance, delivery, license or sublicense of the Assets to Buyer, Buyer will assume the Assumed Liabilities and pay and deliver or cause to be paid and
delivered to Seller, in the manner set forth in this Section, an aggregate purchase price (the “Purchase Price”) equal to the sum of the Initial Purchase Price set forth in Section 3.1(a) and the Milestone and Revenue
Payments, if applicable, set forth in Section 3.1(b). 
 (a) Initial Purchase Price. On the Closing Date,
Buyer shall pay Seller Eighty Five Million United States Dollars ($85,000,000) (the “Initial Purchase Price”), less the Escrow Amount. 
 (b) Milestone and Revenue Payments. In addition to the payment made by Buyer pursuant to Section 3.1(a), after the Closing Date, Buyer shall make the following non-refundable cash payments to
Seller, in each case, subject to the satisfaction of the respective milestones: 
 i. Cardene PMB Product Approval
Milestone Payment. Twenty Five Million United States Dollars ($25,000,000) shall become payable upon Buyer’s receipt of the Initial FDA Approval, such payment to be made promptly, and in no event later than [****]*, after receipt of such
approval. 
 ii. Revenue Milestone Payments. 
 (1) Thirty Million United States Dollars ($30,000,000) payable to Seller if and when the Net Sales of the Cardene PMB Product in any
twelve consecutive month period, calculated as of the end of each calendar month, first exceed Eighty Million United States Dollars ($80,000,000). 
 (2) Thirty Million United States Dollars ($30,000,000) payable to Seller if and when the Net Sales of the Cardene PMB Product in any twelve consecutive month period, calculated as of the end of each calendar month,
first exceed One Hundred Fifty Million United States Dollars ($150,000,000). 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 16 

 (3) Each payment pursuant to subsections (1) and (2) shall, if applicable, be
made promptly, but no later than [****]*, following the occurrence of the relevant milestone. 
 The milestone payments under subsections (i) and
(ii) of this Section 3.1(b) are collectively referred to as “Milestone Payments”. 
 iii.
Other Revenue Payments. Buyer shall pay to Seller, on a [****]* basis as provided in Section 3.3, (A) an amount equal to ten percent (10%) of the Net Sales of the Cardene PMB Product from sales occurring after the
Closing Date and prior to the earlier to occur of (i) December 31, 2014 and (ii) the [****]*, and (B) on a country-by-country basis, an amount equal to five (5%) of the Net Sales of any Ularitide product from sales occurring
after the Closing Date and prior to the later to occur of (i) the expiration of the applicable exclusivity period in such country, and (ii) the expiration of the last Patent covering Ularitide in such country. The payments under this
subsection iii of Section 3.1(b) are referred to as “Revenue Payments” and Revenue Payments and Milestone Payments are collectively referred to as “Milestone and Revenue Payments”. 
 (c) Deposit in Escrow. At Closing, Buyer shall deliver cash from the Initial Purchase Price in the amount of Six Million United
States Dollars ($6,000,000) (the “Escrow Amount”) to the Escrow Agent pursuant to the Escrow Agreement, to be held and disbursed upon and subject to all of the terms and conditions set forth therein. 
 3.2 Method of Payment. The payments to be made pursuant to Section 3.1 shall be made by wire transfer in immediately available funds
as follows: 
 (a) delivery of the Initial Purchase Price, less the Escrow Amount, to such account as Seller shall have
designated to Buyer in writing not less than two (2) business days prior to the Closing Date, and any such payment shall be deemed to have been paid when recorded in the proper account; 
 (b) delivery to Wells Fargo Bank, National Association (the “Escrow Agent”) of the Escrow Amount in accordance with the
wire transfer instructions of the Escrow Agent delivered to Buyer in writing not less than two (2) business days prior to the Closing Date. The Escrow Amount shall be held in escrow by the Escrow Agent pursuant to the terms of an escrow
agreement in substantially the form of Exhibit H attached hereto (the “Escrow Agreement”) in order to provide a source for the payment of any [****]*. The Escrow Agreement shall provide for the release of any remaining escrow
funds to Seller [****]* from the Closing Date [****]*; and 
 (c) delivery of the Milestone and Revenue Payments to such
account as Seller shall have designated to Buyer in writing not less than two (2) business days prior to the Closing Date (or such other account as designated by Buyer after Closing delivered pursuant to the notice provision herein).

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 17 

 3.3 Revenue Payments; Reports. Buyer shall pay to Seller, [****]*, any Revenue Payments that
become due. Such payments will be accompanied by a report containing the following information as it pertains to the [****]* just ended: 
 (a) the gross sales of the Cardene PMB Product (in the aggregate and separately stated for each selling party); 
 (b) the computation of the Net Sales of Cardene PMB Product actually received by Buyer based on the U.S. dollar value determined in (a) above, including an accounting of any Net Sales Adjustments from the gross
sales to arrive at the Net Sales amount, and the exchange rates used for converting foreign currency to U.S. dollars in accordance with Section 3.4 hereof; 
 (c) the computation of earned Revenue Payments; and 
 (d) such other information necessary to confirm the Revenue Payments payable pursuant to Section 3.1(b)(iii) as Seller may
reasonably request. 
 If no earned Revenue Payments are due for a [****]*, Buyer will so report. At the end of the [****]* in which the Revenue Payments are
no longer due, Buyer will provide to Seller a final written report that complies in all respects with this Section 3.3. Buyer will require each Affiliate and sublicensee to make appropriate reports to Buyer in a timely manner to enable
Buyer to comply with this Section 3.3. Buyer shall provide Seller a similar report containing the information in subsections (a) and (b) above upon payment of the Milestone Payments. 
 3.4 Accounting. The Net Sales used for computing the Revenue Payments payable to Seller by Buyer will be computed in U.S. dollars. If Buyer or an
Affiliate or a sublicensee sells any Cardene PMB Product for currency other than U.S. currency, for purposes of calculating the earned Revenue Payments payable to Seller, Buyer will determine the Net Sales for the Cardene PMB Product in such
currency and then convert the Net Sales into its equivalent in U.S. currency using the average New York foreign exchange selling rate for such currency for the month in which such sale is reported, as published by The Wall Street Journal. If such
rate is not so published, the conversion will be at the average selling rate for such currency for the month in which such sale is reported, as published by a leading New York, New York bank chosen by Buyer and reasonably acceptable to Seller (such
acceptance not to be unreasonably withheld, delayed or conditioned). 
 3.5 Records; Audits. Buyer shall keep, and shall cause its
Affiliates and third party sublicensees to keep, full and accurate records and books of account containing all particulars that may be necessary for the purpose of calculating Net Sales. Such records and books of account, with all necessary
supporting data, shall be kept by Buyer (or its Affiliates or sublicensees) at its place of business or at another location under Buyer’s control for the [****]* next following the end of the calendar year to which each shall pertain. Upon
written request from Seller, and in no event more than (i) [****]* and (ii) [****]* of the Closing Date 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 18 

 thereafter, Buyer shall permit an independent nationally recognized accounting firm selected by Seller and reasonably
acceptable to Buyer, which acceptance shall not be unreasonably withheld, delayed or conditioned, to have access after reasonable advance notice ([****]*) and during normal business hours to such records and books of account as may be reasonably
necessary to verify the accuracy of the Buyer’s reports of Net Sales as provided herein. Notwithstanding the preceding sentence, Seller may make additional requests if Seller in good faith believes that there is reasonable cause to make such
additional requests based on findings in prior reports. All such verifications shall be conducted at the expense of Seller. In the event any such audit concludes that adjustments should be made in Seller’s favor, Seller shall provide to Buyer a
complete copy of the accountant’s written report reflecting such adjustments. Buyer shall have the right to dispute such adjustments in good faith by providing written notice of such dispute to Seller within thirty (30) days of the date on
which the applicable written report is received by Buyer. Any dispute shall be resolved in accordance with the provisions of Section 14.4. Buyer shall pay the amounts, if any, finally determined to be due (plus accrued interest thereon,
from the date originally due, at the annual rate announced by the Bank of America (or any successor) as its prime rate in effect on the date that such payment was first due [****]* promptly, and in no event later than thirty (30) days after the
date Buyer receives Seller’s accounting firm’s written report or the dispute is resolved in accordance with Section 14.4, as the case may be. The fees charged by the accounting firm shall be paid by [****]* unless the audit (or
final resolution, if applicable) reflects that adjustments in favor of [****]* for the [****]* or more of the aggregate amount paid or payable by [****]* to [****]* during the period, in which case [****]* shall pay the reasonable fees and expenses
charged by such accounting firm, promptly after receipt of the invoice for such audit. Seller agrees that all information subject to review under this Section 3.5 is Confidential Information of Buyer and that it shall cause its
accounting firm to retain all such information subject to the confidentiality restrictions set forth in this Agreement. 
 3.6 Late
Payments. Any payment owed under this Agreement that is not paid on or before the date that is [****]* following the date on which such payment becomes due pursuant to this Agreement shall accrue interest, to the extent permitted by law, at the
annual rate announced by Bank of America (or its successor) as its prime rate in effect on the date that such payment was first due [****]* until the date on which such payment is made. 
 3.7 Allocation of Purchase Price. Prior to Closing, Buyer and Seller will make reasonable efforts to agree on an allocation of the Initial
Purchase Price (and any Assumed Liabilities properly included for tax purposes) among the Assets in a manner that is consistent with the principles of Section 1060 of the Internal Revenue Code of 1986, as amended (or any successor provision of
any future tax law, or any comparable provision of state, local or foreign tax law). If the parties are able to agree to an allocation of the Initial Purchase Price pursuant to the preceding sentence, Buyer and Seller will (i) act in accordance
with such allocation in the preparation and filing of all Tax returns (including the preparation and filing of IRS Form 8594), (ii) take no position inconsistent with the allocation for all Tax purposes, and (iii) allocate any post-Closing
payments made pursuant to Sections 3.1 or 3.3 consistent with the methodology used in such allocation. In the event that such allocation is disputed by any taxing authority, the party receiving notice of the dispute shall promptly
notify the other party hereto and shall forward to such other party copies of all correspondence with such taxing authority in respect of such disputed allocation. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 19 

 ARTICLE 4 
 CLOSING 
 4.1 Closing. The Closing of the sale, transfer, assignment, conveyance, delivery,
license or sublicense of the Assets to Buyer, and the consummation of the other transactions contemplated hereby shall be held at the offices of Seller (the “Closing”) as promptly as practicable, but no later than the date five
(5) business days after all conditions (other than the respective delivery obligations of the parties) hereto have been satisfied or waived, or at such other time or date as may be agreed to by the parties to this Agreement (the
“Closing Date”). The Closing shall have deemed to have occurred on 11:59 pm on the Closing Date. 
 4.2 Actions at
Closing. At the Closing, sale, transfer, assignment, conveyance, delivery, license or sublicense of the Assets to Buyer will be effected by Seller pursuant to such good and sufficient instruments of conveyance, transfer and assignment as shall
be necessary to transfer to Buyer good and valid title to the Assets. 
 (a) Deliveries by Seller at Closing. The
purchase of the Assets by Buyer in accordance with the terms of this Agreement are subject to Seller’s delivery to Buyer at the Closing of the following instruments, documents, agreements and certificates: 
 i. the General Assignment and Bill of Sale substantially in the form attached hereto as Exhibit A (the “Bill of
Sale”), duly executed by Seller; 
 ii. a counterpart of the Assignment and Assumption Agreement substantially in the
form attached hereto as Exhibit B (the “Assignment and Assumption Agreement”), duly executed by Seller; 
 iii. the Patent Assignment Agreement substantially in the form attached hereto as Exhibit C (the “Patent Assignment Agreement”), duly executed by Seller; 
 iv. the Trademark Assignment Agreement substantially in the form attached hereto as Exhibit D (the “Trademark Assignment
Agreement”), duly executed by Seller; 
 v. the Domain Name Assignment Agreement substantially in the form attached
hereto as Exhibit E (the “Domain Name Assignment Agreement”), duly executed by Seller; 
 vi. a
counterpart of the Transition Services Agreement, substantially in the form attached hereto as Exhibit F, duly executed by Seller; 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 20 

 vii. the Third Party Consents listed in Attachment 4.2(a), in substantially the
form attached hereto as Exhibit G, signed by an authorized representative of each of the consenting parties to such agreements, and such Third Party Consents (a) shall not be subject to the satisfaction of any condition that has not been
satisfied or waived, and (b) shall be in full force and effect; 
 viii. a counterpart of the Escrow Agreement, ,
substantially in the form attached hereto as Exhibit H, duly executed by Seller and Escrow Agent; 
 ix. a counterpart
of the Litigation Cooperation Agreement, duly executed by Seller; 
 x. such other documents and agreements as may be
necessary to effect the transactions contemplated by this Agreement; 
 xi. a certificate executed by a duly authorized
officer of Seller certifying that (i) each of the representations and warranties of Seller set forth in Article 6 of this Agreement that is qualified by materiality is true and correct in all respects, (ii) each of such
representations and warranties that is not so qualified is true and correct in all material respects, in each case, as of the Closing Date as though made on and as of the Closing Date or, in the case of representations and warranties made as of a
specified date earlier than the Closing Date, on and as of such earlier date, except that any such representation or warranty made as of a specified date shall only need to have been true and correct on and as of such date, and (iii) all of the
terms, covenants and conditions of this Agreement to be complied with and performed by Seller, at or prior to the Closing have been duly complied with and performed in all material respects; 
 xii. a certificate of the Secretary of Seller, in form and substance reasonably satisfactory to Buyer, as to the authenticity and
effectiveness of the actions of the board of directors of Seller authorizing this Agreement and the transactions contemplated in this Agreement; 
 xiii. evidence, in form and substance reasonably satisfactory to Buyer, that Seller has fully paid all fees, costs and expenses payable pursuant to Section 8.6; 
 xiv. for each NDA identified and each IND identified on Attachment 2.1(e), a letter from Seller to the FDA, in form and substance
reasonably satisfactory to Buyer, stating that all rights with respect to the respective application have been transferred to Buyer as of the Closing Date; and 
 xv. a certification as to Seller’s non-foreign status in accordance with U.S. Treasury Regulations Section 1.1445-2(b)(2).

 (b) Deliveries by Buyer at Closing. The sale of the Assets by Seller in accordance with the terms of this Agreement
are subject to Buyer’s delivery to Seller (unless noted otherwise) at the Closing of the following instruments, agreements and certificates: 
 i. the Initial Purchase Price, less the Escrow Amount; 
 ii. evidence of payment of the
Escrow Amount to the Escrow Agent; 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 21 

 iii. a counterpart of the Assignment and Assumption Agreement, duly executed by Buyer;

 iv. a counterpart of the Transition Services Agreement, duly executed by Buyer; 
 v. a counterpart of the Escrow Agreement, duly executed by Buyer and Escrow Agent; 
 vi. a counterpart of the Litigation Cooperation Agreement, duly executed by Buyer; 
 vii. a certificate executed by a duly authorized officer of Buyer certifying that (i) each of the representations and warranties of
Buyer set forth in Article 7 of this Agreement that is qualified by materiality is true and correct in all respects, (ii) each of such representations and warranties that is not so qualified is true and correct in all material respects,
in each case, as of the Closing Date as though made on and as of the Closing Date or, in the case of representations and warranties made as of a specified date earlier than the Closing Date, on and as of such earlier date, except that any such
representation or warranty made as of a specified date shall only need to have been true and correct on and as of such date, and (iii) all of the terms, covenants and conditions of this Agreement to be complied with and performed by Buyer, at
or prior to the Closing have been duly complied with and performed in all material respects; 
 viii. a certificate of the
Secretary of Buyer, in form and substance reasonably satisfactory to Seller, as to the authenticity and effectiveness of the actions of the board of directors (and shareholders, if applicable) of Buyer authorizing this Agreement and the transactions
contemplated in this Agreement. 
 ARTICLE 5 
 EMPLOYMENT MATTERS 
 5.1 Employees. 
 (a) Notwithstanding the provisions of the Confidentiality Agreement, Buyer shall have the right prior to Closing to contact the employees
of Seller currently employed in the Business, who are identified on Attachment 5.1(a) (each, a “Business Employee”), and to discuss possible terms of employment with such Business Employees and Buyer may make offers of
employment, contingent on the Closing, to any of such Business Employees in its discretion. Buyer shall deliver to Seller a list of the Business Employees to whom Buyer has or intends to make offers of employment (each, an “Identified
Employee”) at least fifteen (15) days prior to the date of the Closing. The Seller shall use reasonable best efforts to cooperate with Buyer to facilitate the hiring of the Identified Employees. Seller and its Affiliates shall not make
competing offers of employment to the Identified Employees and shall, for a period of [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 22 

 from the Closing Date, refrain from, directly or indirectly, employing, engaging or seeking to employ or
engage any Identified Employee that has been hired by Buyer, unless such employee (i) has resigned voluntarily at least [****]* prior to such employment or engagement (without any solicitation from Seller or any of its Affiliates) or has been
terminated by Buyer after the Closing Date or (ii) responds to any general media solicitation of employment or engagement by the Seller or its Affiliate. Notwithstanding the foregoing, nothing in this Agreement shall constitute a
commitment of Buyer to continue the employment of any Identified Employee for any period following the Closing Date, nor limit the right of Seller or its Affiliates to change any terms or conditions of employment of any employed Identified Employee
following the Closing Date. 
 (b) Prior to the Closing Date, or as promptly as possible thereafter, and not withstanding any
otherwise applicable Employee Benefit Plan, Seller shall take such actions, to be in effect as of the Closing Date or as promptly as possible thereafter, as are necessary to cause all Identified Employees who accept offers of employment from Buyer
(the “Hired Employees”) to be paid, on a pro-rata basis, any earned sales incentive compensation and other comparable pay for the period of employment ending on the date of termination of employment (including, without limitation,
the applicable bonuses for 2007 that would otherwise have been payable pursuant to any Seller Employee Benefit Plan, to the extent that such bonuses have not been paid prior to Closing), as well as any accrued vacation pay, sick leave, or other
payroll entitlements. Seller shall waive any notice requirements or other conditions applicable to any Hired Employee in connection with such employee’s termination of his or her employment with Seller. 
 (c) Seller shall take all action necessary to give any notification required by the Worker Adjustment and Retraining Notification Act
(“WARN”), comply with any requirements of the Consolidated Omnibus Budget Reconciliation Act of 1985 and pay any and all severance, vacation, paid time off, unpaid wages, unpaid bonuses, unpaid commissions or other sums that may be
due to Business Employees in connection with their termination of employment with Seller, if any, or otherwise pursuant to the terms of any of Seller’s employee benefit plan. Buyer shall provide to Seller in a timely manner any information
reasonably necessary to determine whether an Identified Employee has been offered employment in a comparable position and such other information as is reasonably necessary for Seller to comply with its obligations, if any, under WARN or any similar
state law, rule or regulation with respect to Seller’s termination of the employment of any Business Employees. 
 ARTICLE 6 

REPRESENTATIONS AND WARRANTIES OF SELLER 
 Subject to the exceptions and disclosures listed in the Disclosure Schedule (including the attachments and exhibits thereto) Seller represents and warrants to Buyer as follows: 
 6.1 Organization and Authority. Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of
Delaware with full corporate power and authority to execute and consummate this Agreement, and such other instruments, agreements and transactions as may be contemplated hereunder and thereunder. Seller has all requisite corporate power and
authority and all authorizations, licenses, permits and certifications necessary to carry on the Business as now being conducted and to own, lease and operate the 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 23 

 Assets. Seller is qualified as a foreign corporation to do business in every jurisdiction in which the nature of its
business or its ownership of property requires it to be qualified and in which the failure to be so qualified would have a Material Adverse Effect. All corporate acts and other proceedings required to be taken by or on the part of Seller to
authorize Seller to execute, deliver and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken, and no further action on the part of Seller or its
stockholders is necessary. This Agreement has been duly executed and delivered by Seller and constitutes legal, valid and binding obligations of Seller enforceable in accordance with its terms, except as such enforceability may be subject to or
limited by (i) applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting the enforcement of creditors’ rights generally and (ii) the rules governing the availability of specific performance, injunctive
relief or other equitable remedies and general principles of equity, regardless of whether considered in a proceeding in law or equity. 
 6.2 No Violation or Conflict. The execution and delivery by Seller of this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, and the consummation by Seller of the transactions
contemplated hereby and thereunder will not (i) violate any law, statute, rule or regulation or judgment, order, writ, injunction or decree of any Governmental Entity applicable to Seller, or (ii) materially conflict with, result in any
material breach of, or constitute a material default (or an event which with notice or lapse of time or both would become a material default) under the Certificate of Incorporation or bylaws of Seller or any agreement to which Seller is a party,
(iii) materially interfere with Seller’s performance of its obligations hereunder, or (iv) result in the creation or imposition of any lien or encumbrance on Seller or the Assets, and to the Knowledge of Seller, there are currently no
proceedings pending before, or threatened by, any Governmental Entity that could reasonably be expected to result in the adoption, amendment or issuance of any law, statute, rule or regulation or judgment, order, writ, injunction or decree
materially adverse to the Assets or the Business. 
 6.3 Consents and Approvals. Except as set forth in Schedule 6.3 of the
Disclosure Schedule, no notice to, declaration, filing or registration with, or authorization, consent or approval of, or permit from, any Governmental Entity, or any other person or entity, is required to be made or obtained by Seller in
connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, except with respect to the HSR Filings and any declarations, filings, registrations, authorizations, consents,
approvals or permits which if not obtained or made have not had and would not reasonably be expected to have individually or in the aggregate a Material Adverse Effect or materially interfere with Seller’s performance of its obligations
hereunder. 
 6.4 Assumed Contracts. Seller has made available to Buyer complete and correct copies of the Assumed Contracts and any
amendments, modifications and supplements thereto. All the Assumed Contracts are in full force and effect and are valid, binding and enforceable in accordance with their terms by and against Seller, except as such enforceability may be subject to or
limited by (i) applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting the enforcement of creditors’ rights generally; and (ii) the rules governing the availability of specific performance, injunctive
relief or other equitable remedies and general principles of equity, regardless of whether considered in a proceeding in law or equity; provided that there may be Assumed Contracts that have expired by their terms, but contain surviving 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 24 

 
rights or Liabilities that will be assumed by Buyer. Except as set forth in Schedule 6.4(a) of the Disclosure Schedule, neither Seller nor, to the
Knowledge of Seller, any other party to such Assumed Contract is, or has received notice that it is, in violation or breach of or default under any such Assumed Contract (or with notice or lapse of time or both, would be in violation or breach of or
default under any such Assumed Contract) in any material respect. Schedule 6.4(b) of the Disclosure Schedule sets forth a list of all Assumed Contracts which require the consent or waiver of any party to such Assumed Contracts, to the
Assignment of such Assumed Contract as a result of the transactions contemplated hereby (the “Third Party Consents”). 
 6.5
Title to Assets. Upon the consummation of the transactions contemplated under this Agreement, Buyer will obtain good, valid and marketable title to all the Assets, free and clear of any and all liens, encumbrances, charges, claims, pledges,
or security interests of any kind (including those of secured parties). Except as set forth in Schedule 6.5 of the Disclosure Schedule, Seller beneficially owns all of the right, title or other interests to be transferred to Buyer hereunder
with respect to all the Assets, and none of the Assets is leased, rented, licensed, or otherwise not owned by Seller. The transactions contemplated hereby constitute the sale and assignment of substantially all of Seller’s business relating to
the CV Products. 
 6.6 Intellectual Property. 
 (a) Attachment 2.1. Attachment 2.1 sets forth a complete and accurate list of all of the following throughout the world
granted to, applied for, owned or licensed by Seller in relation to the CV Products: (i) Patents; (ii) Licensed IP Rights; (iii) Trademarks and Trademark Registrations; and (iv) Domain Names. Such list includes, where applicable,
the record owner, jurisdiction and registration and/or application number, and date issued (or filed) for each of the foregoing. The inventorship of the Patents and patent applications within Intellectual Property other than the Licensed IP Rights
(the “Owned IP Rights”) is true and correct as of the Effective Date. 
 (b) Title. Except as
otherwise stated on Attachment 2.1, Seller is the sole and exclusive owner of all Owned IP Rights and has the right to use the Licensed IP Rights as set forth in the applicable Assumed Contracts. Seller has the right to assign to Buyer the
Intellectual Property required to be assigned to Buyer under this Agreement, subject to obtaining the third party consents listed in Attachment 4.2(a). The Intellectual Property was either (i) developed by employees of Seller within the
scope of their employment; (ii) developed by independent contractors who have vested all rights in and to such Intellectual Property to Seller pursuant to written agreements (such as by assignment or work-made-for-hire provisions); or
(iii) obtained by Seller from a third party via a written agreement that transferred all rights in the Owned IP Rights to Seller or granted Seller a license to the Licensed IP Rights, as applicable. No current or former director, officer, or
employee of Seller or its Affiliates (or, to the Knowledge of Seller, any of its predecessors in interest) will, after giving effect to the transactions contemplated herein, own or retain any rights to use, and will not have any claim with respect
to any Intellectual Property. No royalties, honoraria or other fees are currently due and payable to any third parties for the use of or the right to use any (i) Owned IP Rights; or (ii) except as set forth in the Assumed Contracts,
Licensed IP Rights. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 25 

 (c) All Rights Transferred. After the consummation of the transactions
contemplated herein, Buyer will own all rights, title, and interest in and to or have a valid written license to use all Intellectual Property and the patents included within the Licensed IP Rights, subject to obtaining the Third Party Consents, on
the same terms and conditions as Seller enjoyed immediately prior to such transactions. Except for the Third Party Consents, there is no law, contract or arrangement that would prevent Seller from assigning all licenses and rights required to be
assigned under this Agreement. 
 (d) Sufficiency of Title. Seller is the sole and exclusive owner of or has valid
right to use pursuant to a written signed agreement, free and clear of all liens with respect to Owned IP Rights and, to the Knowledge of Seller, free and clear of all liens with respect to Licensed IP Rights. To the Knowledge of Seller, the
Intellectual Property constitutes all of the material intellectual property assets used in or necessary for the conduct of the Business as conducted by Seller as of the Effective Date. The Owned IP Rights, and, to the Knowledge of Seller, the
Licensed IP Rights, currently used in the Business, are in each case subsisting, in full force and effect, and have not been cancelled, expired, been abandoned, or otherwise terminated, and payment of all renewal and maintenance fees in respect of
the Owned IP Rights, and, to the Knowledge of Seller, the Licensed IP Rights, and all filings related thereto, have been duly made. Seller has been diligent in prosecuting all applications pending as of the Effective Date related to Owned IP Rights.

 (e) Non-infringement. To the Knowledge of Seller, the manufacture, sale and distribution of each CV Product as
conducted as of the Effective Date does not infringe upon, misappropriate, violate or constitute the unauthorized use of (either directly or indirectly, such as through contributory infringement or inducement to infringe) any intellectual property
rights of any third party in the relevant portion of the Territory for such CV Product. 
 (f) Pending Claims. Except
as set forth in Schedule 6.6(f) of the Disclosure Schedule, there are no pending or, to the Knowledge of Seller, threatened claims, suits, arbitrations or other adversarial proceedings before any court, agency, arbitral tribunal, or
registration authority in any jurisdiction in the applicable Territory challenging Seller’s ownership or use of any Intellectual Property, or the validity, enforceability, or registrability of any Owned IP Rights or, to the Knowledge of Seller,
any Licensed IP Rights. 
 (g) Third Party Infringement. Except as set forth in Schedule 6.6(g) of the Disclosure
Schedule, to the Knowledge of Seller, no third party in any Territory in which Intellectual Property rights have been granted, is misappropriating, infringing, diluting or violating any Owned IP Rights, or to the Knowledge of Seller, any
Licensed IP Rights, and no claims, suits, arbitrations or other adversarial claims have been brought or, to the Knowledge of Seller, threatened against any third party by Seller. 
 (h) Settlements. Except as set forth in Schedule 6.6(h) of the Disclosure Schedule, there are no settlement agreements,
coexistence agreements, consents, licenses, assignments, security agreements, judgments, consent decrees or judicial or administrative decisions relating to Owned IP Rights, or to the Knowledge of Seller, the Licensed IP Rights. 
 (i) Confidentiality. Seller has taken commercially reasonable measures to protect the confidentiality of its Trade Secrets and
Confidential Information, including requiring its employees with access to such Trade Secrets and Confidential Information and other parties having access thereto to execute written non-disclosure agreements. To the Knowledge of 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 26 

 
Seller, none of the Trade Secrets or Confidential Information have been disclosed or authorized to be disclosed to any third party other than pursuant to a
non-disclosure agreement. To the Knowledge of Seller, no third party to any non-disclosure agreement with Seller is in breach, violation or default thereof. 
 (j) Employee Cooperation. Each present or past employee, officer, consultant or any other person who participated on behalf of
Seller in the development of any of the CV Products or any of the Intellectual Property has executed a valid and enforceable agreement with Seller that (i) conveys any and all right, title and interest in and to all Intellectual Property
developed by such Person in connection with such Person’s employment or contract to Seller, (ii) requires such Person, during and after the term of employment or contract, to cooperate with Seller in the prosecution of any patent
applications filed in connection with such Intellectual Property, (iii) establishes a representation and covenant by such Person that no process, technique, innovation or other work product provided to Seller is or will be derived from or
otherwise constitute the proprietary information of a prior employer or contractor, in contravention of any prior confidentiality agreement, and (iv) obligates such Person to keep any Confidential Information of Seller confidential both during
and after the term of the employment or contract. To the Knowledge of Seller, no employee or consultant of Seller is in violation of any laws or regulations relating to Intellectual Property applicable to such employee or consultant, or any term of
any employment agreement, confidentiality agreement, patent or invention disclosure agreement or other contract relating to the relationship of such employee or consultant with Seller or any prior employer or client, as the case may be. 

(k) Notices. As of the Effective Date, Seller has not received any notice (including, without limitation, any [****]*) pursuant
to [****]* by and between Seller and [****]*, as such agreement may be amended from time to time, and to the Knowledge of Seller as of the Effective Date, there are no facts or circumstances that could reasonably be expected to result in any such
notice. 
 (l) Registrations; Regulatory Matters. All Registrations held by Seller with respect to the CV Products are
listed on Attachment 2.1(e). The Registrations are owned exclusively by Seller. To Seller’s Knowledge, all of the Registrations are valid and in full force and effect as of the Effective Date. The Registrations (i) are in the name
of Seller; and (ii) except as set forth in Schedule 6.6(l) of the Disclosure Schedule, constitute all licenses, permits, approvals, qualifications, authorizations or requirements of any Governmental Entity in the applicable Territory
necessary to manufacture and sell the Marketed Products in the applicable Territory. Seller has furnished Buyer with access to a complete copy of the NDA, including all amendments and supplements thereto. Each of the Registrations has been approved
by the FDA or other relevant Governmental Entity, as the case may be, and each of the Registrations is in good standing with the FDA or other relevant Governmental Entity, as the case may be. There is no action or proceeding by any Governmental
Entity pending or, to the Knowledge of Seller as of the Closing Date, threatened seeking the revocation or suspension of any Registration relating to the manufacture or sale of the Marketed Products in the applicable Territory. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 27 

 6.7 Regulatory Status of Marketed Products. Except as set forth on Schedule 6.7 of the
Disclosure Schedule, there have been no recalls, withdrawals, or market replacements of the Marketed Products in the applicable Territory in the past [****]*. 
 6.8 Product Net Sales. Seller’s net sales of each of the Marketed Products as set forth on Schedule 6.8 of the Disclosure Schedule, for the periods specified therein, are accurate and were
determined in accordance with GAAP. 
 6.9 Violations of Law. The utilization of the Assets and the conduct of the Business by Seller
and its Affiliates and their respective agents and employees do not violate any applicable law, governmental specification, authorization or requirement or any decree, judgment, order or similar restriction binding on the Seller or any of its
Affiliates in any material respect. Seller has not received notice of any Governmental Entity investigation, claim or proceeding concerning compliance matters relating to the CV Products or the Business, or the business practices of Seller or any of
its Affiliates or any of their respective agents or employees, including without limitation business practices related to the pricing, promotion and manufacturing of the Marketed Products. 
 6.10 Litigation. Neither the Assets nor the Business is the subject of any outstanding judgment, order, writ, injunction or decree of any court,
arbitrator or administrative or Governmental Entity limiting, restricting or affecting the Assets or the Business in any material aspect. Except as set forth on Schedule 6.10 of the Disclosure Schedule, there are no claims, suits, proceedings
pending or, to the Knowledge of Seller, threatened in writing against Seller or any of its Affiliates or any of their respective agents or employees with respect to the Assets, Business or transactions contemplated in this Agreement. 
 6.11 Employees. Except as set forth in Schedule 6.11 of the Disclosure Schedule, the Business Employees listed in Attachment 5.1(a)
are all the employees of Seller whose efforts and responsibilities are material to the Business. As of the Effective Date, to the Knowledge of Seller, no Business Employee and no group of Business Employees has any plans to terminate his or her
employment with Seller. To the Knowledge of Seller, Seller and its Affiliates have complied with all laws relating to the employment of labor, including provisions thereof relating to wages, hours, equal opportunity, collective bargaining and the
payment of social security and other taxes. Seller and its Affiliates have no material labor relations problem pending relating to the Business Employees and their labor relations relating to the Business Employees are satisfactory. There are no
workers’ compensation claims pending against Seller or its Affiliates relating to a Business Employee nor is Seller or its Affiliates aware of any facts that would give rise to such a claim. To the Knowledge of Seller, no Business Employee is
subject to any secrecy or non-competition agreement or any other agreement or restriction of any kind that would impede in any way the ability of such employee to carry out fully all activities of such employee in furtherance of the Business. With
respect to each Employee Benefit Plan (i) Seller and its Affiliates have complied and are now in compliance with all laws and regulations applicable to such Employee Benefit Plans and (ii) each Employee Benefit Plan has been 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 28 

 administered in all material respects in accordance with its terms. Attachment 5.1(a) lists, as of the date set
forth on such attachment, each Business Employee and the position, title, remuneration (including any scheduled salary or remuneration increases), date of employment and accrued vacation pay of each such Business Employee. 
 6.12 Taxes. As of the Effective Date, there are no, and, at the Closing, there will not be, any liens for Taxes accrued upon the Assets. Any and
all Taxes related to the Assets or the Business, to the extent payable prior to the Closing, have been or will be paid by Seller prior to the Closing. No jurisdiction (whether within or without the United States) in which the Seller or any Affiliate
of Seller has not filed a specific Tax Return with respect to the Assets or the Business has asserted that the Seller or such Affiliate is required to file such Tax Return in such jurisdiction. Seller and each Affiliate of Seller has complied (and
until the Closing Date will comply) with all applicable laws, rules, and regulations relating to the payment and withholding of Taxes relating to the Assets or the Business (including withholding and reporting requirements under Code
§§3401 through 3406, 6041 and 6049 and similar provisions under any other laws) and has, within the time and in the manner prescribed by law, withheld from employee wages and paid over to the proper governmental authorities all required
amounts. 
 6.13 Customers and Suppliers. Schedule 6.13 of the Disclosure Schedule lists the [****]* largest customers and
suppliers of Seller relating to each of the Marketed Products for the fiscal years ended December 31, 2006 and December 31, 2007 and sets forth opposite the name of each such customer or supplier the approximate percentage of gross sales
attributable from such customers or cash payments attributable to such suppliers, and unit sales for each such customer, for each such period. Since December 31, 2006, no customer or supplier listed on Schedule 6.13 of the Disclosure
Schedule has advised in writing that it will stop or materially decrease the rate of business done with Seller except for changes in the ordinary course of Seller’s business. 
 6.14 Inventory; Raw Materials and WIP. The Product Inventory, Raw Materials and WIP relating to the Marketed Products consist of items of a
quality and quantity usable and, with respect to finished goods only, salable at Seller’s normal profit levels, in each case, in the ordinary course of the business. Seller’s inventory of finished goods generated by the Business is not
slow-moving as determined in accordance with past practices, obsolete or damaged and is merchantable and fit for its particular use. Seller has on hand or has ordered and expects timely delivery of such quantities of Raw Materials and has on hand
such quantities of WIP and Product Inventory as are reasonably required to timely fill current orders on hand with respect to the Marketed Products which require delivery within [****]* and to maintain the manufacture and shipment of products at its
normal level of operations. Schedule 6.14(a) of the Disclosure Schedule contains a materially complete and accurate summary of the Product Inventory, Raw Materials and WIP relating to each of the Marketed Products as of December 31,
2007. Since January 1, 2007, sales of the Marketed Products by Seller to its distributors, licensees and 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 29 

 wholesalers were made consistent with past practices and were not the result of any special or extraordinary sales
efforts or promotions by Seller or such distributors, licensees and wholesalers. The level of inventory of the Marketed Products held by Seller’s distributors, licensees and wholesalers is consistent with practice in effect during calendar year
2007 and, on the Closing Date, will not exceed a level that would be reasonably expected to be sold in the ordinary course of business, consistent with past practice, during calendar year 2007, within [****]* thereof. Seller has no reason to believe
that such inventory will be subject to returns, discounts or charge-backs that, in the aggregate, are materially worse than those experienced during calendar year 2007. Schedule 6.14(b) of the Disclosure Schedule lists all of the Packaging
Inventory owned by Seller as of the Effective Date. 
 6.15 Clinical Trials. 
 (a) Schedule 6.15(a) of the Disclosure Schedule is an accurate and complete list of all Clinical Trials initiated by Seller prior
to the Effective Date. To Seller’s Knowledge, the Clinical Trials were conducted in material compliance with Good Clinical Practice, the reporting of adverse events, the filing of reports and security promulgated by the FDA and similar
regulations promulgated by other Governmental Entities as applicable to such trials. For the purposes of this Section 6.15, “Good Clinical Practice” means current good clinical practice pursuant to the FD&C Act and
the relevant U.S. regulations in Title 21 of the U.S. Code of Federal Regulations (including Parts 11, 50, 54, 56, 312, 314 and 601). 
 (b) Other than as disclosed on Schedule 6.15(b) of the Disclosure Schedule, during the Clinical Trials, there have been no deaths or serious adverse events. 
 (c) Seller has not received any written notices or other written correspondence from the FDA or any other Governmental Entity requiring
the termination or suspension of any Clinical Trials. 
 6.16 Absence of Change. Except as disclosed in Schedule 6.16 of the
Disclosure Schedule, except for the execution and delivery of this Agreement and the transactions to take place pursuant hereto on or prior to the Closing Date, since September 30, 2007 there has not been any Material Adverse Change, or any
event or development which, individually or together with other such events, could reasonably be expected to result in a Material Adverse Change. Without limiting the foregoing, except as disclosed in Schedule 6.16 of the Disclosure Schedule,
there has not occurred, between September 30, 2007 and the date hereof, any physical damage, destruction or other casualty loss (whether or not covered by insurance) affecting any of the assets of Seller or its Affiliates used or held for use
in the conduct of the Business in an aggregate amount [****]*. 
 6.17 No Undisclosed Liabilities. There are no Liabilities against,
relating to or affecting the Business or any of the Assets, other than Liabilities (i) incurred in the ordinary course of business consistent with past practice, (ii) under the Assumed Contracts, or (iii) which, individually or in the
aggregate, are not material to the condition of the Business. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 30 

 6.18 Sufficiency. The Assets and Buyer’s rights under this Agreement constitute all of the
material assets that are necessary for Buyer to operate the Business as of and after the Closing Date in substantially the same manner as the Business was operated by Seller (and Seller’s Affiliates) on the Effective Date. 
 6.19 Brokers and Finders. Except as set forth in Schedule 6.19 of the Disclosure Schedule, Seller has not employed any broker or finder or
incurred any Liability for any brokerage fee, commission or finder’s fee in connection with the transactions contemplated by this Agreement. 
 6.20 No Implied Warranty. THE REPRESENTATIONS AND WARRANTIES GIVEN HEREIN BY SELLER ARE IN LIEU OF ANY IMPLIED WARRANTIES WHICH MAY OTHERWISE BE APPLICABLE BECAUSE OF THE PROVISIONS OF THE UNIFORM COMMERCIAL CODE OR ANY OTHER
STATUTE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. Seller makes no representation or warranty with respect to (i) any forecasts, projections, estimates or budgets delivered or made
available to Buyer of future revenues, future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof) of the Business or (ii) any other information or documents made available
to Buyer or its counsel, accountants or advisors with respect to the Business, except as expressly set forth in this Agreement or the exhibits hereto; provided, that Seller does represent and warrant that it has neither intentionally provided
or made available to Buyer any untrue information, nor intentionally omitted any material fact or information regarding the Assets, the Product or the Business or any of the other matters dealt with in this Article 6 relating to Seller or the
transactions contemplated by this Agreement. 
 ARTICLE 7 
 REPRESENTATIONS AND WARRANTIES OF BUYER 
 7.1 Organization and Authority. Buyer is a
corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Buyer has full corporate power and authority to execute and deliver this Agreement and such other instruments, agreements and transactions as
may be contemplated hereunder, and to perform its obligations hereunder and thereunder. All corporate acts and other proceedings required to be taken by or on the part of Buyer to authorize Buyer to execute, deliver and perform this Agreement and
such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken, and no further action on the part of Buyer or its stockholders is necessary. This Agreement has been duly executed and delivered
by Buyer and constitutes the legal, valid and binding obligation of Buyer enforceable in accordance with its terms, except as such enforceability may be subject to or limited by (i) applicable bankruptcy, reorganization, insolvency, moratorium
and similar laws affecting the enforcement of creditors’ rights generally and (ii) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity, regardless of
whether considered in a proceeding in law or equity, regardless of whether considered in a proceeding in law or equity. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 31 

 7.2 No Conflict or Violation. The execution and delivery by Buyer of this Agreement and such other
instruments, agreements and transactions as may be contemplated hereunder and the consummation by Buyer of the transactions contemplated hereby and thereunder will not (i) violate any law, statute, rule or regulation or judgment, order, writ,
injunction or decree of any Governmental Entity applicable to Buyer, or (ii) materially conflict with, result in any material breach of, or constitute a material default (or an event which with notice or lapse of time or both would become a
material default) under the Certificate of Incorporation or bylaws of Buyer or any agreement to which Buyer is a party, or (iii) materially interfere with Buyer’s performance of its obligations hereunder. 
 7.3 Consents and Approvals. Except as set forth in Schedule 7.3, no notice to, declaration, filing or registration with, or authorization,
consent or approval of, or permit from, any Governmental Entity, or any other person or entity, is required to be made or obtained by Buyer in connection with the execution, delivery and performance of this Agreement and the consummation of the
transactions contemplated hereby, except with respect to the HSR Filings and except for declarations, filings, registrations, authorizations, consents, approvals or permits which if not obtained or made have not had and would not reasonably be
expected to have individually or in the aggregate a material adverse effect on Buyer or materially interfere with Buyer’s performance of its obligations hereunder. 
 7.4 Cash Resources. Buyer has, prior to the execution of this Agreement, delivered to Seller, true and complete copies of written commitments of third parties to provide Buyer with the financing (in the form of
both equity and debt) required for Buyer’s acquisition of the Business hereunder. Subject to the funding of the funds set forth in the written commitments, in each case, in accordance with and subject to their terms and conditions, Buyer will
have at Closing cash in an amount sufficient to pay the Purchase Price at the Closing and any and all fees and expenses relating to the transactions contemplated under this Agreement and specifically acknowledges Seller has entered into this
Agreement in reliance upon this representation. 
 7.5 Litigation. There are no actions, suits, proceedings or claims pending or, to
the Knowledge of Buyer, threatened in writing concerning Buyer or any of its Affiliates with respect to the transactions contemplated in this Agreement. 
 7.6 Brokers and Finders. Except as set forth in Schedule 7.6, Buyer has not employed any broker or finder or incurred any Liability for any brokerage fee, commission or finder’s fee in connection
with the transactions contemplated by this Agreement. 
 7.7 Buyer Due Diligence. Buyer is experienced, and/or has engaged expert
advisors experienced in the evaluation and purchase of property and assets such as the Assets contemplated hereunder. Buyer has undertaken such investigation and has been provided with and has evaluated such documents and information as it has
deemed necessary to permit it to make an informed and intelligent decision with respect to the execution, delivery and performance of this Agreement. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 32 

 ARTICLE 8 
 PRE-CLOSING COVENANTS 
 8.1 Governmental Filings. Buyer and Seller shall cooperate in promptly
undertaking all filings required to be filed with any Governmental Entity in connection with the transfer of Assets and other rights under this Agreement and to cooperate with one another as reasonably necessary to accomplish the foregoing,
including, but not limited to, the filings required of both parties pursuant to the HSR (such filings sometimes being referred to in this Agreement as the “HSR Filings”), and the filing of any additional information as required with
respect to such HSR Filings as soon as practicable after receipt of request therefor from the United States Federal Trade Commission. All filing fees related to the HSR Filings shall be [****]*. 
 8.2 Conduct of Business. During the period on and from the Effective Date through and including the Closing Date, Seller will conduct the Business
only in the ordinary course consistent with past practices, unless Buyer shall otherwise agree in writing. Without limiting the generality of the foregoing, 
 (a) Seller will: 
 i. use commercially reasonable efforts to (i) keep available (subject to dismissals and retirements in the ordinary course of business consistent with past practice) the services of the Business Employees, (ii) maintain the good
will of wholesalers, customers, suppliers, lenders and other persons and entities to whom Seller sells goods or provides services or with whom Seller otherwise has significant business relationships in connection with the Business, and
(iii) continue all current sales, marketing and promotional activities relating to the Business; 
 ii. except to the
extent required by applicable law, (i) cause the Books and Records to be maintained in the usual, regular and ordinary manner, and (ii) not permit any material change in any pricing, investment, accounting, financial reporting, inventory,
credit, allowance or Tax practice or policy of Seller or its Affiliates that would adversely affect the Business, the Assets or the Assumed Liabilities; 
 iii. comply, in all material respects, with all laws and orders applicable to the Business and promptly following receipt thereof give Buyer copies of any notice received from any Governmental Entity or any other
person or entity alleging any violation of any such law or order; 
 iv. work diligently and in good faith to complete, as
promptly as reasonably practicable, the application to be submitted to the FDA to obtain the Initial FDA Approval, such application to be in form and substance reasonably satisfactory to Buyer; provided, if Seller completes such application
prior to the Closing Date and the application is in form and substance reasonably satisfactory to Buyer, then Seller will promptly file such application with the FDA; 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 33 

 v. work diligently and in good faith to [****]* and any and all work and agreements
relating thereto and [****]* related thereto; and 
 vi. promptly provide to Buyer written notice of (i) any formal
action taken, or non-privileged communication made, by Seller or any other party to the Sun Litigation in connection therewith, and (ii) Seller’s filing of any citizen’s petition or issuance of any other response in connection with
the [****]* and, in the case of this subclause (ii), shall not make any such filing or issue any such response without the prior written consent of Buyer. 
 (b) Seller will refrain from: 
 i. entering into, amending, modifying, terminating (partially
or completely), granting any waiver under or giving any consent with respect to any Assumed Contract or any Registration; 
 ii. violating, breaching or defaulting under, in any material respect, or taking or failing to take any action that (with or without notice or lapse of time or both) would constitute a material violation or breach of, or default under, any
term or provision of any Assumed Contract or any Registration; 
 iii. waiving any right of Seller under any Liability of or
owing to Seller in connection with the Business, other than in the ordinary course of business consistent with past practice; 
 iv. engaging in any transaction with respect to the Business with any officer, director or Affiliate of Seller, either outside the ordinary course of business consistent with past practice or other than on an arm’s-length basis; and

 v. entering into any agreement to do or engage in any of the foregoing. 
 8.3 No Solicitation. Seller will not (and it will use its best efforts to assure that its officers, directors, employees, agents and affiliates do
not on its behalf) (a) take any action to solicit, initiate, seek, or affirmatively support any inquiry, proposal or offer from, any corporation, partnership, person or other entity or group (other than Buyer) relating to any acquisition of the
Business or any of the Assets, other than the marketing, sale and distribution of Product Inventory and use of Raw Materials in the ordinary course consistent with past practices (any such proposed transaction being a “Third Party
Acquisition”); or (b) participate in any discussions or negotiations with, or provide any non-public information to, any corporation, partnership, person or other entity or group (other than Buyer) relating to any proposed Third
Party Acquisition. Seller shall immediately terminate any such negotiations in progress as of the Effective Date. In no event will Seller accept or enter into an agreement concerning any such Third Party Acquisition prior to the termination of the
Agreement pursuant to Article 12. Notwithstanding this provision, nothing herein shall be deemed to in any way restrict or limit the right of Seller to engage in discussions, negotiations, furnishing of information or any other activities
relating to or in support of transactions involving the acquisition or sale of Seller and/or any other product lines or businesses of Seller other than the Business or the Assets, so long as this Agreement shall remain in full force and effect and
shall remain binding on the parties hereto. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 34 

 8.4 Access. During the period from the Effective Date and continuing until the Closing, upon
reasonable advance notice received from Buyer and at Buyer’s expense, Seller shall (i) afford Buyer, its financing sources and their representatives reasonable access to, during regular business hours, or furnish Buyer, its financing
sources and its representatives with copies of, documents used solely and specifically with respect to the Assets or the CV Products as Buyer may reasonably request, and (ii) otherwise cooperate and assist with Buyer’s and its financing
source’s investigation of the Assets and the CV Products as Buyer may reasonably request. 
 8.5 Financing. 
 (a) Buyer will use best efforts to (i) enter into definitive agreements providing for the financing of Buyer’s consummation of
the transactions contemplated hereby, containing terms substantially similar to those set forth in the commitment letters referred to in Section 7.4, (ii) obtain and consummate on the Closing Date the financing contemplated by such
definitive financing agreements, and (iii) ensure that Buyer’s equity investors comply with the provisions of the equity commitment letters referred to in Section 7.4 and enforce such provisions against such equity investors to ensure
the consummation of the financing of Buyer’s consummation of the transactions contemplated hereby. 
 (b) [****]*.

 8.6 Payment of Certain Expenses. Seller shall, on or prior to the Closing Date, pay in full any and all fees, cost and expenses
incurred or accrued with respect to the Sun Litigation (including attorneys’ fees) through the Closing and shall provide Buyer with evidence reasonably satisfactory to Buyer that all such amounts have been paid. 
 8.7 Transition Services Agreement. Seller and Buyer shall enter into the Transition Services Agreement on the Closing Date, in substantially the
same form and on substantially the same terms as set forth in Exhibit F, pursuant to which Seller will provide to Buyer the transition services requested by it, which services may include, without limitation, regulatory, supply chain
management, intellectual property and other services. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 35 

 ARTICLE 9 
 CONDITIONS TO CLOSING 
 9.1 Conditions to Obligations of Buyer. All obligations of Buyer
hereunder are, at the option of Buyer, subject to the conditions precedent that (all or any of which may be waived by Buyer, in whole or in part), at the Closing: 
 (a) All consents, approvals and actions of, filings with and notices to any Governmental Entity necessary to permit Buyer and Seller to
perform their obligations under this Agreement and to consummate the transactions contemplated hereby (a) shall have been duly obtained, made or given, (b) shall be in form and substance reasonably satisfactory to Buyer, (c) shall not
be subject to the satisfaction of any condition that has not been satisfied or waived and (d) shall be in full force and effect, and all terminations or expirations of waiting periods imposed by any Governmental Entity necessary for the
consummation of the transactions contemplated by this Agreement, including under the HSR, shall have occurred. 
 (b) There
shall not be in effect on the Closing Date any order or law restraining, enjoining or otherwise prohibiting or making illegal the consummation of any of the transactions contemplated by this Agreement or which could reasonably be expected to
otherwise result in a Material Adverse Effect and there shall not be pending or threatened on the Closing Date any action or proceeding in, before or by any Governmental Entity which could reasonably be expected to result in the issuance of any such
order or the enactment, promulgation or deemed applicability to Buyer or the transactions contemplated by this Agreement of any such law. 
 (c) Seller shall have furnished to Buyer all deliverables set forth in Section 4.2(a), and shall have performed and complied with, in all material respects, each agreement, covenant and obligation required
by this Agreement to be so performed or complied with by Seller at or before Closing. 
 (d) Each of the representations and
warranties of Seller set forth in this Agreement that is qualified by materiality shall be true and correct in all respects, and each of such representations and warranties that is not so qualified shall be true and correct in all material respects,
in each case, as of the Closing Date as though made on and as of the Closing Date or, in the case of representations and warranties made as of a specified date earlier than the Closing Date, on and as of such earlier date. 
 (e) The level of inventory of the Marketed Products held by Seller’s distributors, licensees and wholesalers on the Closing Date
shall not exceed a level that would be reasonably expected to be sold in the ordinary course of business, consistent with past practice during the calendar year 2007, [****]*. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 36 

 (f) If Buyer shall have complied in all respects with its obligations under
Section 8.5(a), and Buyer shall have taken all material action that is within its reasonable control and required by it pursuant to the terms of the written commitments of third parties referred to in Section 7.4 and the
definitive agreements entered into in connection therewith, then it shall be a condition to Buyer’s obligations under this Agreement that it shall have obtained financing on terms substantially similar to those set forth in the commitment
letters referred to in Section 7.4 and in an amount sufficient to pay the Initial Purchase Price at Closing. 
 9.2 Conditions
to Obligations of Seller. All obligations of Seller hereunder are, at the option of Seller, subject to the conditions precedent that (all or any of which may be waived by Seller, in whole or in part), at the Closing: 
 (a) All consents, approvals and actions of, filings with and notices to any Governmental Entity necessary to permit Buyer and Seller to
perform their obligations under this Agreement and to consummate the transactions contemplated hereby (a) shall have been duly obtained, made or given, (b) shall be in form and substance reasonably satisfactory to Seller, (c) shall
not be subject to the satisfaction of any condition that has not been satisfied or waived and (d) shall be in full force and effect, and all terminations or expirations of waiting periods imposed by any Governmental Entity necessary for the
consummation of the transactions contemplated by this Agreement, including under the HSR, shall have occurred. 
 (b) There
shall not be in effect on the Closing Date any order or law restraining, enjoining or otherwise prohibiting or making illegal the consummation of any of the transactions contemplated by this Agreement and there shall not be pending or threatened on
the Closing Date any action or proceeding in, before or by any Governmental Entity which could reasonably be expected to result in the issuance of any such order or the enactment, promulgation or deemed applicability to Seller or the transactions
contemplated by this Agreement of any such law. 
 (c) Buyer shall have furnished to Seller all deliverables set forth in
subsections (i)-(iv), (vi), (viii) and (ix) of Section 4.2(b), and shall have performed and complied with, in all material respects, each agreement, covenant and obligation required by this Agreement
to be so performed or complied with by Buyer at or before Closing. 
 (d) Each of the representations and warranties of Buyer
set forth in this Agreement that is qualified by materiality shall be true and correct in all respects, and each of such representations and warranties that is not so qualified shall be true and correct in all material respects, in each case, as of
the Closing Date as though made on and as of the Closing Date or, in the case of representations and warranties made as of a specified date earlier than the Closing Date, on and as of such earlier date. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 37 

 ARTICLE 10 
 POST-CLOSING COVENANTS 
 10.1 Further Assurances. 
 (a) At any time or from time to time after Closing, at Buyer’s reasonable request and without further consideration, Seller shall
execute and deliver to Buyer such other instruments of sale, transfer, conveyance, assignment and confirmation, provide such materials and information and take such other actions as Buyer may reasonably deem necessary or desirable in order more
effectively to transfer, convey and assign to Buyer, and to confirm Buyer’s title to, all of the Assets, and, to the full extent permitted by law, to put Buyer in actual possession and operating control of the Business and the Assets and to
assist Buyer in exercising all rights with respect thereto, and otherwise to cause Seller to fulfill its obligations under this Agreement. Without limiting the foregoing, (i) if, on or prior to the [****]* of the Closing Date, either Buyer or
Seller becomes aware that an asset or property of Seller or its Affiliates that was used solely or primarily in, or that was necessary for the conduct of, the Business on the Effective Date, was not sold, transferred, assigned, conveyed and
delivered to Buyer on the Closing Date, then (A) if such asset or property was used solely in the Business on the Effective Date, Seller shall promptly sell, transfer, assign, convey and deliver such asset or property to Buyer, or (B) if
such asset or property was used primarily in, or was otherwise necessary for the conduct of, the Business on the Effective Date, Seller shall either promptly sell, transfer, assign, convey and deliver such asset or property to Buyer, or make such
asset or property available to Seller under a perpetual, paid-up, irrevocable, royalty-free, non-exclusive license, with the right to sublicense, in each case without any additional consideration being due to Seller, and (ii) in the event that
any Affiliate of Seller has any right, title or interest in any Asset (or any other asset used in the Business that would otherwise be an Asset if owned by Seller), then Seller shall cause such Affiliate to transfer and assign all such right, title
and interest to Buyer. 
 (b) Effective on the Closing Date, Seller hereby constitutes and appoints Buyer the true and lawful
attorney of Seller, with full power of substitution, in the name of Seller or Buyer, but on behalf of and for the benefit of Buyer: (i) to demand and receive from time to time any and all Assets and to make endorsements and give receipts and
releases for and in respect of the same and any part thereof; (ii) to institute, prosecute, compromise and settle any and all actions or proceedings that Buyer may deem proper in order to collect, assert or enforce any claim, right or title of
any kind in or to the Assets; (iii) to defend or compromise any or all actions or proceedings in respect of any of the Assets; and (iv) to do all such acts and things in relation to the matters set forth in the preceding clauses
(i) through (iii) as Buyer shall deem desirable. Seller hereby acknowledges that the appointment hereby made and the powers hereby granted are coupled with an interest and are not and shall not be revocable by it in any manner or for any
reason. Seller shall deliver to Buyer at Closing an acknowledged power of attorney to the foregoing effect executed by Seller. Buyer shall indemnify and hold harmless Seller from any and all Losses caused by or arising out of any breach of law by
Buyer in its exercise of such power of attorney. 
 (c) Seller agrees to cooperate with Buyer in enforcing any rights Seller
may have, contractual or otherwise, which Seller may retain after the Closing Date and which may relate to the Assets and/or the Business; provided, however, such enforcement must include a claim for damages attributable to
post-Closing periods. Seller agrees to appoint Buyer as its agent, with full authority to enforce such rights, and agrees to join in any litigation to the extent 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 38 

 deemed necessary by Buyer to protect Buyer’s interest in the Assets and/or the Business. Buyer shall
have the right to sue for and recover past, present and future damages resulting from Seller’s retained rights; provided, however, such suit must include a claim for damages attributable to post-Closing periods. To the extent such
damages can be attributed to damages occurring before the Closing Date, Buyer shall, to the extent recovered by Buyer, pay to Seller the portion of any total recovery minus costs of litigation attributable to such damages. Seller shall make
available to Buyer any of its employees, officers, and directors as requested by Buyer during the course of litigation. Seller shall promptly cooperate with Buyer at Buyer’s request in gathering information and in responding to any discovery or
other obligation of Buyer in preparation for or during the conduct of litigation. Subject to the allocation of costs of litigation stated above, Buyer shall, with respect to the services provided by Seller on Buyer’s request under this
Section 10.1(c), pay Seller’s expenses and indemnify Seller consistent with the provisions of Section 4 and Section 5 of the Litigation Cooperation Agreement. Seller shall promptly deliver copies of
all proprietary, inventions, confidentiality and similar agreements between Seller and any Business Employee, as well as such other agreements that Buyer may reasonably request from time to time for purposes of exercising its
rights under this Section 10.1(c), including, without limitation, agreements with past or present employees, agents or representatives. 
 10.2 Transfer of Registrations; Interim Responsibility. 
 (a) Promptly after the Closing Date, Seller shall
(i) send letters to the FDA and other Governmental Entities indicating that the Registrations are transferred to Buyer and that Buyer is the new owner of the Registrations as of the Closing Date and (ii) provide to Buyer a copy of said
letters. 
 (b) Promptly after the Closing Date, the parties will cooperate in transferring the Registrations to Buyer. The
target date for the transfer shall be agreed upon by the parties, but shall not be later than [****]* from the Closing Date. Prior to the Closing, the parties will agree upon procedures to ensure a smooth transition from Seller to Buyer of all of
the activities required to be undertaken by the Registration(s) holder, including adverse experience reporting, quarterly and annual reports to FDA, handling and tracking of complaints, sample tracking, and communication with health care
professionals and customers which shall be specified in the Transition Services Agreement or an amendment thereto. Within [****]* after the Closing Date, Seller will forward to Buyer a complete copy of the Registrations for the CV Products, as well
as copies of all correspondence with, and periodic and other reports (including adverse event reports and the underlying data) to, regulatory authorities in the applicable Territory. Seller will cooperate with Buyer to ensure a smooth transition of
the activities contemplated hereby, and in obtaining the cooperation of Seller and its distributors and licensees of the CV Products with the transfer of adverse experience reporting obligations from Seller to Buyer. 
 (c) Until the Registrations have been transferred to Buyer, Seller shall be responsible for maintaining them, at Seller’s sole cost
and expense. After such transfer, Buyer 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 39 

 will assume all responsibility for the Registrations, at Buyer’s sole cost and expense. Each party
shall cooperate with the other in making and maintaining all regulatory filings that may be necessary in connection with the execution, delivery and performance of this Agreement. 
 10.3 Communication With Agencies. Until the Registrations are transferred to Buyer, Seller shall have responsibility for all communications with
the FDA relating to the CV Products, and Seller will promptly provide Buyer with copies of all communications from the FDA with respect to the CV Products and/or the manufacture thereof, and Seller shall consult with Buyer and reflect the
Buyer’s reasonable requests regarding all communications to the FDA with respect to the CV Products and/or the manufacture thereof, prior to making such communication with the FDA. After such transfer has been completed, Buyer shall have
responsibility for all such communication it sends to or receives from any Governmental Entity in the applicable Territory concerning the CV Products. 
 10.4 Adverse Experience Reporting. 
 (a) Until the Registrations are transferred to
Buyer, Seller shall be responsible for the adverse experience and safety reporting for the CV Products in compliance with the requirements of the FD&C Act and the regulations promulgated thereunder. After the Registrations are transferred to
Buyer, Buyer shall assume such responsibility. Buyer and Seller agree to meet promptly after the Closing Date to determine mutually agreeable reporting procedures to communicate the information as required under this Section 10.4.

 (b) On or before the Closing Date, Seller shall provide Buyer with a summary of the information relating to the
investigation and reporting of adverse experiences regarding the CV Products and all appropriate information that is relevant to the safe use of the CV Products as of the Closing Date. 
 (c) After the Closing Date and until the Registrations are transferred to Buyer, Buyer agrees to promptly submit to Seller all adverse
drug experience information and customer complaints brought to the attention of Buyer with respect to the CV Products, as well as any material events and matters concerning or affecting the safety or efficacy of the CV Products. Such information or
customer complaints shall be forwarded to Seller to the attention of: 
  

					
		 	Name:	  	[****]*
		 	Title:	  	Medical Director, Drug Safety
		 	Address:	  	1400 Seaport Blvd
		 		  	Redwood City, CA 94063
		 	Facsimile:	  	650-454-1403
		 	Drug safety mailbox:	  	drugsafety@pdl.com

 (d) After the Registrations have been transferred to Buyer, Seller shall assist
Buyer with the provision of data relating to adverse experiences for the CV Products after such transfer to Buyer. Additionally, after the transfer of the Registrations to Buyer, Seller shall 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 40 

 provide Buyer with all adverse drug experience information and customer complaints brought to the
attention of Seller with respect to the CV Products, as well as any material events and matters concerning or affecting the safety or efficacy of the CV Products, via facsimile to the attention of: 
  

					
		 	Name:	  	[****]*
		 	Title:	  	Director of Regulatory Affairs
		 	Address:	  	7 East Frederick Place
		 		  	Cedar Knolls, NJ 07927
		 	E-mail:	  	[****]*

 10.5 Medical Inquiries. Promptly after the Registrations have been transferred to Buyer,
Buyer shall assume all responsibility for all correspondence and communication with physicians and other health care professionals and customers in the applicable Territory relating to the CV Products. After the Closing Date, Buyer and Seller shall
work together towards an orderly transition of the responsibility for all correspondence and communication with health care professionals and customers in the applicable Territory relating to the CV Products. Seller shall continue to be responsible
for such correspondence and communication under the direction of Buyer until the Registrations have been transferred to Buyer. Buyer shall keep such records and make such reports as shall be reasonably necessary to document such communications in
compliance with all applicable regulatory requirements. After transfer of responsibility to Buyer pursuant to this Article 10, Seller shall, except in the case of medical emergency, refer all questions relating to the CV Products raised by
health care professionals and customers to Buyer for its response. 
 10.6 Non-Use of Trademarks. Buyer covenants that, except as
expressly permitted in this Agreement, Buyer shall not use in any manner any trademark of Seller (other than the Trademarks listed in Attachment 2.1(c) and transferred to Buyer pursuant to this Agreement). 
 10.7 Documents. Seller will permit Buyer, its financing sources and their duly authorized representatives access during normal business hours
(upon written notice to Seller) to contracts and other data relating to the Business, the Assets conveyed and assumed at the Closing to the extent copies of such items were not delivered to Buyer. Buyer will permit Seller and its duly authorized
representatives access during normal business hours (upon written notice to Buyer) to all contracts and other data relating to the Assets conveyed and assumed at the Closing to the extent originals of such items were delivered to Buyer. Such access
by Buyer, Seller or such other person, as the case may be, shall be allowed until the later to occur of the expiration of the statute of limitations for the imposition of Tax with respect to the years to which such data pertain, or seven years from
the year to which such data pertain, provided that such access shall not unduly interfere with the business and affairs of the party or applicable Affiliate permitting such access. Buyer will cooperate with Seller, and Seller will cooperate with
Buyer, with respect to any Tax examinations, audits, contests or other Tax proceedings, relating to the Business. The party requesting assistance hereunder shall reimburse the other party for reasonable expenses incurred in providing such
assistance. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 41 

 10.8 Governmental Inspections. For a period of [****]* following the Closing Date each party shall
advise the other party of any governmental visits to, or written or oral inquiries about, any facilities (to the extent such visit relates to, or the results thereof could affect the manufacture or supply of, the CV Products) or procedures for the
manufacture, storage or handling of the CV Products, or the marketing, selling, promotion or distribution of any of the CV Products, promptly after any such visit or inquiry (or in advance, for any scheduled visits). During this period, each party
shall promptly furnish to the other party any report or correspondence issued by or provided to a Governmental Entity in connection with such visit or inquiry, purged only of Confidential Information of such party wholly unrelated to the other
party’s activities under this Agreement and any information that is unrelated to the CV Products. Each party shall permit the relevant Governmental Entity to inspect its facilities in connection with the activities contemplated by this
Agreement. 
 10.9 Intellectual Property Maintenance. Following the Closing, Buyer will have the sole right (but not the obligation)
to file, prosecute and maintain, at its sole cost and expense any patent applications, Patents, Trademark Registrations and Domain Names that cover or relate to the CV Products. Following the Closing, Buyer shall be responsible for recording the
assignment of the assigned Patents, Domain Names and Trademark Registrations with the U.S. Patent and Trademark Office and other authorities or entities as it deems appropriate, at its own cost and expense (including any attorney fees and filing
fees). Seller shall fully cooperate with Buyer, as and to the extent reasonably requested by Buyer after the Closing Date, at Buyer’s sole cost and expense, to secure any further registration of, or to enforce or defend, any Patents,
Trademarks, Registrations, Domain Names or other intellectual property rights related to the CV Products for the benefit of Buyer and to execute assignments and any other documents to effect the transfer of such Patents, Trademarks, Registrations,
Domain Names or other intellectual property rights related to the CV Products to Buyer. 
 10.10 Insurance. As of the Closing Date,
the coverage under all insurance policies related to the Assets and the Business shall continue in force only for the benefit of Seller, and not for the benefit of Buyer, the Assets or the Business. As of the Closing Date, Buyer agrees to arrange
for its own insurance policies with respect to the Assets and Buyer’s conduct of the Business. 
 10.11 Federal Supply Schedule.
Buyer shall within five (5) business days after the Closing Date, add the Marketed Products to its Federal Supply Schedule. 
 10.12
Promotion, Marketing and Labeling. Promptly after the Registrations have been transferred to Buyer and subject to applicable regulatory approvals, all Buyer advertising and promotional materials for the Marketed Products shall identify Buyer
as the marketer of the Marketed Products in the applicable Territory, in such form as Buyer shall determine. Promptly after the Registrations have been transferred to Buyer, Buyer shall make such changes in the package insert, Marketed Products
labeling and packaging as may be required to reflect Buyer as the marketer of the Marketed Products in the applicable Territory, including making all required 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 42 

 FDA and any other regulatory filings in connection therewith. Promptly after the Registrations have been transferred to
Buyer, Seller shall file with the FDA a notice that Buyer is the marketer and distributor of the Marketed Products in the applicable Territory. To the extent that the FDA requests additional information or meetings regarding Buyer’s
responsibilities as marketer and distributor of the Marketed Products in the applicable Territory, Buyer shall respond to the FDA at its own expense and through its own personnel. Seller is not required to change the Marketed Products’ labeling
or package insert, or packaging for the Drug Products or the Packaged Products. With respect to the Product Inventory purchased by Buyer hereunder, Buyer shall be permitted (i) until [****]* in the case of the [****]* other than [****]*,
(ii) until [****]* in the case of [****]*, and (iii) until [****]* in the case of the [****]* to sell Marketed Products from the Product Inventory as labeled and packaged prior to the Closing Date, without regard to whether such Marketed
Products references Seller or includes any intellectual property rights Seller has in Trademarks that may be included on the labels and packaging but not conveyed to Buyer pursuant to this Agreement, provided that all such Product Inventory shall be
held, maintained, distributed and sold in accordance with the Registrations and all applicable laws. Without the prior written approval from Seller, which approval shall not be unreasonably withheld or delayed, Buyer shall not use or distribute
any marketing, promotional or advertising copy related to the [****]* has been transferred to Buyer; provided, however, that nothing herein shall require any approval from Seller for Buyer to issue invoices for, and collect
revenues from, sales of the [****]* from and after the Closing Date. 
 10.13 Payments from Third Parties. As soon as
reasonably practicable after the Closing Date but not more than [****]* thereafter, Seller will provide Buyer with a list of all of the customers and wholesalers purchasing the Marketed Products from Seller, and Seller and Buyer shall notify those
customers and wholesalers that Buyer has acquired all of Seller’s right, title and interest in and to the marketing and sale of the Marketed Products in the applicable Territory and all payments with respect to the sale of the Marketed Products
after the Closing Date should be paid directly to Buyer at its designated account. Seller and Buyer shall notify customers and wholesalers using the third party notification letter substantially in the form attached hereto as Exhibit J. In
the event that, on or after the Closing Date, either party shall receive any payments or other funds due to the other party, then the party receiving such funds shall promptly forward such funds to the proper party. The parties acknowledge and agree
there is no right of offset regarding such payments and a party may not withhold funds received from third parties for the account of the other party in the event there is a dispute regarding any other issue under this Agreement. Buyer and Seller
shall each keep, and shall cause its respective Affiliates and third party sublicensees to keep, full and accurate records and books of account containing all particulars that may be necessary for the purpose of determining any amounts that may be
payable to the other party hereunder, and shall afford each other with access to books and records and with audit and other rights consistent with the rights set forth in Section 3.5 of this Agreement. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 43 

 10.14 Product Returns, Chargebacks and Rebates. Except as otherwise provided in the Transition
Services Agreement, Buyer shall assume responsibility for handling all returns of the CV Products sold by or for Seller prior to the Closing Date in accordance with Seller’s normal return policies and procedures. Any returns received directly
by Seller after the Closing Date shall be forwarded to Buyer’s designated facility for handling of the returned CV Products and processing of customer credits. Notwithstanding the foregoing, [****]* shall be responsible for [****]* and [****]*
shall be financially responsible for all such chargebacks and rebates related to the CV Products sold after the Closing Date. 
 10.15
Bulk Transfer Laws. Buyer hereby waives compliance by Seller with the provisions of any so-called “bulk transfer law” of any jurisdiction in connection with the sale of the Assets to Buyer. Seller shall indemnify and hold Buyer
harmless from, against and in respect of (and shall reimburse Buyer for) any and all liabilities that may be asserted by third parties against Buyer as a result of noncompliance with any such bulk transfer law. 
 10.16 Non-Competition. 
 (a) Except as otherwise permitted or required under this Agreement or the Transition Services Agreement, Seller shall, from Closing until [****]* from the Closing Date, refrain from, either alone or in conjunction with any other person or
entity, directly or indirectly through Affiliates controlled by Seller, develop, or plan to develop, any other drug candidate or product that, directly or indirectly, reasonably could be expected to be competitive with the Business; provided,
however, that 
 i. any third party that sells drug candidates or products that, directly or indirectly, compete with
the Business, may merge with or otherwise acquire Seller, or all or substantially all of Seller’s assets, and continue to sell such competing drug candidates and products; and 
 ii. such combined entity or third party may thereafter merge with or otherwise acquire any other third party (or all or substantially all
of such third party’s assets) that sells drug candidates or products that, directly or indirectly, compete with a different aspect of the Business, and continue to sell such drug candidates and products. 
 (b) The parties recognize that the laws and public policies of various states and jurisdictions may differ as to the validity and
enforceability of covenants similar to those set forth in this Section. It is the intention of the parties that the provisions of this Section be enforced to the fullest extent permissible under the laws and policies of each jurisdiction in which
enforcement may be sought, and that the unenforceability (or the modification to conform to such laws or policies) of any provisions of this Section shall not render unenforceable, or impair, the remainder of the provisions of this Section.
Accordingly, if any provision of this Section shall be determined to be invalid or unenforceable, such invalidity or unenforceability shall be deemed to apply only with respect to the operation of such provision in the particular jurisdiction in
which such determination is made and not with respect to any other provision or jurisdiction. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 44 

 (c) The parties acknowledge and agree that any remedy at law for any breach of the
provisions of this Section would be inadequate, and Seller hereby consents to the granting by any court of an injunction or other equitable relief, without the necessity of actual monetary loss being proved, in order that the breach or threatened
breach of such provisions may be effectively restrained. 
 ARTICLE 11 
 CONFIDENTIALITY 
 11.1 Confidentiality. Following the Effective Date, the
Confidentiality Agreement will remain in full force and effect in accordance with its terms, except as otherwise modified by this Agreement, and all Confidential Information previously or hereafter disclosed from time to time in the course of the
performance of this Agreement, shall be held in confidence by the other party pursuant to the Confidentiality Agreement, except as permitted under this Agreement or as necessary to carry out the activities contemplated hereby. Notwithstanding
anything to the contrary herein, obligations of the parties under this Agreement are several and not joint with the intention that each party be responsible for their own actions and the actions of their respective representatives and not for
actions of any of the other parties hereto. Neither party shall, without the prior written consent of the other party, use the Confidential Information of the other party for any purpose other than performing its obligations or exercising its rights
under this Agreement. Each party shall disclose the Confidential Information of the other party only to its directors, employees, consultants, vendors, financing sources and clinicians under written agreements of confidentiality at least as
restrictive as those set forth in this Agreement, who have a need to know such information in connection with such party performing its obligations or exercising its rights under this Agreement; provided, however, Buyer shall be
severally responsible for any breach of this Agreement or the confidentiality agreement between Buyer and such third party or its representatives, and Buyer agrees, at its sole expense, to take all reasonable measures to restrain such third parties
and its representatives from prohibited or unauthorized disclosure or use of the Confidential Information. Notwithstanding the foregoing, no provision of this Agreement shall be construed so as to preclude such disclosure of Confidential Information
as may be inherent in or reasonably necessary to the securing from any Governmental Entity of any necessary approval or license related to the CV Products, to the obtaining of patents. Following the Closing, (i) the confidentiality restrictions
contained herein and in the Confidentiality Agreement will not apply to Buyer’s use of documents and information concerning the Business (except to the extent that such documents and information contain information related to Seller’s
other business or the Excluded Assets), the Assets or the Assumed Liabilities, and (ii) any information related to the Business (excluding information related to Seller’s other business or the Excluded Assets), the Assets or the Assumed
Liabilities shall be considered Confidential Information of Buyer for the purposes of this Agreement and the Confidentiality Agreement. Upon the termination of this Agreement, and upon the written request of the other party, each party shall
promptly return to the other party all copies and embodiments of the Confidential Information of such other party, subject to the retention by each party’s legal department of one complete copy for archival purposes. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 45 

 11.2 Publicity. No party to this Agreement shall originate any publicity, news release or other
public announcement, written or oral, whether relating to this Agreement or the existence of any arrangement between the parties, without the prior written consent of the other party whether named in such publicity, news release or other public
announcement or not, except where such publicity, news release or other public announcement is required by law; provided, that in such event, the party issuing same shall still be required to consult with the other party whether named in such
publicity, news release or public announcement or not, a reasonable time prior to its release to allow the other party to comment thereon and, after its release, shall provide the other party with a copy thereof. If either party, based on the advice
of its counsel, determines that this Agreement, or any of the other documents executed in connection herewith, must be filed with the SEC, then such party, prior to making any such filing, shall provide the other party and its counsel with a
redacted version of this Agreement (or any other related documents) which it intends to file, and will give due consideration to any comments provided by the other party or its counsel and use reasonable efforts to ensure the confidential treatment
by the SEC of those sections specified by the other party or its counsel. Notwithstanding the foregoing, Buyer’s financing sources or other professional advisors may publish “tombstones” or other customary announcements relating to
the purchase financing and the transactions contemplated hereby. 
 ARTICLE 12 
 TERM AND TERMINATION 
 12.1 Termination. 
 This Agreement may be terminated prior to the Closing: 
 (a) By Buyer, upon written notice (A) at any time prior to Closing, if Seller shall have failed to comply in any material respect
with any of its obligations in this Agreement, and such failure shall be continuing, or if any one or more of the representations or warranties of Seller contained in this Agreement (i) that is qualified by materiality shall prove to be
inaccurate in any respect or (ii) that is not so qualified shall prove to be inaccurate in any material respect; provided, however, that Buyer shall give Seller thirty (30) days to cure any such failure to so comply or to
remedy any such inaccuracy under this Agreement; or (B) at Closing, if any of the conditions precedent to the performance of Buyer’s obligations at the Closing under Article 9 shall not have been fulfilled (unless the failure
results primarily from Buyer’s breach of any representation, warranty, covenant or agreement contained this Agreement); provided, however, that in the event that Buyer shall desire to terminate this Agreement as a result of the
failure of the accuracy of a representation or warranty at the Closing, Buyer shall be required to give Seller prior notice that it intends to terminate this Agreement as a result of such inaccuracy, and Seller shall have a reasonable period of
time, not to exceed thirty (30) days, to cure such inaccuracies. 
 (b) By Seller, upon written notice (A) at any
time prior to Closing, if Buyer shall have failed to comply in any material respect with any of its obligations in this Agreement and such failure shall be continuing, or if any one or more of the representations or warranties of Buyer contained in
this Agreement (i) that is qualified by materiality shall prove to be inaccurate in any respect or (ii) that is not so qualified shall prove to be inaccurate in any material respect; provided, however, that Seller shall give
Buyer thirty (30) days to cure any such failure to so comply or any such inaccuracy under this Agreement; or (B) at the Closing, if any of the conditions precedent to the performance of its obligations at the Closing under Article 9
shall not have been fulfilled (unless the failure results primarily from Seller’s breach of any 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 46 

 
representation, warranty, covenant or agreement contained this Agreement); provided, however, that in the event that Seller shall desire to
terminate this Agreement as a result of the failure of the accuracy in any material respect of a representation or warranty at the Closing, Seller shall be required to give Buyer prior notice that it intends to terminate this Agreement as a result
of such inaccuracy and Buyer shall have a reasonable period of time, not to exceed thirty (30) days, to cure such inaccuracies. 
 (c) By either party if the Closing shall not have occurred on or before March 31, 2008, provided, that such date shall be extended to June 30, 2008 in the event the waiting period under the HSR is extended, restarted or
renewed beyond the initial 30-day period, unless such failure to close is primarily the result of the breach of any representations, warranties, covenants or agreements contained in this Agreement by the party seeking to terminate. Notwithstanding
the foregoing, in the event the Closing shall not have occurred on or before May 1, 2008 and the [****]* has or have terminated, Buyer may terminate this Agreement on or after May 1, 2008, provided, that Buyer, prior to May 1,
2008, shall have used its best efforts to obtain [****]*. 
 12.2 Effect of Termination. In the event of termination of this Agreement
prior to the Closing, in accordance with its terms: (i) each party will redeliver all documents, work papers and other material of any other party relating to the transactions contemplated hereby, whether so obtained before or after the
Effective Date, to the party furnishing the same; (ii) the provisions of Article 11 shall continue in full force and effect; and (iii) no party hereto shall have any Liability or further obligation to any other party to this
Agreement, except for willful breach. 
 12.3 Effectiveness of Termination. Termination under this Article 12 shall not become
effective so long as the alleged grounds for termination are in dispute and the matter(s) at issue have been submitted for resolution pursuant to this Agreement. 
 ARTICLE 13 
 INDEMNIFICATION 
 13.1 Survivability of Representations and Warranties. The representations and warranties made in Articles 6 and 7 or any instrument
delivered pursuant to this Agreement shall not survive after the Closing Date; provided, however, that the representations and warranties of Seller in Sections 6.5 and 6.6 shall survive until [****]* (the
“Survival Date”). 
 13.2 Indemnification by Buyer. Buyer indemnifies and holds harmless Seller, and any of its
directors, officers, employees, Affiliates, controlling persons, agents and representatives (the “Seller Indemnitees”) from and against any Liabilities (a) to the extent such Liabilities relate to the Assumed Liabilities,
(b) arising from Buyer’s breach of or non-performance of any covenant or agreement under this Agreement or any instrument delivered pursuant to this Agreement, or (c) arising from the conduct of the Business after the Closing.

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 47 

 13.3 Indemnification by Seller. Seller indemnifies and holds harmless Buyer, and any of its
directors, officers, employees, Affiliates, controlling persons, agents and representatives (the “Buyer Indemnitees”) from and against any Liabilities (a) to the extent such Liabilities relate to the Excluded Liabilities,
(b) arising from Seller’s breach of or non-performance of any covenant or agreement under this Agreement or any instrument delivered pursuant to this Agreement, (c) arising from the conduct of the Business on or prior to the Closing,
or (d) arising from any breach of the representations or warranties of Seller contained in Section 6.6 (Intellectual Property). [****]* shall have no obligations with respect to any [****]*. 
 13.4 Claims. Any Buyer Indemnitee or Seller Indemnitee claiming it may be entitled to indemnification under this Article 13 (the
“Indemnified Party”) shall give prompt notice to the other party (the “Indemnifying Party”) of each matter, action, cause of action, claim, demand, fact or other circumstances upon which a claim for indemnification
(a “Claim”) under this Article 13 may be based. Such notice shall contain, with respect to each Claim, such facts and information as are then reasonably available, the specific basis for indemnification hereunder, together
with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith. Failure to give prompt notice of a Claim hereunder shall not affect the Indemnifying Party’s obligations under this Section, except to the
extent the Indemnifying Party is prejudiced by such failure. 
 13.5 Assertion of Claims. No claim shall be brought under Sections
13.2, 13.3 or 13.4 hereof unless the Buyer Indemnitees, or any of them, or the Seller Indemnitees, or any of them, as the case may be, at any time prior to the applicable Survival Date, provide Buyer or Seller, as the case may be,
with written notice of the existence of any such claim, reasonably specifying the nature and basis of such claim and the amount thereof, to the extent known; provided, that, the failure so to provide such notice to Buyer or Seller, as the
case may be, will not relieve Buyer or Seller, as the case may be, from any Liability which they may have to the Buyer Indemnitees or the Seller Indemnitees, as the case may be, under this Agreement or otherwise, except to the extent that Buyer or
Seller, as the case may be, reasonably demonstrates that such failure results in the loss or compromise of any rights or defenses of Buyer or Seller, as the case may be, and that Buyer or Seller, as the case may be, were not otherwise aware of such
action or claim. Upon the giving of such written notice as aforesaid, the Buyer Indemnitees, or any of them, or the Seller Indemnitees, or any of them, as the case may be, shall have the right to commence legal proceedings prior or subsequent to the
Survival Date for the enforcement of their rights under Sections 13.2, 13.3 or 13.4 hereof, as the case may be. 
 13.6
Payment of Claims; Limitation on Indemnification. Notwithstanding anything to the contrary in Sections 13.3 or 13.4, any Liability under Section 13.3(d) shall limited as follows: [****]*. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 48 

 13.7 Limitation; Exclusivity. No Claim shall be made or have any validity unless the Indemnified
Party shall have given written notice of such Claim to the Indemnifying Party. If full recovery under any such Claim is not had within [****]* of such written notice, arbitration, pursuant to Section 14.4, must be commenced within thirty
(30) days following the end of such [****]* or such Claim shall be invalidated. This Article 13 provides the exclusive means by which a party may assert Claims against the other party and Section 14.4 provides the exclusive
means by which a party may bring actions against the other party with respect to any breach by the other party of its indemnification obligations under this Article 13. 
 ARTICLE 14 
 MISCELLANEOUS 
 14.1 Survival of Covenants and Agreements. The covenants and agreements contained in Sections 2.1, 2.2, 2.3 and 2.4
shall survive Closing [****]*. All other covenants and agreements herein shall survive Closing until [****]* the last date on which such covenant or agreement is to be performed or, if no such date is specified [****]*. Any covenant or agreement
that would otherwise terminate in accordance with the above will continue to survive if a notice of a Claim shall have been timely given under Article 13 on or prior to such termination date, until the related claim for indemnification
has been satisfied or otherwise resolved as provided in Article 13. 
 14.2 No Third Party Beneficiaries. Nothing in this
Agreement, express or implied, is intended to or shall (i) confer on any person other than the parties hereto (and Buyer Indemnitees and Seller Indemnitees referred to herein) and their respective successors or assigns any rights (including
third party beneficiary rights), remedies, obligations or liabilities under or by reason of this Agreement, or (ii) constitute the parties hereto as partners or as participants in a joint venture. This Agreement shall not provide third parties
with any remedy, claim, liability, reimbursement, cause of action or other right in excess of those existing without reference to the terms of this Agreement. No third party shall have any right, independent of any right which may exist irrespective
of this Agreement, under or granted by this Agreement, to bring any suit at law or equity for any matter governed by or subject to the provisions of this Agreement. 
 14.3 Force Majeure. If the performance by either party of any obligation under this Agreement is prevented, restricted, interfered with or delayed by reason of any cause beyond the reasonable control of the
party liable to perform, unless conclusive evidence to the contrary is provided, the party so affected shall, upon giving written notice to the other party, be excused from such performance to the extent of such prevention, restriction, interference
or delay, provided that the affected party shall use its reasonable efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise,
the parties shall discuss what, if any, modification of the terms of this Agreement may be required in order to arrive at an equitable solution. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 49 

 14.4 Governing Law; Jurisdiction; Dispute Resolution and Arbitration. This Agreement shall be
deemed to have been made in the State of California and its form, execution, validity, construction and effect shall be determined in accordance with the laws of the State of California, without giving effect to the principles of conflicts of law
thereof. Disputes arising out of, relating to or in connection with this Agreement, or in relations between the parties with respect to the subject matter hereof, for any reason or under any circumstances, will be finally settled by a single
arbitrator in a binding arbitration in accordance with the Judicial Arbitration and Mediation Services (“JAMS”) Comprehensive Arbitration Rules and Procedures (the “JAMS Rules”). Upon receipt of written notice of
the existence of a dispute by one party hereto to the other, the parties shall, within thirty (30) days conduct a meeting of one or more senior executives of each party, with full settlement authority, in an attempt to resolve the dispute. Each
party shall make available appropriate personnel to meet and confer with the other party reasonably within the thirty-day period. Upon the expiration of the thirty-day period, or upon the termination of discussions between the senior executives,
either party may elect arbitration of any dispute by written notice to the other (the “Arbitration Notice”). The arbitration shall be held in San Francisco, California before one (1) arbitrator from JAMS having substantial
experience as a jurist and mediator with significant disputes in the biotechnology and/or pharmaceuticals industry selected by the mutual agreement of the Buyer and the Seller; provided, however, that if such parties cannot agree on an
arbitrator within thirty (30) days of the Arbitration Notice, either party may request JAMS select the arbitrator, and JAMS shall select an arbitrator pursuant to the procedure set out by the JAMS rules, provided, however, that the arbitrator
selected be a former judge with at least fifteen (15) years experience addressing as a jurist and/or mediator significant disputes in the biotechnology and or pharmaceutical industry. The arbitration shall be administered by JAMS pursuant to
its AAA Rules. Judgment on the arbitration award may be entered in any court having jurisdiction. The arbitrator may, in the arbitration award, allocate for payment by the non-prevailing party all or part of the costs of the arbitration, including
fees of the arbitrator and the reasonable attorneys’ fees and costs incurred by the prevailing party. This Section shall not preclude the parties from seeking provisional remedies in aid of arbitration from a court of appropriate jurisdiction.
In respect of any actions for injunctive or other equitable relief hereunder, any action or proceeding may be brought against any party in the state and federal courts located in the city of San Francisco, California and each of the parties consents
to the jurisdiction of such courts in any such action or proceeding and waives any objection to venue laid therein. 
 14.5
Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, it shall be modified, if possible, to the minimum extent necessary to make it valid and enforceable or, if such
modification is not possible, such provision shall be stricken and the remaining provisions shall remain in full force and effect; provided, however, that if a provision is stricken so as to significantly alter the economic arrangements of this
Agreement, the party adversely affected may terminate this Agreement upon [****]* prior written notice to the other party. If any of the terms or provisions of this Agreement is in conflict with any applicable statute or rule of law in any
jurisdiction, then such term or provision shall be deemed inoperative in such jurisdiction to the extent of such conflict and the parties will renegotiate the affected terms and conditions of this Agreement to resolve any inequities. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 50 

 14.6 Entire Agreement. This Agreement and the ancillary transaction documents to be executed and
delivered pursuant to this Agreement are intended to define the full extent of the legally enforceable undertakings and representations of the parties hereto, and no promise or representation, written or oral, which is not set forth explicitly in
this Agreement or such ancillary transaction documents is intended by either party to be legally binding; provided, however, in the event this Agreement terminates, the Confidentiality Agreement shall continue in full force and effect pursuant to
its terms. Each of the parties acknowledge that in deciding to enter into this Agreement and to consummate the transaction contemplated hereby none of them has relied upon any statements or representations, written or oral, other than those
explicitly set forth in this Agreement. 
 14.7 Amendment. This Agreement may not be amended, supplemented or otherwise modified
except by an instrument in writing signed by both parties that specifically refers to this Agreement. 
 14.8 Notices. All notices and
other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile, (iii) five (5) days
after having been sent by registered or certified mail, return receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt. All communications shall be sent to the respective parties at the addresses set forth below (or at such other addresses as shall be specified by notice given in accordance with this Section): 
  

					
		 	If to Seller:	  	 PDL BioPharma, Inc.
 Attention: General
Counsel
 1400 Seaport Boulevard
 Redwood City, CA
94063
 Facsimile: 650-454-1468
 E-mail: Francis.Sarena@pdl.com

			
		 	with a copy to:	  	DLA Piper US LLP
		 	(not to constitute notice)	  	 Attention: Howard Clowes
 153 Townsend Street, Suite
800
 San Francisco, CA 94107-1957
 Facsimile: 415-
659-7410
 E-mail: howard.clowes@dlapiper.com

			
		 	If to Buyer:	  	 EKR Therapeutics, Inc.
 Attention: Richard DeSimone

 7 East Frederick Place
 Cedar Knolls, NJ 07927
 Facsimile: +1 (866) 620-6848
 E-mail:
r.desimone@ekrtx.com

  

 CONFIDENTIAL TREATMENT REQUESTED 
 51 

					
		 	with a copy to:	  	Milbank, Tweed, Hadley & McCloy LLP
		 	(not to constitute notice)	  	 Attention: Robert S. Reder, Esq.
 One Chase Manhattan
Plaza
 New York, New York 10005
 Facsimile No.: +1
(212) 822-5680
 E-mail: RReder@milbank.com

 14.9 Assignment. This Agreement and the rights and obligations hereunder shall be binding
upon and inure to the benefit of the parties hereto, their respective successors and assigns, but this Agreement shall not be assignable by either party hereto without the express written consent of the other party hereto which will not be
unreasonably withheld, provided, however, that Buyer may merge or consolidate with, or assign any or all of its rights, interests and obligations hereunder to, a direct or indirect wholly-owned subsidiary of Buyer, provided that no
such merger, consolidation or assignment shall relieve Buyer of its obligations hereunder, [****]*. 
 14.10 No Agency. It is
understood and agreed that each party shall have the status of an independent contractor under this Agreement and that nothing in this Agreement shall be construed as authorization for either party to act as agent for the other. Neither party shall
incur any Liability for any act or failure to act by employees of the other party. 
 14.11 Construction. 
 (a) This Agreement has been prepared jointly and shall not be strictly construed against either party. 
 (b) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 
 (c) Except as otherwise indicated, all references in this Agreement to “Articles,” “Sections,” “Exhibits”
and “Schedules” are intended to refer to Articles and Sections and Exhibits and Schedules to this Agreement. 
 (d)
The table of contents and headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 14.12 Payment of Expenses. Except as otherwise set forth in this Agreement or in the Transition Services Agreement, all costs and expenses
associated with this Agreement and the transactions contemplated thereby, including the fees of counsel and accountants, shall be borne by the party incurring such expenses. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 52 

 14.13 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but which together shall constitute one and the same instrument. Any executed counterpart delivered by facsimile or other means of electronic transmission shall be deemed an original for all purposes. 
 [Remainder of page intentionally left blank; signature page follows] 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 53 

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this as of the
date first written above. 
  

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	/s/ L. Patrick Gage

			
	Name:	 	L. Patrick Gage
	Title:	 	Chief Executive Officer
		
	By:	 	/s/ Andrew Guggenhime

			
	Name:	 	Andrew Guggenhime
	Title:	 	 Senior Vice President and
 Chief Financial Officer

	
	EKR Therapeutics, Inc.,
	a Delaware corporation
		
	By:	 	/s/ Howard Weisman
	Name:	 	Howard Weisman
	Title:	 	Chairman and Chief Executive Officer
		
	By:	 	/s/ Richard DeSimone
	Name:	 	Richard DeSimone
	Title:	 	Chief Financial Officer

 SIGNATURE PAGE 
 ASSET PURCHASE AGREEMENT 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 54 

 EXHIBIT A 
 GENERAL ASSIGNMENT AND BILL OF SALE 
 THIS GENERAL ASSIGNMENT AND BILL OF SALE (this “Bill of
Sale”) is made and delivered as of [                    ], 2008 (the “Effective Date”) by PDL BioPharma, Inc., a
Delaware corporation (“Seller”) for the benefit of EKR Therapeutics, Inc., a Delaware corporation (“Buyer”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase
Agreement (as defined below). 
 RECITALS 
 WHEREAS, Seller and Buyer have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February [        ], 2008,
pursuant to which, among other things, Seller has agreed to sell, convey, transfer, assign and deliver to Buyer all of Seller’s right, title and interest in and to the Assets. 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the Purchase Agreement, and for other good and valuable consideration, the
receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 
 1.
Transfer of Assets. Seller hereby sells, conveys, transfers, assigns and delivers unto Buyer, and its successors and assigns, forever, all of Seller’s right, title and interest in and to the Assets. Buyer hereby accepts the sale,
transfer, conveyance, assignment and delivery of the Assets. 
 2. Further Assurances. At any time or from time to time after the date
hereof, at Buyer’s request and without further consideration, Seller shall execute and deliver to Buyer such other instruments of sale, transfer, conveyance, assignment and confirmation, provide such materials and information and take such
other actions as Buyer may reasonably deem necessary or desirable in order more effectively to transfer, convey and assign to Buyer, and to confirm Buyer’s title to, all of the Assets, and, to the full extent permitted by law, to put Buyer in
actual possession and operating control of the Business and the Assets and to assist Buyer in exercising all rights with respect thereto, and otherwise to cause Seller to fulfill its obligations under the Purchase Agreement. Without limiting the
foregoing, in the event that any Affiliate of Seller has any right, title or interest in any Asset (or any other asset used in the Business that would otherwise be an Asset if owned by Seller), then Seller shall cause such Affiliate to transfer and
assign all such right, title and interest to Buyer. 
 3. Power of Attorney. Seller hereby constitutes and appoints Buyer the true and
lawful attorney of Seller, with full power of substitution, in the name of Seller or Buyer, but on behalf of and for the benefit of Buyer: (i) to demand and receive from time to time any and all Assets and to make endorsements and give receipts
and releases for and in respect of the same and any part thereof; (ii) to institute, prosecute, compromise and settle any and all actions or proceedings that Buyer may deem proper in order to collect, assert or enforce any claim, right or title
of any kind in or to the Assets; (iii) to defend or compromise any or all actions or proceedings in respect of any of the Assets; and (iv) to do all such acts and things in relation to the matters set forth in the preceding clauses
(i) through (iii) as Buyer shall deem desirable. Seller hereby acknowledges that the appointment hereby made and the powers hereby granted are coupled with an interest and are not and shall not be revocable by it in any manner or for any
reason. Seller shall deliver to Buyer at Closing an acknowledged power of attorney to the foregoing effect executed by Seller. Buyer shall indemnify and hold harmless Seller from any and all losses caused by or arising out of any breach of law by
Buyer in its exercise of the aforesaid powers. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 4. Purchase Agreement Controls. Nothing in this Bill of Sale, express or implied, is intended or
shall be construed to modify, expand or limit in any way the terms of the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall
govern. 
 5. No Additional Remedies. Nothing in this Bill of Sale, express or implied, is intended or shall be construed to confer
upon, or give to, any person other than Buyer and its successors and assigns any remedy or claim under or by reason of this Bill of Sale. 
 6. Binding Effect. This Bill of Sale shall be binding upon and shall inure to the benefit of Buyer and Seller and their respective successors and assigns. 
 7. Governing Law. This Bill of Sale shall be governed by and construed under the laws of the State of California without regard to conflicts of laws principles. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, Seller has executed this Bill of Sale as of the date first above written. 

 

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By: 	 	 

			
		
	Name: 	 	 

			
		
	Title: 	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT B 
 ASSIGNMENT AND ASSUMPTION AGREEMENT 
 THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this
“Agreement”) is made and entered into as of [                    ], 2008 (the “Effective Date”) by and among
PDL BioPharma, Inc., a Delaware corporation (“Seller”) and EKR Therapeutics, Inc., a Delaware corporation (“Buyer”). Buyer and Seller are referred to hereinafter as the “Parties”. 
 RECITALS 
 WHEREAS, the Parties have entered
into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February [        ], 2008, pursuant to which, among other things, Seller has agreed to assign, and
Buyer has agreed to assume, the Assumed Liabilities. 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the
Purchase Agreement, and the premises and mutual covenants hereinafter set forth, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do
hereby agree as follows: 
 1. Capitalized Terms. Capitalized terms used but not defined herein (including in the recitals above)
shall have the meanings ascribed to them in the Purchase Agreement. 
 2. Assignment. In accordance with and subject to the terms of
the Purchase Agreement, Seller hereby sells, assigns, transfers, conveys and delivers to Buyer, to the extent that such are legally assignable and any necessary consents to assignment have been obtained, all of Seller’s right, title and
interest in, to and under the Assumed Liabilities (the “Assignment”). 
 3. Assumption. In accordance with and
subject to the terms of the Purchase Agreement, Buyer hereby (a) accepts, to the extent that the assets and liabilities included therein are legally assignable and necessary consents to assignment have been obtained, the Assignment and
(b) assumes and agrees to honor, pay and discharge when due all of the Assumed Liabilities. For the avoidance of doubt, Buyer assumes no Liability of Seller other than as specifically stated above, and, specifically, does not assume the
Excluded Liabilities, and the Parties agree that all Liabilities that have not been assigned herein shall remain the sole responsibility of Seller. Furthermore, nothing contained herein shall prevent Buyer from having the ability to contest, in good
faith, any claim of Liability asserted by any person or entity other than Seller and its Affiliates. 
 4. Purchase Agreement
Controls. Each of the Parties hereby acknowledges and agrees that the representations, warranties, covenants, agreements and indemnities contained in the Purchase Agreement shall not be superseded hereby but shall remain in full force and effect
to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 5. No Additional Remedies. Nothing in this Agreement, express or implied, is intended or shall be
construed to confer upon, or give to, any person other than Seller, Buyer and their respective successors and assigns any remedy or claim under or by reason of this Agreement. 
 6. Governing Law. This Agreement will be governed by and construed under the laws of the State of California without regard to conflicts of laws
principles. 
 7. Binding Effect. This Agreement shall inure to the benefit of, and shall be binding upon, the Parties hereto and
their respective successors and assigns only. This Agreement shall not provide third parties with any remedy, claim, liability, reimbursement, cause of action or other right in excess of those existing without reference to the terms of this
Agreement. No third party shall have any right, independent of any right which may exist irrespective of this Agreement, under or granted by this Agreement, to bring any suit at law or equity for any matter governed by or subject to the provisions
of this Agreement. 
 8. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but which together shall constitute one and the same instrument. Any executed counterpart delivered by facsimile or other means of electronic transmission shall be deemed an original for all purposes. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 
  

			
	SELLER:
	
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	BUYER:
	
	EKR Therapeutics, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT C 
 PATENT ASSIGNMENT 
 THIS PATENT ASSIGNMENT (this “Assignment”) is made and delivered
as of [                    ], 2008 (the “Effective Date”) by PDL BioPharma, Inc., a Delaware corporation
(“Assignor”) for the benefit of EKR Therapeutics, Inc., a Delaware corporation (“Assignee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement (as
defined below). 
 RECITALS 
 WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February [        ], 2008, pursuant to which,
among other things, Assignor has agreed to sell, convey, transfer, assign and deliver to Assignee all of Assignor’s right, title and interest in and to the Patents set forth on Exhibit A. 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the Purchase Agreement, and for other good and valuable consideration, the
receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 
 1.
Assignment. Assignor hereby sells, assigns, transfers and conveys unto Assignee, all of its right, title and interest together with the benefits and privileges in and to the Patents, including without limitation, all inventions and
discoveries, applications for patents or similar forms of protection in the Territory, and all other applications for patents on such inventions and discoveries in whatsoever countries, as set forth in Exhibit A, including all divisional,
renewal, substitute, continuation and convention applications based in whole or in part upon said inventions or discoveries, or upon said applications, and any and all patents, reissues and extensions of patents or similar forms of protection
granted for said inventions and discoveries or upon said applications, and every priority right that is or may be predicated upon or arise from said inventions, said discoveries, said applications and said patents, and the right to recover for
damages from past, present and future infringements thereof, if any. 
 2. Cooperation. Assignor hereby covenants and agrees to
reasonably cooperate with Assignee to enable Assignee to enjoy to the fullest extent the right, title and interest herein conveyed. Such reasonable cooperation by Assignor shall include production of pertinent facts and documents, giving of
testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed reasonably necessary by Assignee, (a) for perfecting in Assignee the right, title and interest herein
conveyed; (b) for filing and prosecuting substitute, divisional, continuing or additional applications covering the Patents; (c) for filing and prosecuting applications for re-issuance of any of the Patents; (d) for interference or
other priority proceedings involving the Patents; and (e) for legal proceedings involving the Patents for infringement actions and court actions; provided, however, that the costs and expenses incurred by Assignor in providing such cooperation
shall be paid for by Assignee. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 3. Purchase Agreement Controls. Nothing in this Assignment, express or implied, is intended or
shall be construed to modify, expand or limit in any way the terms of the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall
govern. 
 4. No Additional Remedies. Nothing in this Assignment, express or implied, is intended or shall be construed to confer
upon, or give to, any person other than Assignee and its successors and assigns any remedy or claim under or by reason of this Assignment. 
 5. Binding Effect. This Assignment shall be binding upon and shall inure to the benefit of Assignee and Assignor and their respective successors and assigns. 
 6. Governing Law. This Assignment shall be deemed to have been made in, and shall be governed by and construed pursuant to the laws of the State
of California and the United States without regard to any conflicts of laws provisions that would require the application of the laws of any other jurisdiction. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, Assignor has executed and delivered this instrument to Assignee. 
  

									
		 		 	ASSIGNOR:
			
		 		 	PDL BioPharma, Inc.,
		 		 	a Delaware corporation
				
		 		 	By:	 	 
				
		 		 	Name:	 	 
				
		 		 	Title:	 	 
				
	Date:
                                	 		 	By:	 	 
		 		 		 		 	                                (name of officer)
		 		 		 		 	                                  (Title of
officer)

 State
of                                        
     
 County
of                                        
                 
 On
                     before me,
                                        ,
Notary Public, personally appeared                     , personally known to me (or proved to me on the basis of satisfactory evidence) to be
the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity(ies), and that by his/her signature on the instrument the person, or the entity upon behalf of which the
person acted, executed the instrument. 
 Witness my hand and official seal. 
 Notary Public 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT D 
 TRADEMARK ASSIGNMENT 
 THIS TRADEMARK ASSIGNMENT (this “Assignment”) is made and
delivered as of [                    ], 2008 (the “Effective Date”) by PDL BioPharma, Inc., a Delaware corporation
(“Assignor”) for the benefit of EKR Therapeutics, Inc., a Delaware corporation (“Assignee”). Assignor and Assignee are referred to hereinafter as the “Parties”. Capitalized terms used but not
defined herein shall have the meanings ascribed to them in the Purchase Agreement (defined below). 
 RECITALS 
 WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February
[            ], 2008, pursuant to which, among other things, Assignor has agreed to sell, convey, transfer, assign and deliver to Assignee all of Assignor’s right, title and
interest in and to the Trademarks set forth on Exhibit A. 
 NOW, THEREFORE, in consideration of the agreements and covenants
contained in the Purchase Agreement, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 
 1. Assignment. Assignor hereby assigns, sells, transfers and conveys to Assignee all right, title and interest, including any common law rights,
in the Territory and throughout the world, in and to the Trademarks, together with the related goodwill of the Business symbolized by the Trademarks and the right to recover for damages from past, present and future infringements thereof, if any.

 2. Cooperation. Assignor hereby covenants and agrees to reasonably cooperate with Assignee to enable Assignee to enjoy to the
fullest extent the right, title and interest herein conveyed. Such reasonable cooperation by Assignor shall include production of pertinent facts and documents, giving of testimony, execution of oaths, declarations or other papers, and other
assistance as is reasonably necessary for perfecting in Assignee the right, title and interest herein conveyed; provided, however, that the costs and expenses incurred by Assignor in providing such cooperation shall be paid for by Assignee.

 3. Purchase Agreement Controls. Nothing in this Assignment, express or implied, is intended or shall be construed to modify, expand
or limit in any way the terms of the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern. 
 4. No Additional Remedies. Nothing in this Assignment, express or implied, is intended or shall be construed to confer upon, or give to, any
person other than Assignee and its successors and assigns any remedy or claim under or by reason of this Assignment. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 5. Binding Effect. This Assignment shall be binding upon and shall inure to the benefit of
Assignee and Assignor and their respective successors and assigns. 
 6. Governing Law. This Assignment shall be deemed to have been
made in, and shall be governed by and construed pursuant to the laws of the State of California and the United States without regard to any conflicts of laws provisions that would require the application of the laws of any other jurisdiction.

 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, Assignor has caused this Agreement to be executed by its duly authorized
representatives as of the Effective Date. 
  

									
	ASSIGNOR:	 		 	ASSIGNEE:
			
	PDL BioPharma, Inc.,	 		 	EKR Therapeutics, Inc.,
	a Delaware corporation	 		 	a Delaware corporation
					
	By:	 	 	 		 	By:	 	 
					
	Name:	 	 	 		 	Name:	 	 
					
	Title:	 	 	 		 	Title:	 	 
			
	Witnessed by:	 		 	Witnessed by:
			
	 	 		 	 
	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	
			
	Witnessed by:	 		 	Witnessed by:
			
	 	 		 	 
	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	

 State of California 
 County of                                  
 On                          before me,
                                         
                               , personally appeared
                                         
   
                                         
       , who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in
his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. 
 I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. 
  

									
	WITNESS my hand and official seal.	 		 	
				
	Signature	 	 	 		 	(Seal)

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 State of California 
 County
of                                  
 On                      before me,
                                         
                               , personally appeared
                                         
   
                                        
        , who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in
his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. 
 I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. 
  

									
	WITNESS my hand and official seal.	 		 	
				
	Signature	 	 	 		 	(Seal)

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT E 
 DOMAIN NAME ASSIGNMENT 
 THIS DOMAIN NAME ASSIGNMENT (this “Assignment”) is made and
delivered as of [                    ], 2008 (the “Effective Date”) by PDL BioPharma, Inc., a Delaware corporation
(“Assignor”) for the benefit of EKR Therapeutics, Inc., a Delaware corporation (“Assignee”). Assignor and Assignee are referred to hereinafter as the “Parties”. Capitalized terms used but not
defined herein shall have the meanings ascribed to them in the Purchase Agreement (defined below). 
 RECITALS 
 WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February
[        ], 2008, pursuant to which, among other things, Assignor has agreed to sell, convey, transfer, assign and deliver to Assignee all of Assignor’s right, title and interest in and to each of
the internet domain names listed in Exhibit A attached hereto, all of which domain names have been registered with an Internet Corporation for Assigned Names and Numbers (“ICANN”) accredited registrar (all of such domain
names are herein referred to as the “Domain Names”). 
 NOW, THEREFORE, in consideration of the agreements and covenants
contained in the Purchase Agreement, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 
 1. Assignment. Assignor hereby assigns, sells, transfers and conveys to Assignee all right, title and interest, in and to the Domain Names,
together with the related goodwill of the Business symbolized by the Domain Names and the right to recover for damages from past, present and future infringements thereof, if any. 
 2. Cooperation. Assignor hereby covenants and agrees to reasonably cooperate with Assignee to execute and deliver all papers, instruments and
assignments, and to provide transfer authorization codes to Assignee, send confirming emails to the appropriate Registrar and follow other electronic procedures, as may be reasonably necessary to vest all right, title and interest in and to the
Domain Names with Assignee, including, the proper transfer of the registration of the Domain Names as required by ICANN. Assignor will complete Assignor’s portion of the assignment procedure established by the applicable domain name
Registrar(s) and inform Assignee of the completion of such procedures (or any other assignment procedure reasonably specified by the Registrar(s) at the time of the assignment) within ten (10) business days from the Effective Date.

 3. Purchase Agreement Controls. Nothing in this Assignment, express or implied, is intended or shall be construed to modify, expand
or limit in any way the terms of the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 4. No Additional Remedies. Nothing in this Assignment, express or implied, is intended or shall be
construed to confer upon, or give to, any person other than Assignee and its successors and assigns any remedy or claim under or by reason of this Assignment. 
 5. Binding Effect. This Assignment shall be binding upon and shall inure to the benefit of Assignee and Assignor and their respective successors and assigns. 
 6. Governing Law. This Assignment shall be governed by and construed under the laws of the State of California without regard to conflicts of laws
principles. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, Assignor has caused this Agreement to be executed by its duly authorized
representatives as of the Effective Date. 
  

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 

			
		
	Name: 	 	 

			
		
	Title: 	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT F 
 TRANSITION SERVICES AGREEMENT 
 THIS TRANSITION SERVICES AGREEMENT (this
“Agreement”), dated as of [            ], 2008 (the “Effective Date”), is made by and between, EKR Therapeutics, Inc., a Delaware corporation
(“Buyer”), and PDL BioPharma, Inc., a Delaware corporation (“PDL”). 
 WHEREAS, pursuant to that certain
Asset Purchase Agreement, dated as of February,             , 2008, by and between Buyer and PDL (the “Asset Purchase Agreement”), Buyer has purchased certain assets
(the “Acquisition”) from PDL relating to the CV Products (as defined in the Asset Purchase Agreement); and 
 WHEREAS, in
connection with the Acquisition, Buyer desires to engage PDL to perform the Transition Services (as defined below), upon the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, Buyer and PDL agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.1
Definitions. As used in this Agreement, the following terms shall have the meanings ascribed to them below. Terms used in this Agreement that are not otherwise defined herein shall have their respective meanings as set forth in the Asset
Purchase Agreement. 
 “Acquisition” has the meaning set forth in the recitals. 
 “Affiliate” means, with respect to any Person, any other Person that directly or indirectly Controls, is Controlled by or is under
common Control with such first Person. A Person will be deemed to “Control” another Person if such first Person has the power to direct or cause the direction of the management and policies of such other Person, whether through
ownership of securities, by contract or otherwise. 
 “Governmental Rules” means any applicable law, judgment, order, award,
decree, statute, ordinance, rule or regulation issued or promulgated by any Governmental Entity. 
 “Losses” means any and
all damages, losses, Taxes, Liabilities, Claims, judgments, penalties, costs and expenses, including reasonable attorneys fees and litigation expenses. 
 “PDL” has the meaning set forth in the introductory paragraph. 
 “Person”
means any individual, corporation, partnership, limited liability company, joint venture, trust, business association, organization, Governmental Entity or other entity. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 “Term” has the meaning set forth in Section 5.1. 
 “Transaction Documents” mean any and all agreements between PDL and Buyer executed in connection with or arising under the Acquisition.

 “Transfer Taxes” means any sales, use, services, transfer or similar taxes imposed on PDL’s provision of Transition
Services to Buyer. 
 “Transition Services” mean those services set forth on Exhibit A, which shall be consistent
with PDL’s practices during the six (6) months prior to the Effective Date for similar services performed by PDL in connection with the Business. 
 “Transition Services Team” has the meaning set forth in Section 2.2(c). 
 Section 1.2 Interpretation. 
 (a) When used in this Agreement, the words “include,”
“includes” and “including” shall be deemed to be followed by the words “without limitation.” 
 (b) Any terms defined in the singular shall have a comparable meaning when used in the plural, and vice-versa. 
 (c)
All references to any introductory paragraph, recitals, Articles, Sections, Exhibits and Schedules shall be deemed references to the introductory paragraph, recitals, Articles, Sections, Exhibits and Schedules to this Agreement unless otherwise
specifically set forth herein. 
 (d) This Agreement shall be deemed drafted jointly by Buyer and PDL and shall not be
specifically construed against either party based on any claim that such party or its counsel drafted this Agreement. 
 ARTICLE II

 TRANSITION SERVICES 
 Section 2.1 Transition Services. During the Term, upon the terms and subject to the conditions of this Agreement, PDL hereby agrees to perform the Transition Services as requested by Buyer from time to time. Buyer shall reimburse PDL
for the fees and expenses set forth on Exhibit B, as applicable, in connection with PDL’s performance of the Transition Services. 
 Section 2.2 Personnel; Quality of Work. 
 (a) PDL shall provide the services of appropriately skilled and
experienced Persons in numbers sufficient to complete the performance of the Transition Services under this Agreement, for so long as PDL shall be responsible for the same as provided herein, in a prompt, thorough and efficient manner. In such
performance of the Transition Services, PDL may, as it deems necessary or appropriate in its reasonable discretion, use its personnel or that of its Affiliates. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 (b) PDL shall perform or cause the Transition Services to be performed in a professional
and workmanlike manner and in accordance with all applicable Governmental Rules. 
 (c) PDL and Buyer shall, as soon as
practicable following the Effective Date, form a transition services team (the “Transition Services Team”) of [two (2) individuals] with appropriate experience and authority, one to be designated by PDL and one to be designated
by Buyer. The Transition Services Team shall meet on a periodic basis, as reasonably requested by Buyer or PDL, during the Term and shall address all issues related to the performance of the Transition Services under this Agreement. The meetings of
the Transition Services Team may be conducted by telephone. 
 (d) Upon termination of this Agreement, PDL shall provide Buyer
with copies of all books and records (in any format, electronic or otherwise) in PDL’s possession or under PDL’s control to the extent related to the provision of the Transition Services under this Agreement. 
 (e) PDL and Buyer shall each exercise commercially reasonable efforts such that the Transition Services do not materially interfere with
the other party’s operations. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 Section 3.1 Authority. Each party hereby represents and
warrants to the other party that (i) it has all requisite corporate power and authority necessary to perform the actions contemplated to be performed by it hereunder and (ii) this Agreement has been duly executed and delivered by such
party and constitutes legal, valid and binding obligations of such party enforceable in accordance with its terms, except as such enforceability may be subject to or limited by (A) applicable bankruptcy, reorganization, insolvency, moratorium
and similar laws affecting the enforcement of creditors’ rights generally and (B) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity, regardless of
whether considered in a proceeding in law or equity. 
 ARTICLE IV 
 PAYMENTS 
 Section 4.1 Invoices. PDL shall send invoices (for fees
associated, and expenses incurred, with respect to the Transition Services, as applicable) to a single address specified in writing by Buyer. All payments to be made hereunder shall be made by Buyer to PDL within [****]* after receipt of an invoice
by electronic funds transmission, without any offset or deduction of any nature whatsoever, to such account as PDL specifies in writing to Buyer with written confirmation of payment sent by facsimile to such address as PDL specifies in writing to
Buyer. If Buyer fails to pay any invoiced amount when due and payable a service charge may be imposed by PDL equal to [****]* of the outstanding amount for each month or portion thereof 
  
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 
that such amount is overdue; provided, however, that Buyer shall have the right to dispute in good faith any such invoice in accordance with
the provisions of Section 14.4 of the Asset Purchase Agreement, upon which service charge shall only be payable if and to the extent such invoice is finally determined to be correct. 
 Section 4.2 Taxes. Except as otherwise provided in Section 2.6 of the Asset Purchase Agreement, Buyer shall bear the cost of any Transfer
Taxes, and Buyer shall forthwith pay to PDL all such sums upon demand; provided, however, that Buyer shall not be liable for any Taxes to the extent payable or assessed based upon the income or worth of PDL. 
 Section 4.3 Record Retention. PDL shall retain records and supporting documentation sufficient to document the fees and expenses paid or
payable by Buyer under this Agreement in accordance with PDL’s then-current record retention procedures, as in effect from time to time. Buyer and its representatives shall receive access, upon reasonable prior written notice to PDL, to such
records and supporting documentation, during normal business hours, as may be reasonably necessary to verify the accuracy of such fees and expenses provided, however, that such access shall not unreasonably interfere with PDL’s
business operations. In connection therewith, all costs and expenses incurred by Buyer related to the foregoing shall be solely borne by Buyer. 
 ARTICLE V 
 TERM AND TERMINATION 
 Section 5.1 Term. This Agreement shall commence on the Effective Date and shall expire on the date set forth on Exhibit A with respect to each such Transition Service, unless earlier terminated in accordance
with this Article V (the “Term”). 
 Section 5.2 Termination. 
 (a) PDL and Buyer shall each have the right to terminate this Agreement with immediate effect upon written notice to the other upon the
occurrence of any of the following: 
 (i) the other party files a petition in bankruptcy, or enters into an agreement with
its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law; or 
 (ii) the other party fails to cure any material noncompliance with any of the terms and conditions hereof within the time period specified
in any written notice (which shall be at least thirty (30) days) delivered to such non-compliant party. 
 (b) Buyer
shall have the additional right to terminate this Agreement upon written notice delivered to PDL. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Section 5.3 Termination or Expiration of Agreement. 
 (a) It is understood and agreed that Buyer shall be solely responsible to perform all the work for which Transition Services have been
rendered after the earlier of the termination or expiration of this Agreement. 
 (b) Termination or expiration of this
Agreement shall not relieve the parties of any obligation accruing prior to such termination. The rights and obligations of the parties under Articles V, VII, VIII and IX of this Agreement (as well as any applicable
provisions of the Asset Purchase Agreement) shall survive any expiration or termination of this Agreement. 
 ARTICLE VI 
 FORCE MAJEURE 
 Section 6.1 Force
Majeure. If the performance by either party of any obligation under this Agreement is prevented, restricted, interfered with or delayed by reason of any cause beyond the reasonable control of the party liable to perform, unless conclusive
evidence to the contrary is provided, the party so affected shall, upon giving written notice to the other party, be excused from such performance to the extent of such prevention, restriction, interference or delay, provided that the affected party
shall use its reasonable efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise, the parties shall discuss what, if any,
modification of the terms of this Agreement may be required in order to arrive at an equitable solution. 
 ARTICLE VII 
 INDEMNIFICATION 
 Section 7.1 By
PDL. PDL shall indemnify, defend and hold harmless the Buyer Indemnitee(s) (and, as applicable, any contractors of Buyer) from and against any and all Losses resulting from claims of third Persons (i.e., Persons other than the parties
hereto and their Affiliates) to the extent such Losses arise out of or result from the performance of the Transition Services or the failure to perform such services, as the case may be. 
 Section 7.2 By Buyer. Buyer shall indemnify, defend and hold harmless the Seller Indemnitee(s) (and, as applicable, any contractors of PDL) from
and against any and all Losses resulting from claims of third Persons (i.e., Persons other than the parties hereto and their Affiliates) to the extent such Losses arise out of or result from (a) any breach of this Agreement by Buyer, and
(b) any act done or suffered by PDL in reliance upon any instruction, order or other instrument given or executed by Buyer, except to the extent that the Losses arise from the gross negligence or willful misconduct of PDL. 
 Section 7.3 Procedures. In the event of any claims for indemnification made by one party (or, in the instance of Buyer or PDL, any other Buyer
Indemnitee(s) or Seller Indemnitee(s) respectively, or its contractors or assignees, as applicable) against the other party under this Article VII, the procedure to be used for the administration and resolution of such claims shall be as set
forth in Section 14.4 of the Asset Purchase Agreement. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Section 7.4 Exclusive Remedy. Each party acknowledges and agrees that seeking remedy for Losses
pursuant to the indemnification provided in this Article VII shall be the sole and exclusive remedy against the other party for the Buyer Indemnitee(s) and the Seller Indemnitee(s), as applicable (and, as applicable, any contractors of Buyer
and PDL) from and against any and all Losses arising out of or resulting from this Agreement or the activities contemplated hereby. 
 ARTICLE
VIII 
 INTELLECTUAL PROPERTY RIGHTS; ACCESS 
 Section 8.1 License. Buyer hereby grants to PDL, and to each Affiliate and subcontractor which PDL or any of its Affiliates may cause to perform the Transition Services, for the Term, a royalty-free,
nontransferable, non-exclusive right and license (with the right to sublicense) under the intellectual property related to the CV Products to perform the Transition Services as contemplated hereby. 
 Section 8.2 Access. Buyer shall provide to PDL, and to each Affiliate and subcontractor which PDL or any of its Affiliates may cause to perform
the Transition Services, for the Term, access to the Assets (together with any other assets or rights related to any of the Assets or otherwise used in the development, manufacture or commercialization of the CV Products) as reasonably necessary or
appropriate to perform the Transition Services as contemplated hereby. 
 Section 8.3 Disclosure and Records. PDL shall disclose
promptly in writing to Buyer each and every invention, discovery, improvement, copyrightable material, computer program, compound, micro-organism or other cell types, genetic or other biological material, process, manufacturing technique, trade
secret, formula or know-how, whether or not patentable, discovered, conceived, made, reduced to practice or learned by PDL in the course of (i) performing any Transition Services or (ii) PDL’s use of Buyer’s confidential or trade
secret information, equipment, supplies or facilities (collectively, “Inventions”). PDL shall at all times create and maintain accurate, dated and detailed records related to each and every Invention, including without limitation
records sufficient under the patent laws of the United States to establish the date(s) of conception and reduction to practice of potentially patentable Inventions. 
 Section 8.4 Assignment of Inventions to Buyer. The parties agree that any intellectual property of Buyer made available to PDL in connection with the Transition Services, and any derivative works,
additions, modifications or enhancements thereof created by PDL pursuant to this Agreement, are and shall remain the sole property of Buyer. To the extent that PDL uses its own or third-party intellectual property in connection with providing the
Transition Services, such intellectual property shall remain the sole property of PDL or the third party. PDL hereby assigns to Buyer any and all rights, title and interest in and to each and every Invention. 
 Section 8.5 Assistance. With respect to all Inventions assigned to and owned by Buyer pursuant to Section 8.4, PDL shall assist Buyer in
any reasonable manner to obtain and enforce patents, copyrights, and other proprietary rights in any and all countries, and PDL shall execute, when requested, patent applications and application assignments to Buyer and any other lawful documents
considered necessary by Buyer to carry out the purpose of this Agreement, at 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 
Buyer’s expense. PDL further agrees that the obligations and undertakings stated in this Section 8 will continue beyond the expiration or
termination of this Agreement as set forth in Section 9.1 and the Asset Purchase Agreement, provided, that if called upon to render such assistance after the expiration or termination of this Agreement, then PDL will be entitled to a
fair and reasonable hourly or per diem fee, as appropriate, in addition to reimbursement of any reasonable expenses incurred at Buyer’s request; provided, however, that in the event of a dispute over the amount of payment due to
PDL under this Section 8.5, PDL shall without delay provide all necessary assistance requested by Buyer, and shall submit any payment dispute regarding such assistance for later resolution pursuant to the Asset Purchase Agreement. 

ARTICLE IX 
 MISCELLANEOUS

 Section 9.1 Incorporation. The provisions of Article 11 (Confidentiality) and Article 14 (Miscellaneous)
(except for Sections 14.1 and 14.3) of the Asset Purchase Agreement are incorporated herein, mutatis mutandis, by reference. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed by their respective
representatives thereunto duly authorized, all as of the Effective Date. 
  

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	EKR Therapeutics, Inc.,
	a Delaware corporation.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT G 
 [PDL LETTERHEAD] 
 [                    ], 2008 
  

			
	
	 
	
	 
	
	 
	Attn:	 	 
		
	Via:	 	 

 Re: Consent to Assignment 
 Dear                     : 
 PDL BioPharma, Inc. (“PDL”) has entered into that certain Asset Purchase Agreement dated February [            ], 2008 (the
“Asset Purchase Agreement”) with EKR Therapeutics, Inc., a Delaware corporation (“EKR”) pursuant to which PDL has agreed to sell to EKR substantially all of PDL’s assets related to the
[            ] line of business (the “Acquisition”). The Acquisition is expected to close in
[                    ], 2008. 
 In connection with the Acquisition, PDL intends to assign to EKR that certain
                                 [insert agreement name] Agreement dated
            ,              between PDL and
                                 [insert name of company] (the
“Company”) (the “Agreement”). Pursuant to Section              of the Agreement, PDL hereby requests the consent of the Company to the assignment of
the Agreement, and all of PDL’ s rights and obligations thereunder, to EKR in connection with the Acquisition (the “Assignment”). 
 [Note: Some agreements require EKR to expressly assume the agreement, so this letter may have to be modified accordingly. In addition, some agreements cover more than one compound, so the letter may have to be modified to limit
the assignment to rights and obligations related to the particular compound.] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Please provide your consent to the Assignment by co-signing this letter where indicated below. By
co-signing this letter you acknowledge that all of the terms and conditions of the Agreement shall remain in full force and effect as of and following the Acquisition. Please fax an executed copy of this letter to
                     attention at
                     as soon as possible, but in no event later than
                    , 2008, and send the original via courier to
                     attention at the following address: DLA Piper US LLP, 153 Townsend Street, Suite 800, San Francisco, CA 94107.

 Feel free to contact me at
                     or
                     with any questions regarding this consent. 
  

	
	Sincerely,
	
	  
	[Name/title]

 ACKNOWLEDGED AND AGREED 
 this              day of                     , 2008 
                                        
  [Insert name of company] 
  

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		 	(Please print name and title)

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT H 
 ESCROW AGREEMENT 
 This ESCROW AGREEMENT, dated
[                 ], 2008 (“Escrow Agreement”) is entered into by and among EKR Therapeutics, Inc., a Delaware corporation
(“Buyer”) and PDL BioPharma, Inc., a Delaware corporation (“Seller”), and Wells Fargo Bank, National Association (“Escrow Agent”). 
 RECITALS 
 Seller has agreed to sell to Buyer all right, title and interest in
and to certain assets in its business pursuant to the terms of that certain Asset Purchase Agreement entered into as of February [            ], 2008 between Seller and Buyer (the
“Purchase Agreement”). 
 The Purchase Agreement provides that an amount equal to Six Million United States Dollars
($6,000,000) shall be deposited in cash in escrow for the purpose of providing a fund for the payment of certain amounts that may be owed by Seller to Buyer in connection with certain obligations of Seller under the Purchase Agreement. Accordingly,
Buyer has agreed to deposit such amount (together with any interest or other investment income earned thereon, the “Escrow Amount”) with Escrow Agent, in compliance with the Purchase Agreement. 
 This Escrow Agreement shall govern the terms upon which Escrow Agent may distribute the Escrow Amount to Buyer and Seller. 
 AGREEMENT 
 NOW, THEREFORE, in
consideration of the premises set forth above and other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Acceptance of Appointment; Deposit of Escrow Amount. Wells Fargo Bank, National Association, hereby agrees to act as Escrow Agent under this Escrow Agreement subject to the conditions set forth herein. Buyer
and Seller agree to deposit the Escrow Amount with Escrow Agent on the date hereof. 
 2. Claim Certificates. Buyer, from time to time
on or prior to twelve (12) months from the Closing Date (as such term is defined in the Purchase Agreement) (the “Claim Period”), may make a claim to some or all of the Escrow Amount (a “Claim”) by delivering
to Escrow Agent a certificate (a “Claim Certificate”) signed by an authorized signer of Buyer stating: 
 (a)
that Buyer is entitled to payment from the Escrow Amount under the Purchase Agreement, or reasonably expects to have a claim for such payment; 
 (b) the reasons therefor, set forth in reasonable detail; 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 (c) the amount of the claim by Buyer, and where the amount of the claim is not a
liquidated sum, shall be the amount reasonably estimated by Buyer, and 
 (d) that Buyer has delivered a copy of such Claim
Certificate to Seller and the date on which such copy was delivered. 
 Whenever a Claim Certificate is delivered to Escrow Agent, Escrow
Agent shall thereupon promptly notify Settler of its receipt. 
 3. Disputed Claims. 
 3.1 Seller may, in good faith, dispute or object to any claim, in whole or in part, by delivering to Escrow Agent a notice (an
“Objection Notice”) signed by an authorized signatory of Seller within twenty (20) business days following the day on which Buyer has delivered a Claim Certificate to Escrow Agent (such period, the “Objection
Period”), stating: 
 (a) that Seller, in good faith, disputes or objects to all or a portion of such Claim;

 (b) the reasons for such objections or dispute, set forth in reasonable detail; 
 (c) that Seller has delivered a copy of said Objection Notice to Buyer and the date on which such copy was delivered; and 
 (d) the portion of the Claim set forth in the Claim Certificate, if any, for which there is no dispute or objection. 
 3.2 Whenever there shall be delivered to Escrow Agent an Objection Notice, Escrow Agent shall thereupon notify Buyer of its receipt.

 3.3 Any part of a Claim being disputed by delivery of an Objection Notice (a “Disputed Claim”) shall be
resolved by settlement negotiations or arbitration as set forth in Section 14.4 of the Purchase Agreement. Upon any final resolution of the Disputed Claim by mutual agreement, Buyer and Seller shall deliver to Escrow Agent a joint written
notification signed by an authorized officer of Buyer and an authorized officer of Seller, certifying (A) that the Disputed Claim has been resolved, and (B) whether any part of the Escrow Amount is to be released to Buyer (a
“Dispute Resolution Notice”). Upon any final resolution of a Disputed Claim by arbitration, a copy of the applicable arbitration award shall be delivered to the Escrow Agent by either Buyer or Seller, accompanied by a certification
from the submitting party’s counsel, that such Disputed Claim has been resolved (such documents, a “Final Decision”). 
 3.4 Upon Escrow Agent’s receipt of (a) a Dispute Resolution Notice stating that any part of the Escrow Amount is to be released to Buyer, or (b) a Final Decision in favor of Buyer, Escrow Agent shall
promptly pay to Buyer from the Escrow Amount an amount equal to the amount stated in such document, together with any interest or other investment income accrued thereon. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 4. Undisputed Claims. If following receipt of a Claim (i) Escrow Agent receives from Seller
written notice of consent or agreement to all or part of such Claim, (ii) an Objection Notice objects to only part of such Claim, or (iii) within the Objection Period, Seller shall not have delivered to Buyer and Escrow Agent an Objection
Notice with regard to such Claim, then Escrow Agent shall promptly pay to Buyer from the Escrow Amount an amount equal to the part of such Claim that is consented to by Seller, uncontested, or requested by Buyer, as applicable, together with any
interest or other investment income accrued thereon. 
 5. Distributions of Escrow Amount. 
 5.1 Any distributions (or releases) pursuant to Sections 3, 4 or 9 of this Escrow Agreement, shall be made by the Escrow Agent by means of
a wire transfer of immediately available funds to the bank account designated by Buyer or Seller, as applicable, in “Exhibit B”. 
 5.2 If the Escrow Amount is not sufficient to pay in full any amounts payable to Buyer under this Escrow Agreement, Escrow Agent shall pay to Buyer such Escrow Amount as is available. 
 6. Investment of Escrow Amount. The Escrow Amount shall be credited by Escrow Agent and recorded in an escrow account. Escrow Agent shall be
permitted, and is hereby authorized to deposit, transfer, hold and invest all funds received under this Escrow Agreement, including principal and interest or other investment income in Wells Fargo Funds Money Market Deposit Account as set forth in
Exhibit A, during the period of this escrow. Escrow Agent may invest the Escrow Amount in alternative investments in accordance with written instructions as may from time to time be provided to Escrow Agent and signed by both Buyer and
Seller. Any interest or other investment income received by Escrow Agent with respect to the Escrow Amount, including reinvested interest or other investment income shall become part of the Escrow Amount and shall be released in accordance with the
provisions of this Escrow Agreement. The parties agree that, for tax reporting purposes, all interest or other taxable investment income earned on the Escrow Amount in any tax year shall be taxable to Buyer. 
 The parties hereto shall on or prior to the date hereof, provide Escrow Agent with certified tax identification numbers by furnishing appropriate IRS
forms W-9 or W-8 and other forms and documents that Escrow Agent may reasonably request. The parties hereto understand that if such tax reporting documentation is not so provided to Escrow Agent, Escrow Agent may be required by the Internal Revenue
Code of 1986, as amended, to withhold a portion of any interest or other investment income earned on the Escrow Fund pursuant to this Escrow Agreement. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 To the extent that Escrow Agent becomes liable for the payment of any taxes in respect of income derived
from the investment of funds held or payments made hereunder, Escrow Agent shall satisfy such liability to the extent possible from the Escrow Amount. The parties agree to indemnify and hold Escrow Agent harmless from and against any taxes,
additions for late payment, interest, penalties and other expenses that may be assessed against Escrow Agent on or with respect to any payment or other activities under this Escrow Agreement unless any such tax, addition for late payment, interest,
penalties and other expenses shall arise out of or be caused by the actions of, or failure to act, by Escrow Agent. 
 7. Notices. All
notices, requests, demands, and other communications under this Escrow Agreement shall be in writing and shall be deemed to have been duly given (a) on the date of service if served personally on the party to whom notice is to be given,
(b) on the day of transmission if sent by facsimile/email transmission to the facsimile number/email address given below, and telephonic confirmation of receipt is obtained promptly after completion of transmission, (c) on the day after
delivery to Federal Express or similar overnight courier or the Express Mail service maintained by the United States Postal Service, or (d) on the fifth day after mailing, if mailed to the party to whom notice is to be given, by first class
mail, registered or certified, postage prepaid, and properly addressed, return receipt requested, to the party as follows: 
 If to Buyer:

 EKR Therapeutics, Inc. 
 Attention: Richard DeSimone 
 7 East Frederick Place 
 Cedar Knolls, NJ 07927 
 Facsimile: +1 (866) 620-6848 
 E-mail: r.desimone@ekrtx.com 
 with a copy to
(not to constitute notice): 
 Milbank, Tweed, Hadley & McCloy LLP 
 Attention: Robert S. Reder, Esq. 
 One Chase
Manhattan Plaza 
 New York, New York 10005 
 Facsimile No.: +1 (212) 822-5680 
 E-mail: RReder@milbank.com 
 If to Seller: 
 PDL BioPharma, Inc.

 Attention: General Counsel 
 1400 Seaport Boulevard 
 Redwood City, CA 94063 
 Facsimile: [                    ] 
 E-mail:
[                          ] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 with a copy to (not to constitute notice): 
 DLA Piper US LLP 
 Attention: Howard Clowes

 153 Townsend Street, Suite 800 
 San Francisco, CA 94107-1957 
 Facsimile: 415- 659-7410 
 E-mail: howard.clowes@dlapiper.com 
 If to
Escrow Agent: 
 Wells Fargo Bank, National Association 
 Corporate Trust Services 
 707 Wilshire Blvd.,
17th Floor 
 Los Angeles, CA 90017

 Attention:
[                    ] 
 Telephone: [                    ] 
 Facsimile: [                    ] 
 or to such other address as a party shall designate by written notice to all other parties to the Escrow Agreement. 
 8. Escrow Agent’s Liability. Escrow Agent undertakes to perform such duties and only such duties as are specifically set forth in this Escrow Agreement, and no implied covenants or obligations shall be read into this Escrow
Agreement against Escrow Agent. In the absence of gross negligence or willful misconduct on its part, Escrow Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or
opinions furnished to Escrow Agent. Escrow Agent may act upon any instrument, certificate, opinion or other writing believed by it without gross negligence to be genuine, and shall not be liable in connection with the performance by it of its duties
pursuant to the provisions of the Escrow Agreement, except for its own gross negligence or willful misconduct. Escrow Agent may consult with counsel of its own choice and shall have full and complete authorization and protection for any action
taken, suffered or omitted by it hereunder in good faith and in accordance with the opinion of such counsel. Escrow Agent may execute powers hereunder or perform any duties hereunder either directly or by or through agents or attorneys. 

9. Termination of Escrow. 
 9.1 Subject to Section 9.2, within thirty (30) days after the termination of the Claim Period, Upon receipt of signed written direction from the Buyer and Seller with the detail calculation of the amount to be distributed, Escrow
Agent shall (i) deduct from any Escrow Amount remaining an amount equal to forty-five percent (45%) of the interest or other taxable investment income included in such Escrow Amount, and pay such amount to Buyer, and (ii) pay to
Seller the remaining Escrow Amount 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 9.2 If upon termination of the Claim Period there are any Claims or Disputed Claims
pending, Escrow Agent shall continue to hold pursuant to this Escrow Agreement such portion of the Escrow Amount that is equal to the amount of any such Claim or Disputed Claim (including any interest or other investment income thereon), until such
time all Claims and Disputed Claims are resolved pursuant to Section 3 or Section 4. Upon resolution of all pending Claims or Disputed Claims, Escrow Agent shall (x) pay to Buyer any amount to be paid pursuant to Section 3 or
Section 4, as applicable; and (y) with respect to any amount remaining thereafter, if any, (i) deduct from such amount an amount equal to forty-five percent (45%) of the interest or other taxable investment income included
therein, and pay such amount to Buyer, and (ii) pay to Seller the remaining amount. 
 9.3 All obligations of Escrow
Agent hereunder shall terminate upon the full disbursement of the Escrow Amount in accordance with the provisions of this Escrow Agreement. 
 10. Reliance. The Escrow Agent shall not be liable for any action taken or not taken by it in accordance with the direction or consent of the parties or their respective agents, representatives, successors, or assigns. The Escrow
Agent shall not be liable for acting or refraining from acting upon any notice, request, consent, direction, requisition, certificate, order, affidavit, letter, or other paper or document believed by it to be genuine and correct and to have been
signed or sent by the proper person or persons, without further inquiry into the person’s or persons’ authority. Concurrent with the execution of this Escrow Agreement, the parties shall deliver to the Escrow Agent authorized signers’
forms in the form of Exhibit B-1 and Exhibit B-2 to this Escrow Agreement. 
 11. Fees and Expenses. Escrow Agent is entitled to
compensation in accordance with “Exhibit C” attached hereto and incorporated herein by reference and shall be payable by the Buyer. The fee agreed upon for the services rendered hereunder is intended as full compensation for the
Escrow Agent’s services as contemplated by this Escrow Agreement; provided, however, that in the event that the conditions for the disbursement of funds under this Escrow Agreement are not fulfilled, or the Escrow Agent renders any
material service not contemplated in this Escrow Agreement or there is any assignment of interest in the subject matter of this Escrow Agreement, or any material modification hereof, or if any material controversy arises hereunder, or the Escrow
Agent is made a party to any litigation pertaining to this Escrow Agreement, or the subject matter hereof, then the Escrow Agent shall be reasonably compensated for such extraordinary services and reimbursed for all reasonable costs and expenses,
including reasonable attorney’s fees, occasioned by any delay, controversy, litigation or event. 
 12. Indemnification of Escrow
Agent. Buyer and Seller both jointly and severally hereby indemnify and hold harmless the Escrow Agent from and against, any and all loss, liability, cost, damage and expense, including, without limitation, reasonable counsel fees, which the
Escrow Agent may suffer or incur by reason of any action, claim or proceeding brought against the Escrow Agent arising out of or relating in any way to this Escrow Agreement or any transaction to which this Escrow Agreement relates unless such
action, claim or proceeding is the result of the willful misconduct or gross negligence of the Escrow Agent. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 13. Disagreements. If any conflict, disagreement or dispute arises between, among, or involving
any of the parties hereto concerning the meaning or validity of any provision hereunder or concerning any other matter relating to this Escrow Agreement, or the Escrow Agent is in doubt as to the action to be taken hereunder, the Escrow Agent is
authorized to retain the Escrow Amount until the Escrow Agent (i) receives a final non-appealable order of a court of competent jurisdiction or a final non-appealable arbitration decision directing delivery of the Escrow Amount,
(ii) receives a written agreement executed by each of the parties involved in such disagreement or dispute directing delivery of the Escrow Amount, in which event the Escrow Agent shall be authorized to disburse the Escrow Amount in accordance
with such final court order, arbitration decision, or agreement, or (iii) files an interpleader action in any court of competent jurisdiction, and upon the filing thereof, the Escrow Agent shall be relieved of all liability as to the Escrow
Amount and shall be entitled to recover attorneys’ fees, expenses and other costs incurred in commencing and maintaining any such interpleader action. The Escrow Agent shall be entitled to act on any such agreement, court order, or arbitration
decision without further question, inquiry, or consent. 
 14. Resignation. Escrow Agent may resign upon 30-days advance written
notice along with payment of all fees and expenses to which it is entitled through the date of termination to the parties hereto. If a successor escrow agent is not appointed within the 30-day period following such notice, Escrow Agent may petition
any court of competent jurisdiction to name a successor Escrow Agent or interplead the Escrow Amount with such court, whereupon Escrow Agent’s duties hereunder shall terminate. 
 15. Successors and Assigns. Except as otherwise provided for in this Escrow Agreement, no party hereto shall assign this Escrow Agreement or any
rights or obligations hereunder without the prior written consent of the other parties hereto and any such attempted assignment without such prior written consent shall be void and of no force and effect. Notwithstanding the foregoing, Buyer may
assign any or all of its rights, interests and obligations hereunder to any financial institution providing purchase money or other financing to Buyer from time to time as collateral security for such financing. This Escrow Agreement shall inure to
the benefit of and shall be binding upon the successors and permitted assigns of the parties hereto. 
 16. Governing Law;
Jurisdiction. This Escrow Agreement shall be construed, performed, and enforced in accordance with, and governed by, the internal laws of the State of California, without giving effect to the principles of conflict of laws thereof. 

17. Amendments; Waivers. This Escrow Agreement may be amended or modified, and any of the terms, covenants, representations, warranties, or
conditions hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party waiving compliance. Any waiver by any party of any conditions, or of the breach of any provision, term, covenant,
representation, or warranty contained in this Escrow Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such conditions, or of the breach of any other provision, term, covenant,
representation, or warranty of this Escrow Agreement. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 18. Counterparts. This Escrow Agreement may be executed in two or more counterparts, all of which
taken together shall constitute one instrument. 
 19. Entire Agreement. This Escrow Agreement contains the entire understanding among
the parties hereto with respect to the escrow contemplated hereby and supersedes and replaces all prior and contemporaneous agreements and understandings, oral or written, with regard to such escrow. 
 20. Section Headings. The section headings in this Escrow Agreement are for reference purposes only and shall not affect the meaning or
interpretation of this Escrow Agreement. 
 21. Severability. In the event that any part of this Escrow Agreement is declared by any
court or other judicial or administrative body to be null, void, or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Escrow Agreement shall remain in full force and effect.

 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the parties hereto have caused this Escrow Agreement to be signed the day and
year first above written. 
  

			
	SELLER:
	
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	BUYER:
	
	EKR Therapeutics, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	ESCROW AGENT:
	
	Wells Fargo Bank, National Association
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT I 
 LITIGATION COOPERATION AGREEMENT 
 THIS LITIGATION COOPERATION AGREEMENT (this
“Agreement”) is made and entered into as of [                    ], 2008 (the “Effective Date”) by and among
PDL BioPharma, Inc., a Delaware corporation (“Seller”) and EKR Therapeutics, Inc., a Delaware corporation (“Buyer”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the
Purchase Agreement (as defined below). 
 RECITALS 
 WHEREAS, Seller and Buyer have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February [    ], 2008, pursuant to which, among
other things, Seller has agreed to sell, convey, transfer, assign and deliver to Buyer all of Seller’s right, title and interest in and to the Assets, and Buyer has agreed to assume the Assumed Liabilities. 
 WHEREAS, the Assets and Assumed Liabilities include, without limitation, certain rights and obligations related to the Sun Litigation (the
“Action”). 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the Purchase Agreement, and for
other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 
 AGREEMENT 
 [****]* 
 [SIGNATURE PAGE FOLLOWS] 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 
  

			
	BUYER:
	
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	SELLER:
	
	EKR Therapeutics, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 LITIGATION MANAGEMENT AGREEMENT 
 SIGNATURE PAGE 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT J 
 [PDL LETTERHEAD] 
 Via U.S. Mail 
 [Name of customer] 
 [Address of customer] 
 [Attention:                 ] 
  

	 	Re:	Notice of Asset Purchase Agreement 

 Dear
                        : 
 PDL BioPharma, Inc. (“PDL”) has entered into that certain Asset Purchase Agreement dated February [            ], 2008 with EKR
Therapeutics, Inc., a Delaware corporation (“Buyer”) pursuant to which PDL has agreed to sell to Buyer substantially all of PDL’s assets related to
[                ] (the “Product”) line of business. 
 PDL is hereby delivering this notice to all customers and wholesalers that Buyer has assumed responsibility for the manufacturing, marketing and sale of the Product. All payments with respect to the sale of the
Product after the date hereof should be deposited with Buyer at the account designated below. In addition, all future correspondence should be directed to Buyer at the address below. 
 EKR Therapeutics, Inc. 
 7 East Frederick
Place 
 Cedar Knolls, NJ 07927 
 Facsimile: +1 (866) 620-6848 
 [Designated Account] 
 Feel free to contact                     , at
                     or
                     with any questions regarding this notice. 
  

	
	Sincerely,
	
	  
	[Name]
	[Title]

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 1.70(A) 
 Product Specifications for Bulk Active Pharmaceutical Ingredients for each CV Product 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 1.70(B) 
 Product Specifications for Drug Products 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(A) 
 List of Patents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(B) 
 List of Licensed IP Rights 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(C) 
 List of Trademark Registrations 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(E) 
 List of Registrations 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(L) 
 List of Tangible Assets 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(M) 
 List of Domain Names 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(P) 
 List of Assumed Contracts 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 4.2(A) 
 List of Third Party Consents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 5.1(A) 
 List of Business Employees 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 DISCLOSURE SCHEDULES 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 AMENDMENT NO. 1 
 TO 
 ASSET PURCHASE AGREEMENT 
 This Amendment No. 1 to Asset Purchase Agreement is being entered into as of March 7, 2008 (this “Amendment”) by and between
PDL BioPharma, Inc., a Delaware corporation (the “Seller”) and EKR Therapeutics, Inc., a Delaware corporation (the “Buyer”). 
 RECITALS 
 WHEREAS, the parties hereto entered into an Asset Purchase Agreement, dated as of
February 4, 2008 (the “Purchase Agreement”; capitalized terms used but not defined herein shall have the meanings assigned to them in the Purchase Agreement); 
 WHEREAS, the parties hereto desire to amend the Purchase Agreement in accordance with Section 14.7 thereof and in the manner set forth herein.

 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the parties hereto agree as follows: 

1. Section 1 of the Purchase Agreement is hereby amended by adding the following definitions, and the other definitions contained
in Section 1 of the Purchase Agreement are correspondingly re-numbered (together with any internal cross-references in the Purchase Agreement) to reflect the addition of the following definitions: 
 “1.20 “Centocor Agreement” shall mean that certain Asset Purchase Agreement entered into as of January 31, 2005 between PDL
BioPharma, Inc. (as successor in interest to ESP Pharma, Inc.) and Centocor, Inc. (“Centocor”), as amended by Amendment No. 1 effective June 24, 2005, Amendment No. 2 effective September 14, 2005 and Amendment
No. 3 entered into as of September 19, 2007.” 
 “1.21 “Centocor Licensed IP Rights” shall have the
meaning given in Section 10.17.” 
 “1.22 “Centocor Sublicense” shall mean the sublicense to the
Licensed Patent Rights (as that term is defined in the Centocor Agreement) granted to Seller by Centocor pursuant to Section 2.2 of the Centocor Agreement.” 
 “1.70 “PDL/EKR – Centocor Sublicense” shall have the meaning given in Section 10.17.” 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 2. The first sentence in paragraph (p) of Section 2.1 of the Purchase Agreement
is hereby deleted in its entirety and replaced with the following new sentence which shall read in its entirety as follows: 
 “Upon
Closing, Seller shall sell, transfer, assign, convey and deliver or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all rights and benefits of Seller in existence as of the Closing Date or arising after the Closing
Date under the contracts listed in Attachment 2.1(p) (or, in the case of contracts identified in Attachment 2.1(p) as being assigned to Buyer in part, under the applicable portion of such contracts so assigned) (the “Assumed
Contracts”), including any rights to Intellectual Property.” 
 3. Paragraph (v) of Section 2.1 of the
Purchase Agreement is hereby deleted in its entirety and replaced with the following new sentence which shall read in its entirety as follows: 
 “(v) Packaging Inventory. Upon Closing, Seller shall sell, transfer, assign, convey and deliver or shall cause to be sold, transferred, assigned, conveyed and delivered to Buyer, all packaging material existing or in the process
of manufacture pursuant to a contract with Seller or its Affiliates for the Marketed Products, including all package labels and product inserts used in connection with the Marketed Products owned or controlled by Seller or its Affiliates as of the
Closing (the “Packaging Inventory”).” 
 4. Paragraph (a) of Section 2.3 of the Purchase
Agreement is hereby deleted in its entirety and replaced with the following new paragraph (a) which shall read in its entirety as follows: 
 “(a) all Liabilities of Seller under the Assumed Contracts, but only to the extent such Liabilities arise from any event, circumstance or condition occurring after the Closing Date (but excluding, in the case of each Assumed Contract
that is identified in Attachment 2.1(p) as being assigned to Buyer in part, all Liabilities of Seller that relate to or arise out of the portion of such partially assigned contract retained by Seller);” 
 5. Section 2.3 of the Purchase Agreement is hereby amended by adding a new paragraph (h) following paragraph (g) of
Section 2.3, which shall read in its entirety as follows: 
 “(h) all Liabilities of Seller under the Centocor Agreement, but only
to the extent such Liabilities arise from any event, circumstance or condition occurring after the Closing Date and excluding any Liabilities that arise as a result of actions taken or omitted by Seller after the Closing but prior to the date, if
any, on which consent for the assignment thereof is obtained, unless such actions or omissions are at the request or direction of Buyer or pursuant to a consent granted by Buyer,.” 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 6. The fifth sentence of Section 2.7 of the Purchase Agreement is hereby deleted in
its entirety and replaced with the following new sentence which shall read in its entirety as follows: 
 “If any such consent shall not
be obtained, Seller shall cooperate with Buyer in any reasonable arrangement designed to provide for Buyer the benefits intended to be assigned to Buyer under the relevant Assumed Contract, Intellectual Property or Registration, including
enforcement at the cost and for the account of Buyer of any and all rights of Seller against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise; provided that, in connection with receiving any
such benefits, Buyer shall assume the Liabilities of Seller thereunder, but only to the extent such Liabilities (x) arise from any event, circumstance or condition occurring after the Closing Date and (y) relate to the benefits received by
Buyer, and excluding any Liabilities that arise as a result of actions taken or omitted by Seller after the Closing but prior to the date, if any, on which consent for the assignment thereof is obtained, unless such actions or omissions are at the
request or direction of Buyer or pursuant to a consent granted by Buyer.” 
 7. Section 2.7 of the Purchase
Agreement is hereby amended by adding the following sentence to the end of Section 2.7: 
 “With respect to each Assumed Contract
that is not assigned to Buyer on the Closing Date as a result of a required consent or waiver not having been obtained, until such time as it is reasonably determined by Buyer and Seller that such required consent or waiver cannot be obtained,
Seller shall not, without the prior written consent of Buyer, (i) breach, amend, modify, terminate or waive any provision of such contract or agreement in any manner that would have an adverse effect on Buyer’s rights or benefits under
such Assumed Contract or the Assets, or (ii) pledge, sell or otherwise dispose of (by operation of law or otherwise) such Assumed Contract or any rights or benefits thereunder.” 
 8. Section 10.1 of the Purchase Agreement is hereby amended by adding new paragraph (d) which shall read in their entirety as
follows: 
 “(d) With respect to each Assumed Contract that is comprised of a partial assignment of a contract or other agreement, or of
Seller’s rights thereunder, Seller (i) shall not, without the prior written consent of Buyer, amend, modify, terminate or waive any provision of such contract or agreement in any manner that would have an adverse effect on Buyer’s
rights or benefits under such Assumed Contract, and (ii) shall provide Buyer with (x) prompt written notice of any violation or breach of, or default under, any such Assumed Contract of which it has knowledge to the extent that any such
violation, breach or default could in Seller’s good faith judgment be reasonably expected to have an adverse effect on Buyer 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 
rights or benefits under such partially assigned contract or other agreement, and (y) a copy of any written notice that it receives in respect of any
violation, breach or default of any such Assumed Contract to the extent that any such violation, breach or default could in Seller’s good faith judgment be reasonably expected to have an adverse effect on Buyer rights or benefits under such
partially assigned contract or other agreement.” 
 9. Section 10.12 of the Purchase Agreement is hereby deleted in
its entirety and replaced with the following new section which shall read in its entirety as follows: 
 “10.12 Promotion, Marketing
and Labeling. Promptly after the Registrations have been transferred to Buyer and subject to applicable regulatory approvals, all Buyer advertising and promotional materials for the Marketed Products shall identify Buyer as the marketer of the
Marketed Products in the applicable Territory, in such form as Buyer shall determine. Promptly after the Registrations have been transferred to Buyer, Buyer shall make such changes in the package insert, Marketed Products labeling and packaging as
may be required to reflect Buyer as the marketer of the Marketed Products in the applicable Territory, including making all required FDA and any other regulatory filings in connection therewith. Promptly after the Registrations have been transferred
to Buyer, Seller shall file with the FDA a notice that Buyer is the marketer and distributor of the Marketed Products in the applicable Territory. To the extent that the FDA requests additional information or meetings regarding Buyer’s
responsibilities as marketer and distributor of the Marketed Products in the applicable Territory, Buyer shall respond to the FDA at its own expense and through its own personnel. Seller is not required to change the Marketed Products’ labeling
or package insert, or packaging for the Drug Products or the Packaged Products. With respect to the Product Inventory purchased by Buyer hereunder, Buyer shall be permitted (i) until [****]* in the case of the [****]* other than [****]*,
(ii) until [****]* in the case of [****]*, (iii) until [****]* in the case of the [****]*, to sell Marketed Products from the Product Inventory as labeled and packaged prior to the Closing Date, and with respect to the Packaging Inventory
purchased by Buyer hereunder, Buyer shall be permitted to use such Packaging Inventory through the same dates, as applicable, all without regard to whether the Marketed Products references Seller or includes any intellectual property rights Seller
has in Trademarks that may be included on the labels and packaging but not conveyed to Buyer pursuant to this Agreement, provided, that all such Product Inventory and Packaging Inventory shall be held, maintained, distributed 
  

	*	 Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 
and sold in accordance with the Registrations and all applicable laws. With respect to Cardene PMB Product packaging, Buyer shall be permitted to manufacture
and use packaging bearing Seller trademarks until [****]* that is substantially the same as the packaging used for testing the Cardene PMB Product. Without the prior written approval from Seller, which approval shall not be unreasonably withheld or
delayed, Buyer shall not use or distribute any marketing, promotional or advertising copy related to the [****]* has been transferred to Buyer; provided, however, that nothing herein shall require any approval from Seller for Buyer to issue invoices
for, and collect revenues from, sales of the [****]* from and after the Closing Date.” 
 10. The Purchase Agreement is
hereby amended by adding a new Section 10.17, which shall read in its entirety as follows: 
 “10.17 Centocor Agreement. Upon
Closing, Seller hereby grants Buyer a perpetual, paid up, irrevocable, non-terminable, royalty free, unlimited (other than as provided in the Centocor Agreement) sublicense under the Centocor Sublicense in the Territory (as that term is defined in
the Centocor Agreement), with the right to further sublicense, without the consent of Seller, such sublicense and any other sublicense thereunder being sole and exclusive for use in the Business (as that term is defined in the Centocor Agreement)
(the “PDL/EKR - Centocor Sublicense”); provided that if after the Closing Buyer and Seller obtain the consent of Centocor to the assignment of the Centocor Agreement to Buyer, upon obtaining such consent (a) the PDL/EKR
- Centocor Sublicense shall automatically terminate, (b) the Centocor Agreement shall be deemed to be an Assumed Contract and the Centocor Licensed Patent Rights shall be deemed to be Licensed IP Rights (the “Centocor Licensed IP
Rights”) hereunder, and (c) such consent shall constitute a transfer and assignment to Buyer of the Centocor Agreement and Centocor Licensed IP Rights with immediate effect. Buyer acknowledges and agrees that the PDL/EKR - Centocor
Sublicense shall be subject to all of the terms and conditions of the Centocor Agreement, including the provisions of Section 2.2 thereof. Nothing contained in this Agreement shall be deemed to convey to Buyer any rights or benefits under the
Centocor Sublicense other than those of Seller contained in the Centocor Sublicense. So long as the PDL/EKR - Centocor Sublicense shall remain in effect, Seller shall not, without the prior written consent of Buyer, (i) breach, amend, modify,
terminate or waive any provision of the Centocor Agreement in any manner that would have an adverse effect on Buyer’s rights or benefits under the Centocor Agreement, or (ii) pledge, sell or otherwise dispose of (by operation of law or
otherwise) the Centocor Agreement or any rights or benefits thereunder. This Section 10.17 shall survive the Closing indefinitely unless otherwise terminated as set forth above.” 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 11. Section 14.9 of the Purchase Agreement is hereby amended by adding the following
language immediately after the word “sources” and before the period at the end of such Section: 
 “[****]*” 
 12. Attachment 2.1(B) to the Purchase Agreement is hereby deleted in its entirety and replaced
with Attachment 2.1(b) attached hereto. 
 13. Attachment 2.1(P) to the Purchase Agreement is hereby deleted in its entirety
and replaced with Attachment 2.1(p) attached hereto. 
 14. Attachment 4.2(A) of the Purchase Agreement is hereby deleted in
its entirety and replaced with a new Attachment 4.2(a) attached hereto. 
 15. Where necessary to give effect to the terms of
this Amendment, all reference in the Purchase Agreement to the “Agreement” shall be deemed to refer to the Purchase Agreement as amended hereby. 
 16. All other provisions of the Purchase Agreement shall be unmodified and shall remain in full force and effect, in accordance with its terms. 
 17. If any provision of this Amendment is held by a court of competent jurisdiction to be invalid or unenforceable, it shall be modified,
if possible, to the minimum extent necessary to make it valid and enforceable or, if such modification is not possible, such provision shall be stricken and the remaining provisions shall remain in full force and effect. 
 18. This Amendment shall be deemed to have been made in the State of California and its form, execution, validity, construction and effect
shall be determined in accordance with the laws of the State of California, without giving effect to the principles of conflicts of law thereof. 
 19. This Amendment and the rights and obligations hereunder shall be binding upon and inure to the benefit of the parties hereto, their respective successors and assigns, but this Amendment shall not be assignable by
either party hereto without the express written consent of the other party hereto which will not be unreasonably withheld, provided, however, that Buyer may merge or consolidate with, or assign any or all of its rights, interests and obligations
hereunder to, a direct or indirect wholly-owned subsidiary of Buyer, provided that no such merger, consolidation or assignment shall relieve Buyer of its obligations hereunder, and Buyer may assign any or all of its rights and interests hereunder as
collateral to one or more of its financing sources. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 20. This Amendment may be executed in two or more counterparts, each of which shall be
deemed an original, but which together shall constitute one and the same instrument. Any executed counterpart delivered by facsimile or other means of electronic transmission shall be deemed an original for all purposes. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this Amendment as
of the date first written above. 
  

			
	PDL BioPharma, Inc., 
	a Delaware corporation
		
	By:	 	/s/ L. Patrick Gage
	Name:	 	L. Patrick Gage
	Title:	 	Chief Executive Officer
		
	By:	 	/s/ Andrew Guggenhime
	Name:	 	Andrew Guggenhime
	Title:	 	Senior Vice President and Chief Financial Officer
	
	EKR Therapeutics, Inc.,
	a Delaware corporation
		
	By:	 	/s/ Howard Weisman
	Name:	 	Howard Weisman
	Title:	 	Chairman and Chief Executive Officer
		
	By:	 	/s/ Richard DeSimone
	Name:	 	Richard DeSimone
	Title:	 	Chief Financial Officer

 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT 
 SIGNATURE PAGE 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(B) 
 List of Licensed IP Rights 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 2.1(P) 
 List of Assumed Contracts 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ATTACHMENT 4.2(A) 
 List of Third Party Consents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]